Tesamorelin + AOD-9604 — Visceral Fat Adjunct Protocol

Purpose. This is the Module 5 (Weight Loss & Metabolic) clinical protocol for the body-composition adjunct stack built around tesamorelin (Theratechnologies; FDA-approved for marketing claims as Egrifta original 1 mg/vial November 2010, Egrifta SV 2 mg/vial June 2019, Egrifta WR 2024; BLA022505; on-label indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy) and AOD-9604 (Metabolic Pharmaceuticals development discontinued 2007; not FDA-approved for marketing claims for any drug indication; FDA 503A bulks list category 2; Australian TGA listing as a complementary medicine ingredient for joint/cartilage — a regulatory pathway distinct from FDA drug approval), produced under the Protocol Template v1.0. Evidence base: the canonical files at /Peptides/Tesamorelin.md and /Peptides/AOD-9604.md, the M5.5 v3 lesson, the Falutz Phase 3 program (Falutz 2007 NEJM PMID 18057338; Falutz 2008 AIDS PMID 18690162; Falutz 2010 JAIDS PMID 20101189), the Stanley 2014 JAMA hepatic-fat RCT (PMID 25038357), and the 2025 body-composition meta-analysis (PMID 41545261). The structural authority is the Protocol Template; the content authority is the canonical and its verified primary sources.

Adjunct-protocol framing — load-bearing precision. This protocol covers a body-composition adjunct strategy for visceral and targeted adipose tissue reduction, used alongside primary weight-management therapy. It is NOT a standalone obesity treatment. The mechanism class — GHRH-R-mediated pulsatile growth-hormone release (tesamorelin) and decoupled-from-GH-receptor lipolysis (AOD-9604) — is distinct from the GLP-1 / GIP / glucagon receptor-agonist class that anchors first-line chronic weight management (per Module 5 protocols for semaglutide, tirzepatide, liraglutide, retatrutide, survodutide, cagrilintide, CagriSema, IcoSema, orforglipron). Tesamorelin and AOD-9604 target specific body-composition components — visceral adipose tissue (VAT) and, in AOD-9604’s case, hypothesized but evidence-limited lipolytic fat-loss — as adjuncts to a primary weight-management core therapy (most commonly a GLP-1 RA). The protocol is read through this adjunct framing throughout: §1 leads with what the stack IS (a VAT-selective, GH-axis body-composition adjunct), §5 maintenance is paired with an assumed GLP-1 RA backbone in most patients, §9 combination rules treat the GLP-1 RA + tesamorelin co-administration as standard rather than as exotic, and §10 counseling beats anchor on the “visceral-fat redistribution at approximately neutral total weight” mechanism rather than on the “weight-loss-drug” framing.

FDA-approved for marketing claims — load-bearing precision (Editorial Framework §1.2.1; Pattern AA.marketing-claims). The phrase “FDA-approved” throughout this protocol is shorthand for “FDA-approved for marketing claims for [indication X].” FDA approval is indication-specific, not drug-specific; off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug, regulatorily and operationally distinct from use of a compound that is not FDA-approved for marketing claims for any drug indication. The protocol uses the convention “FDA-approved for marketing claims for [X]; off-label for [Y]” wherever both registers apply. Tesamorelin is FDA-approved for marketing claims for HIV-associated lipodystrophy abdominal-fat reduction (Egrifta SV / Egrifta WR; BLA022505); off-label use for visceral adiposity in non-HIV populations is off-label use of an FDA-approved-for-marketing-claims drug — a standard clinical-practice pathway distinct from research-use-only or 503A-compounded non-FDA-approved peptide use. AOD-9604 is not FDA-approved for marketing claims for any drug indication; current US clinical access is via 503A compounding pathway (bulks list category 2) and research-use-only channels; the 2007 FDA GRAS (Generally Recognized as Safe) determination applies to oral use as a food-supplement ingredient — a food-regulatory category distinct from drug approval.

Compound-class framing — both compounds are peptides. Pattern N.1 enforcement: this protocol lives at /Protocols/ under the peptides folder structure, not at /Small-Molecules/. Tesamorelin is a 44-amino-acid synthetic GHRH(1-44) analog with a trans-3-hexenoic acid N-terminal modification (molecular weight ~5135 Da; PubChem CID 44147413; CAS 218949-48-5). AOD-9604 is a 16-amino-acid peptide fragment corresponding to human growth hormone residues 177-191 with an N-terminal tyrosine addition (molecular weight ~1815 Da; PubChem CID 9831659). Both belong at /Peptides/. Orforglipron and aleniglipron — the small-molecule oral GLP-1 receptor agonists — are the Pattern N.1 contrast cases; this protocol does not share that classification.

Adjunct-specific calibration notes (load-bearing for the production agent and the verification gate).

Distinct mechanism class — not a GLP-1 / GIP / glucagon agonist; not a “weight-loss-drug.” Tesamorelin engages the GHRH receptor on anterior pituitary somatotrophs, driving Gαs-coupled pulsatile endogenous GH release; downstream GH/IGF-1 axis activation drives VAT-selective lipolysis without total-weight reduction at population level (the FDA label explicit Limitation of Use is “EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect”). AOD-9604 engages a lipolysis pathway decoupled from GH-receptor signaling — it does not bind the GH receptor, does not produce JAK2/STAT5b phosphorylation cascades, and does not elevate circulating IGF-1 in animal models (Heffernan 2001 Endocrinology PMID 11713213; mechanism characterization is preclinical and incompletely established at the molecular-target level). Neither compound’s mechanism is a glucose-dependent insulinotropic / satiety / gastric-emptying signal characteristic of the GLP-1 / GIP / glucagon class. The protocol’s §1 indication scope, §4 initiation framing, §5 maintenance metrics, §6 AE class profile, §7 plateau algorithm, §9 combination rules, and §10 counseling beats all reflect this mechanistic distinction — they are adjunct framing, not “weight-loss-drug” framing.
Tesamorelin regulatory state — FDA-approved-for-marketing-claims for HIV lipodystrophy; off-label visceral-fat-in-non-HIV use is off-label use of an FDA-approved drug (Pattern AA + AA.marketing-claims). The molecule is FDA-approved; the off-label use is “off-label use of an FDA-approved drug” per Editorial Framework v1.2 §1.2.1. The cross-context distinction matters operationally and regulatorily and is preserved at every §10 counseling beat referencing the off-label non-HIV use.
AOD-9604 regulatory state — not FDA-approved for marketing claims for any drug indication; investigational; development-discontinued by sponsor in 2007 (Pattern AA-precise framing per Z.research-precision). The accurate research-state characterization is development-discontinued, not “emerging,” not “in active FDA review,” not “highly experimental.” Sponsor Metabolic Pharmaceuticals advanced AOD-9604 through Phase 2a (Wilding 2004 narrative review PMID 15134286 notes Phase IIa underway in 2002) and into a Phase 2b obesity trial in 2006–2007; the Phase 2b program did not meet sponsor commercial-development thresholds and obesity development was discontinued in 2007. The Phase 2b human obesity trial has not been published in the peer-reviewed indexed literature in a form supporting primary citation. The load-bearing published evidence for AOD-9604 in obesity is preclinical (Heffernan / Ng cluster animal studies 2000–2001; PMIDs 10950816, 11146367, 11673763, 11713213) plus the Wilding 2004 narrative review. Pattern Z.research-precision discipline: this protocol describes the actual research base (“Phase 2 sponsor-disclosed data; not peer-reviewed-published; preclinical animal-model evidence base; development discontinued 2007”), it does not import bias-vocabulary (“highly experimental,” “fringe,” “unproven,” “speculative”).
Mechanism distinction within the GH-axis adjunct class. Tesamorelin and AOD-9604 are both “GH-axis-adjacent” but engage different receptor biology:
- Tesamorelin (GHRH-R agonist): pulsatile endogenous GH release → hepatic IGF-1 elevation → VAT-selective lipolysis via differential β3-AR / hormone-sensitive lipase / perilipin biology between visceral and subcutaneous adipose. IGF-1 elevation is a biomarker of activity and, at supraphysiological magnitudes, a clinical-concern signal warranting dose adjustment. Cancer-history contraindication is absolute per FDA label.
- AOD-9604 (hGH C-terminal fragment; no GHR engagement): lipolysis stimulation in adipose tissue via hypothesized β3-AR pathway involvement and lipogenesis inhibition; no IGF-1 elevation in animal models (the design-feature claim of the original Monash University / Metabolic Pharmaceuticals development hypothesis); chondroprotective activity in preclinical OA models (basis for the Australian TGA listing).
- The two compounds engage non-redundant biology — co-administration is mechanism-additive, not mechanism-duplicative — though the AOD-9604 contribution to a co-administration regimen is constrained by the evidence base (preclinical + sponsor-disclosed Phase 2b not peer-reviewed-published).
Synergistic use framing — co-administration is hypothesized additive; clinical evidence is preliminary. When tesamorelin + AOD-9604 are administered together (the protocol’s full-stack option), the hypothesized effect is additive VAT-selective lipolysis (tesamorelin GHRH-R-mediated) plus general adipose lipolysis (AOD-9604 GH-fragment-mediated). The clinical evidence supporting the combination is preliminary — no Phase 3 RCT evaluates the tesamorelin + AOD-9604 co-administration regimen; the rationale is mechanism-based and practitioner-experience-based, not RCT-confirmed (Pattern Z.research-precision applied; not “highly experimental” framing). §9 combination rules frames this honestly per Pattern Z anchor 5 and Anchor 4.
Tesamorelin’s “weight neutral effect” Limitation of Use is mechanism-accurate, not regulatory boilerplate. The Egrifta SV FDA label states: “EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect.” This is a mechanism-aligned regulatory framing: tesamorelin redistributes adipose tissue (visceral fat decreases substantially; subcutaneous fat may modestly increase; total body weight is approximately unchanged at population level over the trial duration). Patient-counseling beats anchor on visceral-fat redistribution + metabolic improvement at approximately neutral total weight — not on total-weight reduction. Counseling beats that frame tesamorelin as “fat-loss for weight loss” are misaligned with the mechanism and with the FDA label and are flagged for re-framing.
§10 calibration — Anchors 1–5 with adjunct-specific re-framing.
- Anchor 1 — Lead with what the adjunct stack IS. A body-composition adjunct strategy targeting visceral adipose tissue (tesamorelin) and providing investigational adjunctive lipolytic activity (AOD-9604), used alongside primary weight-management therapy. Not a standalone obesity treatment.
- Anchor 2 — Compounded vs FDA-approved. Tesamorelin is FDA-approved (Egrifta SV / Egrifta WR; specialty-pharmacy distribution; branded list price typically 2, 000–3,000+/month) and is also available through 503A / 503B compounding pathways (typically 200–500/month at the same daily dose). AOD-9604 is not FDA-approved for marketing claims for any drug indication; current US clinical access is 503A compounding (bulks list category 2). Tesamorelin has never been on the FDA shortage list — the 503A compounding pathway for tesamorelin operates under the standard patient-specific-prescription regulatory framework, NOT the FDA shortage-pathway enforcement-discretion windows that drove compounded-semaglutide and compounded-tirzepatide demand during 2022–2024.
- Anchor 3 — Pregnancy planning. Tesamorelin is Category X in the FDA label (absolute contraindication in pregnancy); IGF-1 crosses the placenta and the GH/IGF-1 axis is a tumor-promotion / abnormal-growth concern in pregnancy. AOD-9604 has no robust pregnancy-exposure data; reproductive-age caution warranted on absence-of-data basis, not on positive teratogenicity signal. Pre-conception planning carries the tesamorelin discontinuation decision (PK clearance is rapid — terminal half-life 26–38 minutes — but the GH/IGF-1 axis biology persists for days to weeks post-discontinuation). Anchor 3 LEADS with research-state framing of what is and is not known about the pregnancy-exposure biology, then carries the regulatory contraindication factually.
- Anchor 4 — Comparator framing — visceral-fat-targeted adjuncts vs broader weight-loss agents vs other body-composition tools. Two comparator axes are operative: (a) tesamorelin vs the GLP-1 / GIP / glucagon class on the VAT-reduction question — GLP-1-class agents also reduce VAT (substantially, in proportion to total weight loss; imaging substudies within STEP, SURMOUNT, SCALE demonstrate this); tesamorelin’s distinct contribution is VAT-selective mechanism without total-weight reduction, which is clinically distinctive for the visceral-fat-predominant residual-after-GLP-1 phenotype; (b) adjunct stack vs non-pharmacologic body-composition tools — DEXA-tracked resistance training, dietary intervention, sleep optimization, and the broader behavioral / metabolic toolkit are first-line for body-composition optimization in many phenotypes; the adjunct stack is appropriate when the pharmacologic mechanism class addresses a phenotype-specific component (residual VAT after GLP-1 response; MASLD/MASH where the GH-axis hepatic-fat mechanism is mechanistically additive; GLP-1-intolerant patient with visceral-adiposity-dominant phenotype). Cool-sculpting and other non-pharma localized-fat-reduction approaches are mechanistically distinct (apoptotic/cryolipolytic adipocyte destruction in subcutaneous depots; not visceral) and not direct comparators for the visceral-fat indication. §10.5 Anchor 4 framing presents the multi-dimensional comparator landscape factually, acknowledges each option’s advantages, and closes with shared-decision-making.
- Anchor 5 — Off-label tesamorelin use + investigational AOD-9604 use — DOMINANT for both. The dominant Pattern Z anchor for this protocol is Anchor 5. Tesamorelin off-label use in non-HIV populations is off-label use of an FDA-approved drug; the trial-population scope is the HIV-lipodystrophy enrollment (Falutz Phase 3; Stanley 2014 JAMA); the mechanism translation to non-HIV visceral adiposity is biologically plausible; the effect-size translation is practitioner-extrapolation, not Phase 3 confirmed in non-HIV populations. AOD-9604 use is investigational — the load-bearing published evidence is preclinical; the Phase 2b sponsor-disclosed data did not meet commercial-development thresholds and is not peer-reviewed-published. Counseling beats present the actual research-state factually (Pattern Z.research-precision), invite shared decision-making (Anchor 5), and do not pre-load with bias-vocabulary or with weight-loss-drug framing.
Injection framing — Pattern Z.injection-framing applies. Both compounds are administered as daily subcutaneous injections (tesamorelin 1.4 mg or 2 mg SC daily, abdominal site; AOD-9604 250–500 mcg SC daily, fasted AM). SC self-injection is a routine clinical skill, taught in one clinical visit, refined over the first few self-administrations — equivalent to daily insulin self-injection, daily fertility-hormone self-injection, daily biologic self-injection routinely taught across endocrinology and primary-care practice. The protocol does NOT default-frame daily SC dosing as a “burden,” “barrier,” “the hardest part,” or “what patients struggle with most.” Substantive titration-management discussion is dose tolerance (injection-site reactions, arthralgia, edema, glucose elevation), not injection mechanics.
Research-precision framing — Pattern Z.research-precision applies, particularly to AOD-9604. AOD-9604 evidence base is “Phase 2 / preliminary; development-discontinued 2007; preclinical animal-model + sponsor-disclosed Phase 2b not peer-reviewed-published; current evidence base is research-state-incomplete” — explicit, fact-based, not “highly experimental” or “fringe.” The protocol names the actual research base (trial phase, sponsor, year, publication state, magnitude where reported) and lets the clinician evaluate.

Pattern Z anti-steering discipline summary across the protocol. Anchor 1 (lead with what the adjunct stack IS); Anchor 2 (compounded vs FDA-approved tesamorelin — operational characteristics + quality criteria framed factually); Anchor 3 (pregnancy planning — research-state lead + Category X regulatory framing carried factually); Anchor 4 (multi-dimensional comparator framing — VAT-reduction options across mechanism classes; not-steering); Anchor 5 (off-label tesamorelin + investigational AOD-9604 — dominant anchor; research-state-precise framing throughout). Pattern Z.injection-framing across the protocol. Pattern Z.research-precision across the protocol (particularly load-bearing for AOD-9604 framing).

Indication scope and patient phenotypes
Selection criteria (inclusion / exclusion / contraindications)
Pre-treatment workup
Initiation protocol
Maintenance protocol
Side-effect management
Plateau and non-response algorithm
Discontinuation and tapering
Combination rules
Patient counseling beats (Pattern Z calibration-anchor-compliant)
Source citations
Clinical decision tree

Appendices

A. Verification gate — the four-step cycle applied to this protocol
B. Pattern discipline summary — adjunct-specific enforcement
C. Byte-count audit + production commits

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol covers a body-composition adjunct strategy for visceral and targeted adipose tissue reduction, used alongside primary weight-management therapy. It is NOT a standalone obesity treatment.

The adjunct stack — tesamorelin as the load-bearing FDA-approved-for-marketing-claims component (for HIV-associated lipodystrophy on-label; for non-HIV visceral adiposity off-label), with AOD-9604 as an investigational adjunctive lipolytic option — targets a specific body-composition phenotype: visceral adipose tissue (VAT) accumulation in adult patients whose central adiposity is the dominant clinical concern, either alongside a primary GLP-1-class chronic weight management regimen (most common scenario) or as the primary visceral-fat-targeted intervention in patients where GLP-1-class therapy is not feasible. The protocol’s structural authority is the Module 5 Protocol Template; the content authority is the canonical files at /Peptides/Tesamorelin.md and /Peptides/AOD-9604.md plus the M5.5 v3 lesson plus the Falutz / Stanley / 2025-meta-analysis primary literature.

Pattern R.1 enforcement at this section: §1 opens with what the adjunct stack is (a body-composition adjunct strategy for VAT-selective fat reduction) and for whom (patients with visceral-fat-predominant phenotypes on or alongside primary weight management). The “NOT a standalone obesity treatment” framing appears explicitly in the opening because the adjunct-vs-standalone distinction is the load-bearing protocol framing — but the framing leads with what the stack IS, then states what it is not, not the reverse.

Pattern R.2 enforcement: indication scope is locked at this section before downstream sections (selection criteria, workup, initiation, maintenance, AE, combination, counseling) develop their content. The adjunct-specific framing — that tesamorelin and AOD-9604 are body-composition adjuncts to a primary weight-management strategy — is the design-time anchor that all downstream sections inherit. A protocol that drifts into “tesamorelin as a weight-loss drug” framing mid-draft would fail Pattern R.2 at the design step; this protocol prevents that drift by locking the adjunct framing in §1.1 and carrying it explicitly through §10 counseling beats.

Pattern AA + AA.marketing-claims discipline at this section: every indication claim is precise. Tesamorelin is FDA-approved for marketing claims for HIV-associated lipodystrophy abdominal-fat reduction (Egrifta SV / Egrifta WR; BLA022505) — the labeled indication, not “for visceral fat” generically, not “for weight loss,” not “for body recomposition.” Off-label use for visceral adiposity in non-HIV populations is off-label use of an FDA-approved-for-marketing-claims drug — distinct from research-use-only or non-FDA-approved compound use, and distinct from “no FDA approval” framing. AOD-9604 is not FDA-approved for marketing claims for any drug indication; the 2007 FDA GRAS determination applies to oral use as a food-supplement ingredient (food-regulatory category distinct from drug approval); the Australian TGA listing is for joint/cartilage as a complementary medicine ingredient (a regulatory pathway distinct from FDA drug approval). The FDA bulks-list category-2 status applies to the 503A compounding pathway. Each regulatory claim in this section is anchored to its specific regulatory framework, not generalized.

1.2 Indication categories

The Module 5 Protocol Template enumerates eight indication categories. For this adjunct protocol, the operative indication categories are narrower than for a primary GLP-1-class weight-management protocol — the adjunct stack does not directly address T2D glycemic control, CV risk reduction, HFpEF, CKD, OSA, or chronic weight management as a standalone indication. The two indication categories that apply, in their adjunct-specific framing:

HIV-associated lipodystrophy abdominal-fat reduction — the on-label tesamorelin indication. This is the FDA-approved-for-marketing-claims indication for tesamorelin (BLA022505; Egrifta original FDA approval November 2010; Egrifta SV FDA approval June 2019; Egrifta WR FDA approval 2024). Patient phenotype: HIV-infected adults on antiretroviral therapy with established abdominal-fat accumulation (the antiretroviral-therapy-associated lipodystrophy phenotype historically — modern integrase-inhibitor-era weight-gain phenotypes also documented). Endpoint: VAT reduction by CT or MRI imaging; trunk-fat reduction by DEXA; metabolic-marker improvement (triglycerides, lipid ratios). Pivotal evidence: Falutz 2007 NEJM PMID 18057338 (n=412; 26-week primary readout; VAT −15.2% tesamorelin vs +5.0% placebo; between-group treatment difference −20.2 percentage points); Falutz 2008 AIDS PMID 18690162 (52-week extension; VAT reduction ~−18% from baseline on continued therapy; reversal on switch to placebo); Falutz 2010 JAIDS PMID 20101189 (pooled safety analysis; n>800; safety-and-ADA characterization). The 2025 body-composition meta-analysis (PMID 41545261) is the Level I synthesis of the Phase 3 program.
Body-composition adjunct — visceral adipose tissue reduction, as adjunct to a primary weight-management strategy (most commonly GLP-1-class). This is the off-label tesamorelin indication for non-HIV visceral adiposity, with the AOD-9604 investigational adjunctive option layered in for clinicians and patients who choose to include it. Patient phenotype: adults with visceral-fat-predominant body-composition profile, typically with concurrent metabolic comorbidity (insulin resistance, MASLD/MASH risk, dyslipidemia, hypertension), often in one of four scenarios — (a) residual visceral adiposity after substantial GLP-1-class weight-loss response (the “stubborn belly after sema/tirz” phenotype); (b) visceral-fat-predominant phenotype with concurrent MASLD/MASH where the GH-axis hepatic-fat mechanism (Stanley 2014 JAMA PMID 25038357) is mechanistically additive; (c) body-recomposition phenotype in midlife adults seeking visceral-fat reduction with lean-mass preservation; (d) GLP-1-intolerant patient where visceral adiposity is the dominant clinical concern. Endpoint: VAT reduction (DEXA-tracked or imaging-tracked); waist-circumference reduction; metabolic-marker improvement. Evidence base: extrapolation from the Falutz Phase 3 HIV-lipodystrophy program plus Stanley 2014 JAMA RCT; practitioner-experience-anchored in functional-medicine and concierge-clinic populations; no Phase 3 RCT of tesamorelin in a non-HIV obesity population exists as of 2026-05-13 — the off-label use is biologically-plausible extrapolation, not Phase-3-confirmed in non-HIV populations. Pattern Z.research-precision: this is research-state-incomplete for the non-HIV-population-specific effect-size question, not “highly experimental” or “unproven.”

The six other Module 5 indication categories (T2D glycemic control, chronic weight management as standalone, cardiovascular risk reduction, HFpEF, MASH as standalone indication, CKD in T2D, OSA) are not indications for this adjunct protocol. Where any of these indications co-exists in a patient’s clinical picture, the primary therapy is the indication-specific FDA-approved-for-marketing-claims agent (e.g., semaglutide for ESSENCE-anchored MASH; semaglutide for SELECT-anchored CV risk reduction in obesity + CVD without diabetes; semaglutide for FLOW-anchored CKD in T2D; semaglutide / liraglutide for STEP / SCALE-anchored chronic weight management; tirzepatide for SURMOUNT / SURPASS / SURMOUNT-OSA-anchored indications). The adjunct stack is layered onto that primary therapy when the visceral-fat-specific component remains as a clinical concern after primary-therapy response, or when the patient cannot tolerate primary therapy and visceral adiposity is the dominant phenotype.

1.3 Phenotype-targeting taxonomy

The Module 5 phenotype taxonomy (Protocol Template §1.3) applies, with adjunct-specific refinement on the dimensions most relevant to visceral-fat targeting:

Adiposity distribution — the load-bearing phenotype dimension for this protocol. Visceral-dominant vs subcutaneous-dominant. Android (apple-shaped, central-fat-predominant) vs gynoid (pear-shaped, gluteo-femoral-predominant). Ectopic-fat-positive (liver steatosis on imaging; pancreatic steatosis; epicardial fat by CT or echo) vs ectopic-fat-negative. The adjunct stack’s primary target is the visceral-dominant, android-distribution, ectopic-fat-positive sub-phenotype — typical in metabolic-syndrome adults with central obesity disproportionate to total BMI, in midlife (and post-menopausal female) adults with re-distribution toward central adiposity, and in HIV-lipodystrophy patients (the on-label indication phenotype).
Metabolic phenotype. Insulin-resistant obesity (typical co-presentation with visceral-fat predominance) is the primary metabolic phenotype the adjunct stack addresses. Hepatic-IR-dominant phenotypes with MASLD/MASH are particularly relevant for tesamorelin given the Stanley 2014 JAMA hepatic-fat mechanism. Adipose-IR-dominant phenotypes are also targeted. The adjunct stack is not typically indicated for normoinsulinemic / metabolically-healthy obesity — that phenotype is better-served by behavioral / nutritional / activity intervention or by primary GLP-1-class weight management if pharmacologic intervention is indicated.
Appetite phenotype. This is not an indication-relevant dimension for the adjunct stack — neither tesamorelin nor AOD-9604 engages the central appetite pathways (GLP-1R / GIPR / glucagon-R / amylin-R / leptin-R) that anchor primary-class weight-management appetite-suppression mechanism. The adjunct stack does not address hyperphagia, slow-satiety, hedonic-eating, or nocturnal-eating phenotypes; those phenotypes are GLP-1-class indications.
Energy-expenditure phenotype. Tesamorelin’s GH-axis biology has modest effects on resting energy expenditure (REE) and lean-mass biology; the adjunct stack may be of particular interest in the adaptive-thermogenesis-prone phenotype (post-prior-weight-loss patients where REE is suppressed relative to mass) and in the low-REE-for-mass phenotype (midlife adults with sarcopenic obesity component). AOD-9604’s energy-expenditure profile is incompletely characterized in human populations.
Comorbidity load. Adjunct-stack patients are typically polycondition — visceral adiposity + insulin resistance + MASLD ± dyslipidemia ± hypertension ± OSA. The adjunct-stack rationale strengthens with polycondition presentation because the GH-axis mechanism addresses multiple components (VAT redistribution; hepatic fat; lipid-marker improvement) that align with multiple co-morbidity dimensions.
Pharmacologic history. The most relevant pharmacologic-history dimension is prior or concurrent GLP-1 RA exposure: the typical adjunct-stack candidate is on a GLP-1 RA at maintenance dose with documented response, presenting with residual visceral adiposity disproportionate to total-fat reduction. Adjunct-stack candidates who have NOT tried a GLP-1 RA and whose primary clinical concern is total-weight reduction are routed first to a GLP-1-class evaluation; the adjunct stack is layered later. Prior HIV-lipodystrophy treatment history (for the on-label HIV indication) is the alternate pharmacologic-history dimension.
Life-stage modifier. Reproductive-age female patients carry the Section 8 pre-conception discontinuation consideration (tesamorelin is Category X per FDA label; AOD-9604 has insufficient pregnancy-exposure data). Older adults (≥65) with concurrent sarcopenia risk are a phenotype where the GH-axis biology may be particularly relevant (lean-mass-preserving aspect of GH/IGF-1 axis activation) but where IGF-1 elevation should be carefully monitored. Adolescent populations are not indications for the adjunct stack — tesamorelin is FDA-approved for adults; AOD-9604 has no pediatric data.

A protocol identifies which phenotype dimensions are primary targets (visceral-fat-predominant, insulin-resistant, MASLD-positive, polycondition with central-adiposity-dominant component), secondary targets (post-GLP-1-response residual visceral adiposity; adaptive-thermogenesis-prone post-prior-weight-loss; midlife body-recomposition with sarcopenia concern), and tertiary / off-target (appetite-phenotype-dominant obesity without visceral-fat predominance; normoinsulinemic / metabolically-healthy obesity; reproductive-age female with active conception planning; pediatric / adolescent populations; cancer-history patients with active or recent malignancy — Section 2.4 contraindication; pituitary-axis-disruption history — Section 2.4 contraindication).

1.4 Cross-reference to case construction

Worked clinical cases in this protocol (presented in §§4, 5, 6, 7, 8 examples and in §12 worked decision-tree application) are constructed against the phenotype taxonomy in §1.3. Each case anchors to a specific phenotype dimension — visceral-dominant adiposity with concurrent MASLD; residual VAT after GLP-1 response; midlife body-recomposition phenotype; HIV-lipodystrophy on-label indication. The case-construction discipline follows the M5.10 case-construction conventions and the M5.5 v3 lesson’s clinical-vignette structure.

1.5 Worked example — Tesamorelin + AOD-9604 adjunct stack indication scope

Indication 1 — HIV-associated lipodystrophy abdominal-fat reduction (FDA-approved for marketing claims; tesamorelin on-label). Label (verbatim from Egrifta SV prescribing information, BLA022505): “EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.” Limitations of Use: (1) Long-term cardiovascular safety has not been established; (2) EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect; (3) EGRIFTA SV is not shown to improve compliance with anti-retroviral therapies.

Pivotal evidence: Falutz 2007 NEJM (PMID 18057338). Multicenter, randomized, double-blind, placebo-controlled trial; n=412 HIV-infected adults with abdominal fat accumulation; randomized 2:1 to tesamorelin 2 mg SC daily versus placebo for 26 weeks. Primary endpoint: percentage change in VAT by single-slice CT at L4–L5. Pattern V.metric-axis disclosure: the per-arm 26-week change was −15.2% with tesamorelin vs +5.0% with placebo (per-arm change-from-baseline metric); the between-group treatment difference was −20.2 percentage points (between-group treatment-difference metric); p<0.001. Both metric-axes are reported in the trial publication; this protocol’s effect-size citations carry the metric-axis qualifier explicitly at first-mention. Secondary endpoints: trunk fat reduction by DEXA significant vs placebo (between-group difference approximately −10%; p<0.001); subcutaneous adipose tissue no significant change vs placebo (confirming visceral-fat-selective lipolysis); triglycerides −50 mg/dL with tesamorelin vs +9 mg/dL with placebo (per-arm change-from-baseline; p<0.001); total cholesterol / HDL ratio −0.31 with tesamorelin vs +0.21 with placebo (p<0.001); IGF-1 +81% with tesamorelin (mean rise, within upper end of age-appropriate reference range); glycemic measures no significant differences between groups.

Falutz 2008 AIDS (PMID 18690162). 26-week extension phase of Falutz 2007 NEJM trial; patients re-randomized at week 26 to continue tesamorelin or switch to placebo (T-T, T-P, P-T arms); analyzed at week 52. Continued tesamorelin × 52 weeks: VAT reduction approximately −18% from baseline; trunk fat reduction maintained; triglyceride reduction maintained. Patients who switched from tesamorelin to placebo at week 26: VAT reduction reversed — the visceral-fat-redistribution effect requires continued therapy (this is a chronic-therapy mechanism, not an induce-then-maintain mechanism; this finding is load-bearing for §5 maintenance and §8 discontinuation framing).

Falutz 2010 JAIDS (PMID 20101189). Pooled safety analysis of two Phase 3 trials; total n>800; 12-month treatment program. Pooled VAT reduction confirmed; tesamorelin generally well tolerated; anti-tesamorelin antibody (ADA) development: ~50% of treated patients developed ADAs over 52-week observation period (typically non-neutralizing; some patients showed reduced IGF-1 response in association with ADA presence). Glucose effects: small but measurable elevation in glucose and HbA1c in tesamorelin arm vs placebo — within clinically tolerable range for non-diabetic patients but warranting close monitoring in prediabetic or T2D patients.

Stanley 2014 JAMA (PMID 25038357). Single-center RCT (Massachusetts General Hospital / Harvard Medical School); n=50 HIV-infected adults; tesamorelin 2 mg SC daily vs placebo × 12 months. Co-primary endpoints: VAT change by CT; hepatic fat fraction by magnetic resonance spectroscopy. VAT reduction significant vs placebo (confirming Falutz Phase 3 result in independent single-center RCT); hepatic fat fraction reduction significant vs placebo (extending evidence base from VAT-only into hepatic steatosis); improvements in hepatic fibrosis markers; subcutaneous adipose tissue no significant change. Stanley is first-author distinct from the Falutz cluster — Pattern AB.1 disambiguation discipline applies; this protocol’s citations preserve the Stanley vs Falutz first-author distinction throughout.

Tesamorelin 2025 body-composition meta-analysis (PMID 41545261). Level I synthesis of Phase 3 program data confirming: tesamorelin significantly reduces trunk fat and VAT while preserving or increasing lean mass over 26–52 week treatment periods. Directional finding consistent with Falutz triplet and Stanley 2014 JAMA primary RCTs.

Phenotype primary targets for the on-label indication: HIV-infected adults on antiretroviral therapy with established abdominal-fat accumulation phenotype. Modern integrase-inhibitor-era observational data (PMID 38905488) extends the relevance into integrase-inhibitor-associated weight-gain phenotypes.

Indication 2 — Body-composition adjunct for visceral adipose tissue reduction in non-HIV populations (off-label for tesamorelin; investigational for AOD-9604). Tesamorelin off-label use for visceral adiposity in non-HIV populations operates under the broader regulatory umbrella of off-label use of an FDA-approved-for-marketing-claims drug — operationally and regulatorily distinct from research-use-only or compounded non-FDA-approved peptide use. The evidence base for non-HIV use is biologically-plausible mechanism translation from the Falutz Phase 3 program plus practitioner-experience extrapolation; no Phase 3 RCT in a non-HIV obesity population has been conducted as of 2026-05-13. The practitioner-consensus working effect-size anchor for non-HIV populations is the Falutz −15% to −18% VAT-reduction figure, recognizing this is research-state extrapolation, not Phase-3-confirmed.

AOD-9604 evidence base for any human-obesity indication is preclinical animal-model (Heffernan / Ng cluster 2000–2001; PMIDs 10950816, 11146367, 11673763, 11713213) plus sponsor-disclosed Phase 2b human-obesity trial result (2006–2007; not peer-reviewed-published in PubMed-indexed form). The practitioner-consensus “~2.6 kg weight loss vs placebo at 12 weeks” figure that appears in some functional-medicine literature is sponsor-disclosed Phase 2b data, not a peer-reviewed-published primary citation. Pattern AB.1 caution: a citation of “Heffernan et al. J Endocrinol 2001” for the 2.6-kg human weight-loss figure is verifiably incorrect — Heffernan 2001 publications in the J Endocrinol / Endocrinology cluster are animal studies; PMID 11713213 specifically is a mouse / β3-AR-knockout study, not a human Phase 2 trial. The honest framing is sponsor-disclosed Phase 2b result, development discontinued 2007 after the program did not meet sponsor commercial-development thresholds.

Phenotype primary targets for the off-label / investigational adjunct indication: (a) residual visceral adiposity post-GLP-1-class weight-loss response (the “stubborn belly” phenotype in patients on semaglutide / tirzepatide / liraglutide / orforglipron at maintenance dose with substantial total-weight response and disproportionate residual central adiposity); (b) visceral-fat-predominant phenotype with concurrent MASLD/MASH where the GH-axis hepatic-fat mechanism (Stanley 2014 JAMA) is mechanistically additive to the GLP-1-axis hepatic effect (which is largely an indirect consequence of total-weight reduction); (c) body-recomposition phenotype in midlife adults seeking visceral-fat reduction with lean-mass preservation; (d) GLP-1-intolerant patient (severe persistent GI AE, recurrent acute pancreatitis history, or other GLP-1-class limitation) where visceral adiposity is the dominant clinical concern and the GH-axis mechanism class is a feasible alternative.

Investigational extensions and off-target framing. Tesamorelin has supporting RCT data for cognitive function in MCI and healthy older adults (Baker 2012 Archives of Neurology / JAMA Neurology predecessor; PMID 22869065) and for hepatic transcriptomic improvement in HIV-NAFLD (Stanley 2020 RCT sub-study; PMID 32701508). The cognitive-function evidence base supports an investigational extension for cognitive enhancement in aging — this is NOT an indication for this body-composition adjunct protocol; clinicians using tesamorelin for the cognitive indication should reference a cognition-specific protocol, not this VAT-targeted protocol. AOD-9604 has chondroprotective preclinical evidence (PMID 26275694) supporting the Australian TGA listing for joint/cartilage as a complementary medicine ingredient — this is NOT an indication for this protocol; the chondroprotective application is regulatorily distinct from any obesity / body-composition indication.

Phenotype primary targets across the two indications: the §1.3 phenotype-taxonomy dimensions that this protocol’s trial-program-and-extrapolation evidence base populates heavily are visceral-dominant adiposity, insulin-resistant metabolic phenotype, MASLD-positive ectopic-fat-positive phenotype, post-GLP-1-response residual-VAT phenotype, midlife body-recomposition phenotype, and HIV-lipodystrophy on-label phenotype. Phenotypes under-represented in the trial program and thus phenotype-tertiary for this protocol: appetite-driven obesity without visceral-fat predominance (better-served by primary GLP-1 class); normoinsulinemic / metabolically-healthy obesity; pediatric / adolescent populations; reproductive-age female with active conception planning (Section 8 discontinuation arithmetic applies); active or recent malignancy (Section 2.4 hard contraindication); active pituitary-axis disruption (Section 2.4 hard contraindication).

Pattern AB.4 standing scan applied to §1.5. Every PMID above was verified by content (author, title, journal, year, study type) against PubMed at production-step; the trial-name-to-PMID mapping caught the Pattern AB.1 inversion documented in the M5.5 v3 lesson — Falutz NEJM 2007 tesamorelin Phase 3 is PMID 18057338, not PMID 17960012 (which is Vermorken et al, head/neck cancer, NEJM 2007 — same-journal-same-year cluster inversion). This protocol uses PMID 18057338 throughout; the Bibliography (§11) carries verified-identifier table.

Pattern Z calibration self-audit at §1.5. The indication scope opens with what the adjunct stack IS (visceral-fat-targeted body-composition adjunct, FDA-approved for HIV-LD, off-label for non-HIV visceral adiposity, with investigational AOD-9604 layer); regulatory status precisely framed at each indication (FDA-approved-for-marketing-claims with specific label language; off-label use of an FDA-approved drug; investigational with research-state-precise framing of the evidence base); the “NOT a standalone obesity treatment” framing appears explicitly because the adjunct-vs-standalone distinction is load-bearing — but lead-framing is what the stack IS; the not-this framing follows. Pattern R.1 / R.2 / AA / AA.marketing-claims / Z compliance.

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who the adjunct stack is for, who it is not for, and who it must not be given to. §2 operationalizes the §1 indication scope into actionable clinical screening criteria, structured into three sub-blocks: inclusion criteria (positive criteria — the patient phenotype the trial program enrolled and where the off-label / investigational use is biologically reasonable), relative exclusion criteria (clinician-judgment phenotypes where benefit is uncertain or risk is elevated), and hard contraindications (patients in whom the molecule must not be used per FDA label).

Pattern R.1 enforcement at this section: §2 opens with inclusion criteria — who the adjunct stack is for — before exclusions and contraindications. The 2.2 inclusion → 2.3 relative-exclusion → 2.4 contraindication ordering is Pattern R.1 design-time enforcement; reversing the order is a structural framing failure that steers clinicians away from the stack before they have read the inclusion case.

Pattern AA enforcement: every contraindication is anchored to its source classification — Egrifta SV FDA label absolute contraindication (per BLA022505 prescribing information), Egrifta SV labeled precaution / cautionary use, post-marketing pharmacovigilance signal, or clinician-judgment based on mechanism. AOD-9604 contraindications are framed as prudent clinical caution based on absent positive data, not as labeled regulatory contraindication (the compound has no FDA-approved-for-marketing-claims label).

2.2 Inclusion criteria — the trial-enrolled and label-permitted (or biologically plausible) phenotype

Indication 1 — HIV-associated lipodystrophy abdominal-fat reduction (tesamorelin on-label per Egrifta SV PI):

HIV-infected adult patient, age ≥18 years (FDA label specifies adult population)
Documented antiretroviral therapy with established abdominal-fat accumulation (the Falutz Phase 3 enrollment phenotype; modern integrase-inhibitor-associated weight-gain phenotypes also documented per PMID 38905488)
Hypothalamic-pituitary axis intact (no hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, head trauma — see §2.4 hard contraindications)
No active malignancy and any prior malignancy is inactive AND treatment-complete (§2.4 hard contraindication; the Egrifta SV label is unambiguous on this criterion)
Not pregnant (Category X per FDA label; pregnancy is a §2.4 hard contraindication and a §8 immediate discontinuation trigger)
No known hypersensitivity to tesamorelin or mannitol-based diluent excipients
Pre-treatment laboratory and clinical workup complete per §3

Indication 2 — Body-composition adjunct for visceral adipose tissue reduction in non-HIV populations (off-label for tesamorelin; investigational for AOD-9604):

Adult patient, age ≥18 years (no formal upper bound; the GH-axis biology is age-relevant and IGF-1 monitoring is more important in older adults given baseline IGF-1 decline with age)
Visceral-fat-predominant body-composition profile, documented by waist circumference (typically ≥102 cm in men / ≥88 cm in women per ATP-III metabolic syndrome criteria; lower thresholds apply per ethnicity-specific guidance) and/or by DEXA or imaging (CT / MRI visceral-fat quantification) if available
One of the four adjunct-indication scenarios from §1.5 Indication 2: (a) residual visceral adiposity after substantial GLP-1-class weight-loss response (typically ≥6 months on maintenance dose with ≥5% total weight loss); (b) visceral-fat-predominant phenotype with concurrent MASLD/MASH (documented by imaging, FibroScan, or biopsy if available); (c) midlife body-recomposition phenotype with concurrent sarcopenia or lean-mass-preservation concern; (d) GLP-1-intolerant patient with visceral-adiposity-dominant phenotype
Same regulatory / contraindication criteria as Indication 1 — no active malignancy, intact pituitary axis, no pregnancy, no hypersensitivity
Informed consent documented for off-label use of tesamorelin (FDA-approved-for-marketing-claims for HIV-LD; off-label for non-HIV visceral adiposity); informed consent documented for investigational use of AOD-9604 if AOD-9604 layer is included (Pattern Z anchor 5 framing)
Patient on or co-managed with primary weight-management therapy where total-weight reduction is part of the clinical goal — the adjunct stack is not typically initiated as monotherapy when total-weight reduction is part of the patient’s goal, because the GLP-1 class is the load-bearing weight-management agent and the adjunct stack adds the visceral-fat-specific component

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where the molecule is not contraindicated but where benefit is uncertain, risk is elevated, or trial data are sparse. Structure: state the criterion; state the underlying concern; state the magnitude of evidence; state the recommended clinician-judgment posture.

Pre-existing type 2 diabetes mellitus (or prediabetes). Tesamorelin produces measurable but typically modest glucose-metric elevation in Phase 3 data (HbA1c rise on the order of 0.1–0.3% in Falutz Phase 3 non-diabetic enrollment; effect potentially larger in T2D / prediabetic patients due to baseline insulin-resistance burden and reduced beta-cell reserve). The mechanism is GH-mediated counterregulatory effect on insulin sensitivity — GH-axis activation transiently increases hepatic glucose output and reduces peripheral insulin sensitivity. Pre-existing T2D / prediabetes is a relative exclusion with enhanced glucose monitoring posture (HbA1c at baseline / weeks 4 / 8 / 12 / 26 / annual; close coordination with T2D management team; threshold for dose-down or discontinuation is HbA1c rise >0.5% from baseline or fasting glucose entering diabetic range). Patients on concurrent insulin / sulfonylurea require especially careful glucose-monitoring coordination.
Severe gastrointestinal disease (active IBD flare; severe gastroparesis). Tesamorelin’s AE profile does not include the GLP-1-class dominant GI AE pattern (nausea, vomiting, diarrhea, constipation, eructation are NOT typical tesamorelin AEs); the relative exclusion in severe GI disease is therefore less pronounced than for GLP-1-class therapy. Clinician judgment.
Severe renal impairment (eGFR <30). The Falutz Phase 3 program did not enroll severe-CKD patients; tesamorelin clearance is primarily through hepatic and proteolytic pathways with limited renal contribution to elimination at terminal half-life 26–38 minutes. Relative exclusion with clinician-judgment posture; nephrology co-management if eGFR <30 and the adjunct is being considered.
Severe hepatic impairment (Child-Pugh C). Tesamorelin has hepatic-fat-reduction biology (Stanley 2014 JAMA) and the GH-axis modulates hepatic insulin sensitivity; severe hepatic impairment is outside the Phase 3 enrollment range and the clinical translation is uncertain. Relative exclusion with hepatology co-management.
Active carpal tunnel syndrome or fluid-retention-prone comorbidity. GH-axis activation produces fluid retention (peripheral edema in approximately 5–10% of Falutz Phase 3 enrollment; arthralgia in approximately 10–15%); active carpal tunnel or symptomatic fluid-retention comorbidity may worsen on tesamorelin. Clinician judgment with patient counseling on expected fluid-retention timeline (typically self-limiting over 4–8 weeks at stable dose).
Active acromegaly features or supraphysiological baseline IGF-1. Baseline IGF-1 above the age-appropriate reference range, or clinical features of acromegaly (acral changes, prognathism, frontal bossing, soft-tissue overgrowth), is a relative exclusion — the GH-axis pharmacology is counterproductive in patients whose endogenous GH/IGF-1 axis is already activated above physiologic baseline. Pituitary axis evaluation (TSH, prolactin, ACTH, FSH/LH, dynamic GH testing if indicated) and endocrinology co-management before initiation in this phenotype.
Reproductive-age female with active conception planning or active pregnancy intent. Tesamorelin is Category X per FDA label; pregnancy is a §2.4 hard contraindication. Pre-conception planning within tight timeline is a relative exclusion at the §2 selection-criteria step (the §8 discontinuation arithmetic applies — tesamorelin terminal half-life is short at 26–38 minutes, suggesting rapid PK clearance, but the GH/IGF-1 axis effects persist longer; pre-conception discontinuation is appropriate but the timeline arithmetic differs from the GLP-1 class).
AOD-9604 evidence-base preference question. Patients who specifically request AOD-9604 inclusion based on social-media positioning should be counseled honestly on the evidence base (Pattern Z.research-precision; §10.5 Anchor 5 framing) before the decision to include or exclude the AOD-9604 layer is finalized. This is a clinician-judgment posture, not a formal exclusion criterion — but the informed-consent discussion is load-bearing for the AOD-9604 layer specifically.
Patient on concurrent supraphysiological exogenous growth hormone (somatropin) therapy. Direct exogenous GH suppresses endogenous GH production via negative feedback; concurrent tesamorelin (a GHRH-R agonist that works through endogenous pituitary somatotrophs) is mechanistically counterproductive. Coordinate with the patient’s endocrinology / GH-management team to determine which axis intervention is appropriate.

2.4 Hard contraindications — boxed warnings, labeled contraindications, and absolute clinical-mechanism contraindications

Hard contraindications for tesamorelin are absolute per Egrifta SV FDA label (BLA022505). AOD-9604 lacks a formal FDA-approved label; hard contraindications for AOD-9604 are based on mechanism-parallel reasoning to tesamorelin plus prudent clinical caution.

Tesamorelin hard contraindications (verbatim from Egrifta SV FDA label):

Disruption of the hypothalamic-pituitary axis. Hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, head trauma. The mechanism rationale is mechanically required: tesamorelin works through GHRH-R agonism on endogenous pituitary somatotrophs. A patient with disrupted pituitary axis cannot respond to GHRH stimulation; the drug has no expected therapeutic effect and the unmodulated pharmacology may produce unpredictable effects. This is an absolute contraindication, not a relative one — the mechanism cannot operate.
Active malignancy. Any preexisting malignancy must be inactive AND treatment-complete prior to initiating tesamorelin therapy per FDA label. The mechanism rationale is GH/IGF-1 mitogen biology — GH and IGF-1 are growth factors with theoretical tumor-promotion biology for many tumor types (particularly hormone-responsive tumors). The label does not specify a duration of remission required, but standard clinical practice applies the “inactive AND treatment complete” criterion conservatively (typically interpreted as ≥2 years remission and ≥6 months post-treatment completion for solid tumors, though tumor-type-specific considerations should be individualized in consultation with oncology). For hematologic malignancies and for tumors with documented IGF-1-axis biology (breast cancer, prostate cancer, colorectal cancer with established IGF-1R pathway involvement), longer remission intervals and more conservative cancer-history posture may be appropriate. This is an absolute contraindication per FDA label — not a “relative” or “clinician-judgment” criterion when active or treatment-incomplete malignancy is present.
Pregnancy (Category X). IGF-1 crosses the placenta; modifying visceral adipose tissue offers no fetal benefit and could produce harm via fetal-growth axis modulation. Pregnancy is an absolute contraindication; pregnancy discovery during therapy is an immediate-discontinuation trigger (§8). Pre-conception planning carries the discontinuation arithmetic per §8.
Known hypersensitivity to tesamorelin or excipients. Mannitol-based diluent and sterile water for injection are the formulation components; documented serious hypersensitivity to any component is an absolute contraindication.

AOD-9604 hard contraindications (parallel reasoning; no formal FDA-approved label):

Active malignancy. Although AOD-9604 does not elevate IGF-1 in animal models (the design-feature claim of the original development program), prudent clinical caution applies — preclinical mechanism is incompletely characterized at the molecular-target level, and any compound being investigated in cancer-history patients warrants conservative posture. Active malignancy is treated as an absolute contraindication for AOD-9604 by clinical-judgment parallel to tesamorelin.
Pregnancy and lactation. Insufficient pregnancy / lactation exposure data; reproductive toxicity not characterized in human studies. Pregnancy and active conception planning are absolute contraindications by clinical-judgment posture pending data establishment.
Known hypersensitivity to AOD-9604 or compounding-pharmacy excipients. Documented serious hypersensitivity to any component is an absolute contraindication.

2.5 Worked example — Tesamorelin + AOD-9604 adjunct stack selection criteria

Worked example A — non-HIV adult initiating adjunct stack for residual visceral adiposity after GLP-1-class response. A 53-year-old female, BMI 28 (down from baseline 34 over 18 months on semaglutide 2.4 mg weekly per M5.2 Wegovy CWM protocol), waist circumference 102 cm (down from baseline 118 cm), known MASLD on ultrasound + FibroScan CAP 290 dB/m (low-end indeterminate steatosis range), HbA1c 5.6 (non-diabetic; pre-diabetic baseline normalized on semaglutide-mediated weight loss), no T2D, no active malignancy (history of stage 0 ductal carcinoma in situ status post-lumpectomy 2017 — surveillance mammography clear annually × 8 years; treatment complete; in remission >2 years), no pituitary-axis history, post-menopausal (no conception-planning concern), on rosuvastatin 10 mg daily for dyslipidemia, no current carpal tunnel symptoms, no severe GI / renal / hepatic disease.

Selection-criteria walkthrough.

Inclusion (Indication 2): age ≥18 — yes; visceral-fat-predominant phenotype with concurrent MASLD — yes; one of four adjunct-indication scenarios — scenario (a) residual visceral adiposity post-GLP-1 response, plus scenario (b) visceral-fat-predominant with concurrent MASLD; informed consent for off-label tesamorelin use documented; patient is on primary GLP-1 weight-management therapy.

Relative exclusion: pre-existing T2D / prediabetes — no (baseline HbA1c 5.6, no prediabetes diagnosis); severe GI disease — no; severe renal/hepatic impairment — no (MASLD is mild-to-moderate, not Child-Pugh C); active carpal tunnel — no; supraphysiological baseline IGF-1 / acromegaly features — to be confirmed at §3 workup; reproductive-age female with conception planning — no (post-menopausal).

Hard contraindications: disrupted pituitary axis — no; active malignancy — needs careful evaluation. DCIS status post-lumpectomy 2017 with 8 years clear surveillance is consistent with the FDA-label “inactive AND treatment-complete” criterion. DCIS is hormone-responsive biology, so the cancer-history posture is more conservative — co-management with the patient’s oncology / breast-surgery team is appropriate before initiation, and the patient must explicitly understand and consent to the GH/IGF-1-axis-activation context. Standard clinical-judgment posture: proceed with tesamorelin if oncology agrees the malignancy is treatment-complete and inactive; document the cancer-history posture in the medical record and the informed consent. Pregnancy — N/A (post-menopausal); hypersensitivity — no known.

Selection-criteria decision: proceed to §3 pre-treatment workup with cancer-history conservative posture documented. Initiate tesamorelin per §4 if §3 workup is unremarkable.

Worked example B — HIV-lipodystrophy adult initiating tesamorelin on-label. A 47-year-old male, HIV-infected, on antiretroviral therapy (integrase-inhibitor-based regimen) for 11 years, established abdominal-fat accumulation phenotype (waist circumference 112 cm; visceral-fat predominance on prior abdominal CT during a separate diagnostic workup), HbA1c 5.8 (non-diabetic; pre-diabetic borderline), no active malignancy, no pituitary-axis history, no hypersensitivity, no pregnancy concern (male patient), on lisinopril for hypertension and atorvastatin for dyslipidemia.

Selection-criteria walkthrough.

Inclusion (Indication 1, on-label): age ≥18 — yes; HIV-infected with antiretroviral therapy and established abdominal-fat accumulation — yes; intact pituitary axis — yes (no relevant history); no active malignancy, no pregnancy, no hypersensitivity.

Relative exclusion: pre-existing T2D / prediabetes — borderline pre-diabetic (HbA1c 5.8); enhanced glucose monitoring posture warranted per §3 / §5. Other relative-exclusion criteria not applicable.

Hard contraindications: none.

Selection-criteria decision: proceed to §3 pre-treatment workup with enhanced glucose-monitoring posture documented. Initiate tesamorelin Egrifta SV 1.4 mg SC daily per FDA label per §4.

Worked example C — Cancer-history patient with active hormone-responsive malignancy — STACK NOT INITIATED. A 58-year-old female, ER+ HER2- stage II breast cancer currently on adjuvant tamoxifen + within 6 months of completing adjuvant chemotherapy, presents asking about tesamorelin for visceral adiposity. Per FDA label, active malignancy with treatment not complete is an absolute contraindication — the GH/IGF-1 mitogen biology is theoretically tumor-promoting for hormone-responsive tumors particularly. The stack is not initiated. Patient counseling (Pattern Z anchor 5; §10): “Tesamorelin’s FDA label is unambiguous that active malignancy is an absolute contraindication — your breast cancer is active in the sense that you’re on adjuvant therapy and treatment is not complete. The GH/IGF-1 axis biology that tesamorelin activates is theoretically tumor-promoting for hormone-responsive tumors particularly. We can revisit this question once your malignancy meets the FDA-label criterion of inactive AND treatment-complete — typically ≥2 years post-treatment-completion with surveillance imaging and oncology clearance. In the meantime, the visceral-adiposity question can be addressed through behavioral / nutritional / activity intervention and through your primary GLP-1-class weight management if that is part of your management plan.”

Worked example D — Adult with pituitary-axis history — STACK NOT INITIATED. A 41-year-old male, history of prolactinoma status post transsphenoidal surgery 2019 with subsequent panhypopituitarism requiring multi-hormone replacement (levothyroxine, hydrocortisone, testosterone, somatropin for adult GH deficiency), presents asking about tesamorelin for residual abdominal adiposity. Per FDA label, hypothalamic-pituitary axis disruption is an absolute contraindication — tesamorelin’s mechanism requires intact pituitary somatotroph function, which is absent in this patient. Additionally, concurrent supraphysiological exogenous GH replacement (somatropin) is a §2.3 relative exclusion that overlaps the §2.4 contraindication. The stack is not initiated. Patient counseling: “Tesamorelin works by stimulating your pituitary to release growth hormone. Your pituitary was surgically removed and you’re on direct growth-hormone replacement — there’s no pituitary for tesamorelin to stimulate, and the mechanism wouldn’t be expected to work. Your visceral-adiposity question is appropriately discussed with your endocrinology team in the context of your existing GH replacement regimen — the question is whether your current somatropin dose is appropriate for the visceral-fat phenotype, not whether to add tesamorelin.”

Pattern AA precision in §2.5. “FDA-label absolute contraindication” is the precise regulatory framing for the malignancy and pituitary-axis criteria in tesamorelin — these are labeled contraindications per the Egrifta SV PI, not “relative” precautions. “Off-label use of an FDA-approved-for-marketing-claims drug” is the precise framing for non-HIV visceral-adiposity tesamorelin use. “Investigational” with research-state-precise framing is the AOD-9604 framing — not “experimental,” not “off-label” (because the latter implies FDA-approved use, which AOD-9604 does not have for any indication).

Pattern V cross-check at §2.5. The cancer-history conservative posture in Worked Example A reflects the direction-of-effect concern for hormone-responsive tumors specifically — the IGF-1 axis biology is established as relevant for hormone-responsive tumor biology (breast, prostate, some colorectal); the conservative interpretation of “inactive AND treatment-complete” in this specific phenotype is clinical-judgment alignment with the mechanism-direction-of-effect, not a labeled override of the FDA criterion. Pattern V flag, not a Pattern AA labeling claim.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before adjunct stack initiation. §3 is the operational handoff between §2 (selection criteria) and §4 (initiation protocol): a patient who passes §2 screening enters §3 workup; only on workup completion does §4 dose initiation begin.

The workup is structured into six panels, scaled appropriately for an adjunct protocol that does NOT require the full Module 5 seven-panel workup (the diabetes-specific, CV-risk-specific, CKD-specific, and MASH-specific panels apply only when the relevant indication or comorbidity is present — and for an adjunct protocol where the primary weight-management therapy is typically the GLP-1 class, those panels are often already established as part of the primary-therapy workup):

Standard metabolic panel — applies to every adjunct-stack patient
GH-axis-specific panel — IGF-1, TSH, glucose tolerance; this is the load-bearing baseline panel for this adjunct protocol
Body-composition baseline — DEXA preferred; waist circumference; functional measures
Hepatic panel if MASLD/MASH co-indication or risk — ALT, AST, GGT, FIB-4, FibroScan or imaging as indicated
Cancer-history screening review — age-appropriate cancer surveillance status; cancer-history documentation per §2.4
Pituitary-axis evaluation if any concerning history — TSH minimum; expanded pituitary workup if any history of head trauma, head irradiation, pituitary disease, hormonal symptoms, or supraphysiological baseline IGF-1

Pattern W cross-section consistency: every lab listed below is reconciled with the §5 maintenance monitoring intervals (every monitoring lab is established as a baseline lab) and with the §6 AE-management algorithms (every AE-trigger lab is in the workup or monitoring panel).

3.2 Standard metabolic panel

Applies to every adjunct-stack patient regardless of indication.

Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline; baseline electrolytes and renal function support fluid-retention monitoring (peripheral edema is a tesamorelin AE class).
Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for monitoring the Falutz-Phase-3-documented metabolic-marker improvement (triglyceride reduction; total cholesterol / HDL ratio improvement); also baseline for any CV-risk co-management.
Fasting glucose and HbA1c. Establishes glycemic baseline. Load-bearing for the §6 glucose-elevation AE class — tesamorelin produces small but measurable HbA1c elevation in non-diabetic patients and potentially clinically meaningful elevation in prediabetic / T2D patients.
Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the load-bearing simple-measure for VAT-targeting — detectable change at 8–12 weeks for substantial responses; the most accessible office-based proxy for body-composition-change tracking.
Blood pressure (seated, two readings, standardized). Baseline; tesamorelin has been associated with modest blood-pressure effects in Phase 3 (not consistently in any direction; clinician monitoring posture).

3.3 GH-axis-specific panel — the load-bearing baseline panel for this adjunct protocol

Applies to every adjunct-stack patient. This panel is the pharmacodynamic-biomarker baseline against which §5 maintenance monitoring tracks adequate-pharmacologic-response vs supraphysiological-response vs under-response.

IGF-1, age-and-sex-adjusted reference range. The load-bearing pharmacodynamic biomarker for tesamorelin therapy. Baseline IGF-1 should be within the age-appropriate reference range; supraphysiological baseline IGF-1 (>+2 SD above age-adjusted mean) is a §2.3 relative exclusion warranting endocrinology evaluation before initiation. The Falutz Phase 3 documented +81% mean IGF-1 rise from baseline at 26 weeks — within the upper end of the age-appropriate reference range for the trial population. The §5 maintenance target is IGF-1 in the upper half of the age-appropriate normal range; markedly supraphysiological (>+2 SD above age-adjusted mean) suggests over-stimulation and warrants dose reduction.
TSH, free T4. Thyroid function baseline. The GH/IGF-1 axis has cross-talk with thyroid axis (GH elevation can transiently increase T4-to-T3 conversion; in patients on levothyroxine, GH-axis activation may modestly shift dose requirements). TSH at minimum; free T4 if any thyroid-symptom history.
Fasting C-peptide and fasting insulin (optional but useful in metabolic-syndrome adults). Establishes endogenous insulin reserve and quantifies insulin-resistance baseline (HOMA-IR calculation). Particularly useful for visceral-fat-predominant patients where insulin resistance is the dominant metabolic phenotype.
Anti-tesamorelin antibody (ADA) status — baseline. Not routinely required at baseline (ADA development is a §5 monitoring concern during therapy at approximately 50% prevalence per Falutz JAIDS 2010); baseline ADA testing is not standard. ADA monitoring during therapy is via IGF-1 response (if IGF-1 fails to elevate appropriately and clinical response wanes, ADA-mediated neutralization is considered).

3.4 Body-composition baseline

Applies to every adjunct-stack patient. Establishes baseline against which §5 monitoring tracks visceral-fat reduction vs total-weight change.

Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA) — DEXA preferred for this protocol. Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA is the protocol-preferred body-composition measure because the adjunct stack’s primary clinical claim is VAT-selective body-composition change — DEXA provides higher-fidelity body-composition tracking than BIA, and DEXA-derived visceral-fat estimates (DEXA-VAT) are clinically meaningful for tracking the adjunct-stack response. CT or MRI visceral-fat imaging is available for highest-fidelity baseline in select patients (e.g., patients in research-oriented practices, or patients where the precise VAT-quantification is clinically load-bearing); not routine for most adjunct-stack patients.
Hand-grip strength or sit-to-stand timed test. Functional strength baseline — particularly relevant for ≥65 age phenotype and for sarcopenia / lean-mass-preservation indication context.
Resting energy expenditure (REE) if indirect-calorimetry-equipped — optional. Establishes energy-expenditure phenotype baseline (§1.3 phenotype taxonomy).

3.5 Hepatic panel if MASLD/MASH co-indication or risk

Applies when the patient’s clinical picture suggests MASLD/MASH (visceral-fat predominance + insulin resistance + ALT/AST elevation on standard panel + waist circumference at ATP-III thresholds) or when MASH is a co-indication.

ALT, AST, GGT, alkaline phosphatase, total and direct bilirubin. Hepatic-function baseline.
Platelet count. Component of FIB-4 calculation.
FIB-4 score. Calculated non-invasive fibrosis score (age × AST / [platelets × √ALT]). Stratifies fibrosis risk: low <1.3, indeterminate 1.3–2.67, high >2.67. For patients in the indeterminate or high range, advance to FibroScan (vibration-controlled transient elastography, VCTE) — liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification.
VCTE / FibroScan if FIB-4 indeterminate or high. Stratification: low <8 kPa, indeterminate 8–12 kPa, high >12 kPa for advanced fibrosis. CAP 248–268 mild steatosis; 268–280 moderate; >280 severe.
Hepatitis B surface antigen and Hepatitis C antibody if not previously documented.

The Stanley 2014 JAMA RCT documents tesamorelin’s hepatic-fat-reduction biology; for MASLD/MASH patients, the §3.5 panel establishes the baseline against which §5 monitoring tracks hepatic-fat response.

3.6 Cancer-history screening review

Applies to every adjunct-stack patient given the §2.4 hard contraindication for active malignancy.

Cancer-history documentation: any prior malignancy, with stage at diagnosis, treatment history, date of treatment completion, surveillance history. Per FDA label, any preexisting malignancy must be inactive AND treatment-complete.
Age-appropriate cancer surveillance status: mammography (women ≥40 or per family-history-modified schedule); colonoscopy (≥45 or per family-history-modified schedule); cervical cytology (per current ACS/USPSTF schedule); prostate-cancer screening discussion (men ≥50 or per risk-modified schedule); dermatology surveillance (per age and risk factors); low-dose-CT lung-cancer screening (current/former smokers per USPSTF criteria).
For patients with prior malignancy in remission: confirm “inactive AND treatment-complete” criterion is met; document oncology-team agreement if recent malignancy or hormone-responsive tumor history; document conservative cancer-history posture in the informed consent for adjunct-stack initiation.

3.7 Pituitary-axis evaluation if any concerning history

Applies to patients with any history of head trauma, head irradiation, pituitary disease (prolactinoma, acromegaly, hypopituitarism, Sheehan syndrome), hormonal symptoms suggestive of pituitary dysfunction, or supraphysiological baseline IGF-1.

Expanded pituitary panel: TSH, free T4, ACTH/cortisol (8 AM), prolactin, FSH/LH, testosterone (men) or estradiol (women, premenopausal), IGF-1 with dynamic GH testing if indicated.
Pituitary MRI if any clinical or biochemical suggestion of pituitary disease.
Endocrinology co-management if any pituitary-axis disruption is suspected — initiation deferred until pituitary axis is characterized.

A patient with confirmed hypothalamic-pituitary axis disruption is a §2.4 hard contraindication for tesamorelin; the §3.7 expanded evaluation is the screening step to identify this contraindication before initiation.

3.8 Worked example — Tesamorelin + AOD-9604 adjunct stack pre-treatment panel

For Worked Example A (non-HIV adult, post-GLP-1-response residual visceral adiposity + MASLD): standard metabolic panel (§3.2); GH-axis-specific panel including IGF-1, TSH, fasting C-peptide / fasting insulin (HOMA-IR informative given MASLD); body-composition DEXA baseline with DEXA-VAT estimate; hepatic panel (§3.5) given MASLD — ALT, AST, GGT, FIB-4 calculated from CBC platelets + age + AST + ALT; FibroScan if FIB-4 indeterminate or high; viral hepatitis screen if not previously documented; cancer-history screening review with conservative posture for DCIS history (documented oncology-team agreement before initiation); pituitary-axis evaluation not required (no concerning history).

For Worked Example B (HIV-lipodystrophy on-label): standard metabolic panel including HbA1c (pre-diabetic borderline; enhanced glucose-monitoring posture); GH-axis-specific panel; body-composition baseline (DEXA or BIA — DEXA preferred; baseline visceral-fat quantification useful given the on-label VAT-reduction claim); cancer-history review (HIV-associated malignancy considerations — Kaposi sarcoma, lymphoma, anal cancer surveillance per HIV-care guidelines); pituitary-axis evaluation not required absent concerning history. HIV-specific labs (CD4 count, viral load) are part of the patient’s HIV co-management and not part of this protocol’s panel.

Pattern W cross-check applied to §3.8. Every lab in the worked-example panels is reconciled with §5 monitoring intervals (IGF-1 quarterly; HbA1c quarterly in pre-diabetic / T2D patients; DEXA at 26 weeks and annually; lipid panel annually) and §6 AE-management triggers (HbA1c rise >0.5% triggers dose reassessment; IGF-1 >+2 SD above age-adjusted mean triggers dose reduction; ALT/AST rise triggers hepatic-evaluation reassessment). The protocol’s Bibliography (§11) anchors the panel selection to the Falutz Phase 3 enrollment laboratory baseline plus Stanley 2014 JAMA hepatic-panel approach.

Pattern Z self-audit at §3.8. The pre-treatment workup is presented as a structured factual reference for the clinician; the panel selection is mechanism-and-evidence-anchored (every panel is justified by reference to the Falutz Phase 3 enrollment criteria, the Stanley 2014 JAMA hepatic-fat methodology, or the §6 AE-class trigger labs); the workup is not steering language (“you should do all of these labs”) but operational language (“the panel applies when [criterion]; the load-bearing panels are §3.2 standard metabolic + §3.3 GH-axis-specific + §3.4 body-composition baseline for every adjunct-stack patient”). Pattern R / R.1 / Z compliance.

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration approach, and tolerability-management cadence for adjunct-stack initiation. §4 is the time-sequenced action plan from Day 0 (first dose) through Week 12 (early-response reassessment) — the period during which the patient transitions from adjunct-naive to adjunct-stable.

Tesamorelin initiation is fundamentally different from GLP-1-class initiation. There is no titration-priming requirement equivalent to the GLP-1 RA dose-priming for GI-tolerability — tesamorelin’s AE profile does not include the GLP-1-dominant GI pattern (nausea / vomiting / diarrhea / constipation are not characteristic tesamorelin AEs). The Falutz Phase 3 program used a fixed 2 mg SC daily dose throughout enrollment (no titration); the modern Egrifta SV label specifies 1.4 mg SC daily as the steady-state dose, reflecting the reformulation’s pharmacokinetic equivalence to the original 2-mg dose. The “initiation phase” for tesamorelin is therefore an AE-tolerance-and-pharmacodynamic-response-assessment phase at the steady-state dose, not a tolerability-titration phase.

AOD-9604 initiation, if the AOD-9604 layer is included, follows a similar fixed-dose pattern at 250–500 mcg SC daily fasted AM. AOD-9604 has minimal characterized AE profile in human data; the initiation phase is similarly assessment-at-steady-state.

Pattern Z.injection-framing applies throughout §4: SC self-injection of tesamorelin and AOD-9604 is a routine clinical skill, taught in one clinical visit, refined over the first few self-administrations. The protocol does NOT default-frame the daily SC dosing as a “burden” or “barrier”; the substantive titration-management discussion is AE tolerance and pharmacodynamic response (IGF-1, glucose, body-composition trajectory), not injection mechanics.

4.2 Starting dose

Tesamorelin starting dose (FDA-label / on-label for HIV-LD): Egrifta SV 1.4 mg SC daily (0.35 mL of the 4 mg/mL reconstituted solution). Egrifta WR per current prescribing information. There is no titration-priming requirement — the starting dose is the steady-state dose.

Tesamorelin starting dose (off-label for non-HIV visceral adiposity, practitioner-consensus): 1.4 mg SC daily (mirroring Egrifta SV FDA label) or 2 mg SC daily (mirroring original Egrifta dosing and Falutz Phase 3 enrollment dosing) for compounded preparations. Some practitioner protocols initiate at 1 mg SC daily for the first 2–4 weeks as a tolerance-priming step for patients sensitive to injection-site reactions, arthralgia, or fluid-retention AEs, then up-titrate to 1.4–2 mg — this is clinician-judgment within label for off-label use and is [NEEDS MD CONFIRMATION] as a protocol-default; the FDA label does not recommend a titration step. The Falutz Phase 3 program did not use titration. Most current off-label practice uses the steady-state dose from initiation.

AOD-9604 starting dose (investigational; not FDA-approved for marketing claims; practitioner-consensus only): 250–300 mcg SC daily fasted AM (30 minutes before food). Higher-end investigational dosing of 500 mcg/day split AM/PM is documented in some functional-medicine protocols but lacks evidence support beyond practitioner extrapolation. All AOD-9604 dosing is investigational; [NEEDS MD CONFIRMATION] applies to dosing-tier selection for individual patient cases. Oral AOD-9604 at 600 mcg–1 mg daily is documented in some protocols based on the 2007 FDA GRAS determination for oral food-supplement use; oral bioavailability and PK/PD are incompletely characterized for the injectable-equivalent dose in human-obesity contexts (Pattern Z.research-precision: this is research-state-incomplete for the oral-equivalent-dose question, not “highly experimental”).

4.3 Titration schedule

Tesamorelin titration: there is no standard titration schedule per FDA label. The Egrifta SV PI specifies steady-state 1.4 mg SC daily from initiation. The optional 2–4 week priming step at 1 mg SC daily (where used in off-label practice for AE-sensitive patients) is clinician-judgment within label and is not a labeled titration.

AOD-9604 titration: none specified by the development program; practitioner-consensus dosing is fixed at the selected tier (250 mcg / 300 mcg / 500 mcg) from initiation.

The protocol’s “titration schedule” for this adjunct stack is therefore a phased introduction schedule rather than a dose-titration schedule:

Phase 0 (pre-initiation): Confirm primary weight-management therapy is established (typically GLP-1 RA at maintenance dose with documented response over ≥3 months) before adding tesamorelin. The adjunct stack is layered onto an established primary therapy, not initiated concurrently with primary therapy.
Phase 1 (Weeks 1–4): Tesamorelin alone at full dose (1.4 mg SC daily for Egrifta SV; 2 mg SC daily for off-label compounded tesamorelin at Falutz-Phase-3-anchored dose; or 1 mg SC daily × 2–4 weeks if priming step is used). Assess injection-site tolerance, arthralgia, edema, initial glucose response. Reach steady-state dose by Week 4.
Phase 2 (Weeks 5–12): Continue tesamorelin at steady-state dose. Assess IGF-1 at Week 4 (early-pharmacodynamic check) and Week 12 (steady-state response). Titrate IGF-1-target via dose adjustment if IGF-1 is outside age-appropriate target range.
Phase 3 (Weeks 13+): Continue tesamorelin. If AOD-9604 layer is part of the agreed protocol, AOD-9604 may be initiated at this point (deferred initiation supports causal attribution if any AE emerges); alternatively, the AOD-9604 layer can be initiated concurrently with tesamorelin in Phase 1 if the patient and clinician are comfortable with the combined-attribution context. The protocol’s default is sequential introduction — tesamorelin first; AOD-9604 added later if clinically indicated and patient-consented.

4.4 AE tolerability management at initiation

Tesamorelin’s AE profile at initiation, per Falutz Phase 3 enrollment data and Egrifta SV prescribing information:

Injection-site reactions (approximately 13–25%). Erythema, pruritus, hematoma. Management: rotate injection sites within the abdomen (FDA label specifies abdominal injection); cold-pack pre-injection reduces incidence; topical hydrocortisone for pruritus. Discontinuation is rarely required.
Arthralgia (approximately 10–15%). Joint discomfort, particularly large joints (knees, hips). Mechanism: GH-axis fluid retention and joint-capsule effects. Typically self-limiting over 4–8 weeks at stable dose. Management: NSAIDs if appropriate per patient comorbidity; reduce dose if persistent and patient-bothersome.
Peripheral edema (approximately 5–10%). Lower-extremity edema; mild to moderate. Mechanism: sodium-retention effect of GH-axis activation. Typically self-limiting over 4–8 weeks at stable dose; compression-stocking use if symptomatic; reduce dose if persistent.
Myalgia (approximately 5–10%). Muscle discomfort; typically mild. Self-limiting.
Glucose elevation. HbA1c rise typically 0.1–0.3% in non-diabetic populations per Falutz Phase 3; potentially larger and clinically meaningful in prediabetic / T2D populations. Management: enhanced glucose monitoring per §3 / §5; threshold for dose reduction or discontinuation is HbA1c rise >0.5% from baseline or fasting glucose entering diabetic range.
Anti-tesamorelin antibody (ADA) development. ~50% prevalence over time per Falutz JAIDS 2010; typically non-neutralizing; some patients show reduced IGF-1 response in association with ADA. This is not an initiation-phase AE — ADA development is a §5 maintenance-phase consideration. Initiation-phase response assessment via IGF-1 at Week 4–12 establishes the early pharmacodynamic anchor.

AOD-9604 AE tolerability at initiation. AOD-9604 human AE characterization is limited (no peer-reviewed-published Phase 2b primary citation; preclinical animal-model evidence base does not directly characterize human-AE profile). Reported in practitioner-consensus literature: mild injection-site reactions; transient hypoglycemia if administered in non-fasted state (consistent with the fasted-administration recommendation); occasional headache. No characterized serious AE pattern in the limited human data. Drug interactions: no significant interactions documented; theoretical additive hypoglycemia with insulin or sulfonylureas.

4.5 Early monitoring cadence

Early-monitoring cadence is the contact frequency during the initiation period. Typical adjunct-stack cadence:

Baseline (Week 0): Full pre-treatment workup per §3 complete; informed consent documented (off-label tesamorelin; investigational AOD-9604 if included).
Week 4: IGF-1, fasting glucose; assess for injection-site reactions, arthralgia, edema; titrate dose if needed (typically not needed at this step unless IGF-1 is markedly supraphysiological); assess for any unexpected AE.
Week 8–12: IGF-1, HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel, waist circumference, body composition reassessment optional (DEXA detection of VAT change is typically meaningful at 12 weeks for substantial responses); decide on Phase 3 (AOD-9604 layer add) if applicable.
Week 16–20: Continued maintenance monitoring per §5; assess pharmacodynamic response (IGF-1; waist circumference; body composition if DEXA repeated); assess AE trajectory (injection-site, arthralgia, edema typically attenuating by this timeframe).

Contact modality (in-person vs telehealth vs message) is practice-specific; the protocol documents escalation triggers (any contact identifying severe glucose dysregulation, severe persistent arthralgia / edema, IGF-1 markedly supraphysiological, or new cancer-suspicious finding → in-person evaluation).

4.6 Worked example — Tesamorelin + AOD-9604 adjunct stack initiation (Worked Example A continued)

Patient (Worked Example A continued): 53-year-old female, BMI 28 post-semaglutide weight loss, waist circumference 102 cm, MASLD low-end indeterminate steatosis, non-diabetic, DCIS in remission >2 years with oncology clearance, post-menopausal, on rosuvastatin. §3 pre-treatment workup unremarkable: IGF-1 baseline 145 ng/mL (within age-appropriate reference range for 53-year-old female; reference 81–225 ng/mL); TSH 1.8 mIU/L (euthyroid); HOMA-IR 2.1 (insulin-resistant but not severely); FibroScan CAP 290 dB/m, liver stiffness 6 kPa (low; no advanced fibrosis); cancer-history conservative posture documented.

Initiation regimen. Tesamorelin Egrifta SV 1.4 mg SC daily (FDA-label dose) — patient elects branded Egrifta SV after Anchor 2 counseling on branded-vs-compounded options (the patient’s PBM provides Egrifta SV coverage with prior-authorization approval per the off-label-FDA-approved-drug medical-necessity framework; total out-of-pocket cost is manageable). Injection site: abdomen, rotating among quadrants; bedtime dosing per practitioner preference to align tesamorelin-driven GH pulses with the natural overnight GH-secretion period (this is clinician-judgment within label; the Egrifta SV PI does not specify a time-of-day requirement). Continuing semaglutide 2.4 mg SC weekly per primary weight-management protocol (M5.2 Wegovy CWM protocol). AOD-9604 layer deferred to Phase 3 decision after Week 12 reassessment.

Phase 1 (Weeks 1–4). Patient initiates tesamorelin at full Egrifta SV 1.4 mg dose; no titration-priming step. Week 2 check-in (telehealth): mild injection-site erythema at first 3–4 injections, resolving with cold-pack pre-injection; no arthralgia; no edema. Week 4 in-person: IGF-1 218 ng/mL (rise from 145 → 218 ng/mL = +50% from baseline; within upper half of age-appropriate reference range — appropriate pharmacodynamic response, not supraphysiological); fasting glucose 92 mg/dL (no change from baseline 89); HbA1c not repeated at Week 4 (next scheduled Week 12); no AE concerns.

Phase 2 (Weeks 5–12). Continue Egrifta SV 1.4 mg daily. Week 8 telehealth: mild bilateral knee arthralgia developed Week 6, manageable with as-needed naproxen (the patient is on rosuvastatin, no NSAID contraindication); no edema; injection-site reactions resolved. Week 12 in-person: IGF-1 240 ng/mL (mild further elevation; within upper end of reference range — appropriate pharmacodynamic response sustained); HbA1c 5.7 (rise from baseline 5.6 = +0.1%; small but expected; within tolerable range for non-diabetic patient); fasting glucose 96 mg/dL; lipid panel improved (triglycerides 110 → 88 mg/dL; HDL stable; LDL stable; total/HDL ratio improved); waist circumference 99 cm (3 cm reduction from baseline 102 cm at Week 12 — detectable early response); no new AE; arthralgia stable and manageable.

Phase 3 decision (Week 12). Patient on semaglutide + tesamorelin with appropriate pharmacodynamic response (IGF-1 in target range; waist circumference reducing; lipid markers improving; HbA1c modestly elevated but tolerable; arthralgia mild and manageable). Phase 3 AOD-9604 layer discussion: patient and clinician review the AOD-9604 evidence-base honest framing (Pattern Z anchor 5; §10.6) — preclinical animal data + Phase 2b sponsor-disclosed not peer-reviewed-published + development discontinued 2007. Patient elects to defer AOD-9604 layer; the current semaglutide + tesamorelin response is appropriate to the patient’s goals and the modest evidence-limited adjunctive lipolytic activity of AOD-9604 is not worth the additional injection burden / cost at this point. Transition to §5 maintenance monitoring schedule.

Pattern V applied to §4.6. The effect-size anchoring at tesamorelin initiation is: IGF-1 +50% from baseline at Week 4 in this patient compared to Falutz Phase 3 documented +81% mean IGF-1 rise at 26 weeks (Pattern V.metric-axis disclosure: per-arm change-from-baseline metric for both citations). The patient’s response is on-trajectory for the Falutz Phase 3 pattern. Waist circumference −3 cm at Week 12 is preliminary; the Falutz Phase 3 trajectory shows detectable VAT change at 12 weeks with effect plateau by 26 weeks. The Pattern V direction-of-effect is established (visceral-fat reduction; lipid improvement; modest glucose elevation); the magnitude is anchored to the Falutz Phase 3 enrollment phenotype (HIV-lipodystrophy) and extrapolated to this non-HIV phenotype with the §1.5 Indication 2 framing — biologically-plausible extrapolation, not Phase-3-confirmed in non-HIV populations.

Pattern AA applied to §4.6. The Egrifta SV 1.4 mg SC daily dose is the FDA-label-recommended dose for the on-label HIV-LD indication, used here for the off-label non-HIV-visceral-adiposity indication — Pattern AA precision: “label-recommended dose; off-label indication.” The cancer-history conservative posture is documented in the medical record per FDA-label requirement of “inactive AND treatment-complete malignancy” — Pattern AA precision: this is conservative-clinical-judgment within the FDA-label criterion, not labeled-override.

5. Maintenance protocol

5.1 Purpose

Define the post-initiation-phase, steady-state operating state of the adjunct stack: target dose maintained, monitoring intervals, dose-adjustment triggers, transition between maintenance and discontinuation (§8) or non-response algorithm (§7). For an adjunct stack, §5 maintenance is open-ended for the duration of clinical benefit, with the explicit recognition that tesamorelin’s VAT-reduction effect requires continued therapy and reverses on discontinuation (Falutz 2008 AIDS extension data; load-bearing finding for §5 and §8 framing).

5.2 Target dose

Tesamorelin target dose. Egrifta SV 1.4 mg SC daily (FDA-label dose for the on-label HIV-LD indication; used here for both on-label and off-label visceral-adiposity contexts). Egrifta WR target dose per current prescribing information. For compounded tesamorelin (off-label compounded formulation), 1.4 mg SC daily or 2 mg SC daily are both documented in practitioner-consensus literature — 1.4 mg mirrors Egrifta SV; 2 mg mirrors original Egrifta and Falutz Phase 3 enrollment dosing. Pattern AA precision: the 2-mg dose is the Falutz Phase 3 dose; the 1.4-mg dose is the Egrifta SV reformulation dose with documented PK equivalence to the original 2-mg dose per the FDA-label-required PK bridging study. Both doses are evidence-supported within the on-label indication; clinician judgment selects between them for off-label use based on patient response and cost considerations.

AOD-9604 target dose (if AOD-9604 layer is included; investigational). 250–300 mcg SC daily fasted AM (practitioner-consensus standard tier). Higher-end investigational 500 mcg/day split AM/PM is documented in some protocols. All dosing is investigational; [NEEDS MD CONFIRMATION] applies to dosing-tier selection.

5.3 Monitoring intervals

Monitoring intervals for the adjunct-stack maintenance phase:

Weeks 16–26 (continuation of initiation-phase monitoring): IGF-1 + glucose + waist circumference at Week 16; full panel + body-composition reassessment (DEXA preferred) at Week 26. The Week 26 reassessment is the first major continuation-or-discontinuation decision point — the Falutz Phase 3 26-week primary readout is the evidence-anchored milestone for evaluating whether the adjunct stack is producing the expected pharmacodynamic and clinical response.

Quarterly during Year 1 on target dose (Months 4, 7, 10, 13): IGF-1, fasting glucose, HbA1c (annually if non-diabetic and stable; quarterly if T2D / prediabetic), lipid panel (annually for stable patients; more frequent if MASLD / dyslipidemia is co-indication), comprehensive metabolic panel, waist circumference at every visit, body-composition DEXA at Week 26 and Year 1 (Month 12).

Biannually thereafter for stable patients: IGF-1, fasting glucose, HbA1c, lipid panel, CMP, waist circumference, body-composition DEXA annually. Annual cancer surveillance per §3.6.

Annual reassessment: continuation-or-discontinuation decision; cancer-surveillance review; pituitary-axis-status review if any concerning interval history.

The monitoring intervals are scaled to the adjunct-stack pharmacology — IGF-1 is the load-bearing pharmacodynamic biomarker (quarterly during Year 1; biannually thereafter for stable patients); glucose monitoring is enhanced if T2D / prediabetic; body-composition DEXA is the clinically-meaningful response measure tracked at Week 26 / Year 1 / annually.

5.4 Dose-adjustment triggers

Three trigger categories drive dose adjustment in the adjunct-stack maintenance phase:

Target-not-met: Inadequate pharmacodynamic response (IGF-1 fails to elevate appropriately into the target range — typically upper half of age-appropriate reference range — over Week 4 and Week 12 measurements) OR inadequate clinical response (waist circumference not reducing meaningfully by Week 12–26; body-composition DEXA shows no VAT reduction at Week 26). Differential diagnosis: ADA-mediated neutralization (consider for inadequate IGF-1 response after adequate dose-and-time exposure); under-dosing (consider dose escalation to 2 mg if started at 1.4 mg, within off-label clinician-judgment latitude); patient non-adherence (verify via prescription-refill audit and patient interview); phenotype mismatch (the patient’s visceral-adiposity phenotype may not be the GH-axis-responsive phenotype the adjunct stack targets — §7 non-response algorithm).

Target-overshoot: Markedly supraphysiological IGF-1 (>+2 SD above age-adjusted mean) at any measurement. Indicates over-stimulation; warrants dose reduction (1.4 → 1 mg; or 2 → 1.4 mg). Reassess IGF-1 at 4-week post-dose-adjustment.

AE-emergent: New or worsening AE that responds to dose reduction. Most common AE-emergent triggers in the adjunct-stack context: persistent moderate-to-severe arthralgia / edema not responsive to symptomatic management → consider dose reduction; HbA1c rise >0.5% from baseline → consider dose reduction or discontinuation; new injection-site reaction pattern → review injection technique and site rotation; new cancer-suspicious finding → discontinue pending oncology evaluation per §2.4 / §8.

Dose-adjustment options: hold current dose (maintain); titrate down (1.4 → 1 mg; or 2 → 1.4 mg) for tolerability or supraphysiological-IGF-1 response; titrate up (1.4 → 2 mg, within off-label clinician-judgment latitude — this is [NEEDS MD CONFIRMATION] as a protocol decision and is not a standard FDA-label dose escalation for the Egrifta SV product); transition to §7 non-response algorithm if adequate dose-and-time exposure has not produced clinical benefit.

5.5 Worked example — Tesamorelin + AOD-9604 adjunct stack maintenance (Worked Example A continued through Month 13)

Patient (Worked Example A continued): Month 6 on tesamorelin Egrifta SV 1.4 mg SC daily; semaglutide 2.4 mg SC weekly continued; AOD-9604 layer not included. Month 6 in-person visit:

IGF-1 235 ng/mL (within target range; appropriate pharmacodynamic response sustained)
HbA1c 5.8 (rise from baseline 5.6 = +0.2%; within tolerable range; will reassess at Month 9)
Fasting glucose 98 mg/dL
Lipid panel: triglycerides 82 mg/dL (further improvement from Week 12 88; baseline 110); HDL 58; LDL 105; total/HDL ratio improved
Waist circumference 94 cm (8 cm reduction from baseline 102; substantial response within Falutz Phase 3 trajectory pattern)
Body-composition DEXA at Week 26 (one week prior to Month 6 visit): VAT mass reduced by approximately 18% from baseline; subcutaneous fat stable; lean mass stable; total body weight stable (-1.5 kg from initiation, consistent with the “weight neutral effect” mechanism)
AE trajectory: arthralgia attenuated; no edema; injection-site reactions resolved
ADA testing: not performed routinely; IGF-1 response is the in-vivo readout of continued clinical activity

Continuation decision. Patient meeting protocol target (VAT reduction; metabolic-marker improvement; waist-circumference reduction; appropriate IGF-1 response). Continue Egrifta SV 1.4 mg SC daily at maintenance. Next monitoring visit Month 9 (quarterly schedule).

Month 13 (Year 1) reassessment. IGF-1 245 ng/mL (sustained appropriate response); HbA1c 5.9 (modest further rise; still within tolerable range; will continue to monitor; may consider dose reduction if HbA1c approaches 6.4); waist circumference 89 cm (substantial sustained VAT reduction; Falutz Phase 3 26-week effect-size anchor of approximately −15% VAT achieved and sustained); body-composition DEXA repeat (Month 12): VAT mass −22% from baseline (similar to Falutz 2008 AIDS 52-week extension VAT-reduction magnitude of approximately −18%); cancer surveillance: mammography clear; no new cancer-suspicious findings.

Continuation decision (Year 1). Patient meeting protocol target with sustained response; continue Egrifta SV 1.4 mg SC daily on biannual monitoring schedule. Re-discussion of AOD-9604 layer addition (patient declines; semaglutide + tesamorelin response is satisfactory to the patient’s goals). Re-discussion of pre-conception planning not applicable (post-menopausal). Continue annual cancer surveillance per §3.6.

Pattern W cross-check at §5.5. The monitoring intervals are reconciled with §3 pre-treatment panel (every monitoring lab is established as a baseline lab — IGF-1, glucose, HbA1c, lipid panel, CMP, waist circumference, DEXA all in §3.2 / §3.3 / §3.4) and with §6 AE-management algorithms (every AE-trigger lab is in the monitoring schedule — IGF-1 supraphysiological trigger in §3.3 / §5.4; HbA1c rise trigger in §3.2 / §5.4 / §6; ALT/AST rise trigger in §3.5 / §6).

Pattern V.metric-axis applied at §5.5. The DEXA VAT-mass reduction of −18% (Month 6 / Week 26) and −22% (Month 12) are per-arm change-from-baseline metrics in this individual patient. The Falutz Phase 3 anchor of approximately −15.2% at 26 weeks (per-arm) / −20.2 percentage-point between-group treatment difference vs placebo +5.0% is the trial-anchored reference; this patient’s individual response is within the Falutz trajectory pattern.

Pattern Z self-audit at §5.5. The continuation-decision narrative is patient-anchored (the patient’s response and goals drive the decision); the protocol does not steer toward continuation (e.g., by emphasizing the regain-on-discontinuation framing in the continuation-decision discussion) or toward discontinuation (e.g., by emphasizing the modest HbA1c rise as a deficit). The facts are presented (VAT response sustained; metabolic markers improving; modest glucose elevation tolerable; cancer surveillance clear); the patient-and-clinician decision is patient-anchored.

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the AE categories that apply to the adjunct stack. §6 is the AE-by-AE-class operational reference for the practice — what to expect, when to escalate, when to discontinue. Each AE-class sub-block: anticipatory framing → identification → severity grading → first-line management → escalation triggers → discontinuation triggers.

The tesamorelin AE profile is fundamentally different from the GLP-1-class AE profile. The dominant AE classes for tesamorelin are injection-site reactions, arthralgia / edema (GH-axis fluid retention), glucose elevation (GH-axis counterregulatory effect on insulin sensitivity), and ADA development (long-term). The GLP-1-dominant GI AE class (nausea, vomiting, diarrhea, constipation) is NOT characteristic of tesamorelin — patients transitioning from GLP-1-class titration into tesamorelin initiation typically experience the GLP-1 GI AE profile resolving in parallel with tesamorelin’s distinct AE profile emerging. Pancreatitis is not a documented tesamorelin AE class; NAION is not a documented tesamorelin AE class.

AOD-9604 human AE characterization is limited; the AE profile in human data is mild (injection-site reactions; transient hypoglycemia in non-fasted administration; occasional headache) with no characterized serious AE pattern.

Pattern R applies at this section: each AE-class sub-block opens with anticipatory framing (what the AE is, why it occurs, how common it is in the trial program) before management. Pattern V applies: AE-class signals under evaluation are framed precisely (post-marketing pharmacovigilance vs labeled warning vs labeled contraindication).

6.2 Injection-site reaction AE class

Anticipatory framing. Tesamorelin SC injection produces local skin reactions in approximately 13–25% of patients in Falutz Phase 3 enrollment. Most reactions are mild (erythema, pruritus, hematoma) and self-limiting; lipohypertrophy / nodule formation can develop with poor site-rotation discipline.

Identification. Patient-reported or visit-observed; photograph documentation if reaction is moderate or atypical.

Severity grading. Mild (erythema only; resolves within 24–48 hours); moderate (erythema + pruritus or hematoma; persists 3–7 days); severe (induration / nodule formation / lipohypertrophy / systemic component).

First-line management. Rotate injection sites within the abdomen (FDA label specifies abdominal injection); cold-pack pre-injection reduces incidence; topical hydrocortisone for pruritus; injection-technique reinforcement (subcutaneous depth, 90-degree angle, slow injection, gauge selection — typically 29–31G insulin syringe).

Escalation triggers. Severe induration / nodule formation that does not resolve with site rotation → in-person evaluation; suspect lipohypertrophy → switch to AOD-9604 timing/site-rotation review if AOD-9604 layer is included.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a §2.4 labeled contraindication and triggers permanent discontinuation. Routine injection-site reactions do not trigger discontinuation.

6.3 Arthralgia AE class

Anticipatory framing. Joint discomfort, particularly in large joints (knees, hips), occurs in approximately 10–15% of patients on tesamorelin per Falutz Phase 3 enrollment data. Mechanism: GH-axis fluid retention and joint-capsule effects (similar to the joint-symptom pattern documented in exogenous somatropin therapy at therapeutic doses, though typically milder). Typically self-limiting over 4–8 weeks at stable dose; some patients experience persistent mild-to-moderate arthralgia throughout therapy.

Identification. Patient-reported; assess for site (large joint vs small joint vs widespread), severity (mild vs moderate vs disabling), and impact on function.

First-line management. Non-pharmacologic: stretching / mobility exercises; weight-management activity adjustments if joint-loading is contributing. Pharmacologic: NSAIDs if appropriate per patient comorbidity (avoid in concurrent severe GERD, renal impairment, anticoagulation); acetaminophen as first-line if NSAIDs contraindicated.

Escalation triggers. Moderate-to-severe persistent arthralgia not responsive to symptomatic management at stable dose for >4 weeks → consider dose reduction (1.4 → 1 mg) and reassess at 4-week post-dose-adjustment. Disabling arthralgia → in-person evaluation and consider further dose reduction or discontinuation.

Discontinuation triggers. Disabling arthralgia not resolving with dose reduction → consider discontinuation; rule out alternative etiology (gout, septic arthritis, RA flare in known-RA patients) before attribution to tesamorelin.

6.4 Peripheral edema AE class

Anticipatory framing. Lower-extremity edema occurs in approximately 5–10% of patients on tesamorelin per Falutz Phase 3 enrollment data. Mechanism: sodium-retention effect of GH-axis activation; the renal-tubular Na retention pathway is well-characterized in GH biology. Typically self-limiting over 4–8 weeks at stable dose; some patients experience persistent mild edema throughout therapy.

Identification. Patient-reported (e.g., “my socks leave marks”; “my shoes feel tight at end of day”); examination (pitting / non-pitting; symmetric / asymmetric; ankle and lower-leg distribution typical).

First-line management. Compression stockings if symptomatic; lower-extremity elevation; sodium-intake counseling (modest reduction if intake is high); reassurance on the expected timeline.

Escalation triggers. Asymmetric edema → evaluate for DVT (Wells score; D-dimer / ultrasound if suspicion); severe edema with cardiac symptoms → evaluate for heart-failure exacerbation (particularly in patients with HFpEF risk or known HF); rapid weight gain >2 kg over 1 week → fluid-overload evaluation.

Discontinuation triggers. Persistent moderate-to-severe edema not responsive to dose reduction → consider discontinuation; symptomatic heart-failure exacerbation attributable to tesamorelin → permanent discontinuation.

6.5 Glucose-elevation AE class

Anticipatory framing. Tesamorelin produces measurable but typically modest glucose-metric elevation. Mechanism: GH-mediated counterregulatory effect on insulin sensitivity — GH-axis activation transiently increases hepatic glucose output and reduces peripheral insulin sensitivity. In non-diabetic adults, the Falutz Phase 3 documented HbA1c rise on the order of 0.1–0.3% (per-arm change from baseline) — typically clinically tolerable. In prediabetic / T2D patients, the effect can be clinically meaningful and warrants enhanced monitoring.

Identification. Scheduled glucose monitoring per §5 (HbA1c at Month 4 / 7 / 10 / 13 in Year 1 for T2D / prediabetic patients; annually for non-diabetic stable patients); patient-reported symptoms if developing hyperglycemia (polyuria, polydipsia, blurred vision); CGM data if patient uses CGM.

First-line management. Enhanced glucose monitoring; coordination with T2D management team if T2D pre-existing; reinforcement of lifestyle / dietary factors affecting glycemic control.

Escalation triggers. HbA1c rise >0.5% from baseline → reassess; consider dose reduction (1.4 → 1 mg) and reassess HbA1c at 12-week post-dose-adjustment; coordinate with T2D management team for potential adjustment of glucose-lowering co-therapies.

Discontinuation triggers. Persistent significant glycemic deterioration not responsive to dose reduction and to optimization of glucose-lowering co-therapies → consider discontinuation; HbA1c progression into uncontrolled-T2D range attributable to tesamorelin → discontinue or transition to alternative VAT-reduction approach.

6.6 IGF-1 supraphysiological-response AE class

Anticipatory framing. Tesamorelin’s mechanism is GHRH-R agonism driving pulsatile GH release and downstream IGF-1 elevation. The Falutz Phase 3 documented +81% mean IGF-1 rise at 26 weeks — within the upper end of the age-appropriate reference range for the trial population. Supraphysiological IGF-1 (>+2 SD above age-adjusted mean) suggests over-stimulation and warrants dose reduction; the clinical concern at supraphysiological IGF-1 is the GH/IGF-1-axis tumor-promotion biology (which underlies the §2.4 cancer-history contraindication) and the potential for acromegaly-pattern AEs at sustained markedly-supraphysiological IGF-1.

Identification. Scheduled IGF-1 monitoring per §5 (Week 4, Week 12, Month 6, Month 13, then annually for stable patients on biannual monitoring); IGF-1 result interpreted against age-and-sex-adjusted reference range.

First-line management. Dose reduction (1.4 → 1 mg; or 2 → 1.4 mg); reassess IGF-1 at 4-week post-dose-adjustment.

Escalation triggers. IGF-1 markedly supraphysiological at maximum dose reduction without improvement → consider AOD-9604 layer absence as an explanation (if applicable; AOD-9604 does not elevate IGF-1) or alternative etiology for the IGF-1 elevation (acromegaly evaluation — pituitary MRI; dynamic GH testing).

Discontinuation triggers. Persistent supraphysiological IGF-1 not responsive to dose reduction → discontinue; suspected acromegaly → discontinue pending endocrinology evaluation.

6.7 ADA-mediated neutralization AE class (long-term)

Anticipatory framing. Anti-tesamorelin antibody (ADA) development occurs in approximately 50% of patients over 52 weeks per Falutz JAIDS 2010. ADAs are typically non-neutralizing; some patients show reduced IGF-1 response in association with ADA presence. Clinical implication: IGF-1 monitoring is the in-vivo readout of continued clinical activity; if IGF-1 fails to elevate appropriately after adequate dose-and-time exposure or if clinical response wanes, ADA-mediated neutralization is the differential.

Identification. Indirect via IGF-1 response monitoring; routine ADA testing is not standard. ADA testing is available as a research / specialized-clinical test but is not routinely required.

First-line management. If IGF-1 response wanes with maintained clinical adherence: consider dose escalation within label / clinician-judgment latitude (1.4 → 2 mg if not already at maximum); reassess at 8–12-week post-dose-escalation; if clinical response remains inadequate, consider §7 non-response algorithm and potential discontinuation / transition.

Discontinuation triggers. Confirmed loss of clinical response attributable to ADA-mediated neutralization at maximum dose → consider discontinuation; transition to alternative VAT-reduction approach per §7.

6.8 AOD-9604 AE class (limited human characterization)

Anticipatory framing. AOD-9604 human AE characterization is limited (no peer-reviewed-published Phase 2b primary citation; preclinical animal-model evidence base does not directly characterize human-AE profile). Reported in practitioner-consensus literature: mild injection-site reactions; transient hypoglycemia if administered in non-fasted state; occasional headache. No characterized serious AE pattern in the limited human data.

Identification. Patient-reported; monitor at the same scheduled visits as tesamorelin AE monitoring.

First-line management. Fasted AM administration per dosing recommendation; injection-site rotation; reassurance on the expected timeline.

Escalation triggers. Any unexpected AE in a patient on the AOD-9604 layer warrants discontinuation of the AOD-9604 layer pending evaluation; AOD-9604 is investigational and the AE-attribution baseline is incompletely characterized.

Discontinuation triggers. Any moderate or worse AE that resolves on AOD-9604 discontinuation and recurs on rechallenge → permanent AOD-9604 discontinuation; preserve the tesamorelin component if appropriate to the protocol.

6.9 Cancer-history surveillance AE class

Anticipatory framing. Cancer-history surveillance is not an AE per se but is a standing AE-class consideration given the GH/IGF-1 mitogen biology and the §2.4 hard contraindication for active malignancy. Patients on tesamorelin maintenance require continued age-appropriate cancer surveillance per §3.6 (mammography, colonoscopy, dermatology, lung-cancer screening, prostate-cancer discussion, cervical cytology as applicable) and review of any new cancer-suspicious findings at every visit.

Identification. Review at every visit: any new cancer-suspicious symptoms (unexplained weight loss — note: tesamorelin patients are typically weight-stable, so unexplained weight loss is more notable; persistent unexplained fatigue; new persistent lymphadenopathy; new persistent gastrointestinal / urinary / respiratory symptoms; new skin lesion change; new breast / testicular finding; new musculoskeletal pain not explained by tesamorelin arthralgia pattern).

First-line management. Standard age-appropriate cancer surveillance per primary-care or specialty-care framework; tesamorelin does not require alternative cancer surveillance beyond the standard schedule.

Escalation triggers. New cancer-suspicious finding → diagnostic workup per standard of care; tesamorelin discontinued pending evaluation.

Discontinuation triggers. New cancer diagnosis → permanent tesamorelin discontinuation per §2.4 / §8; transition to non-GH-axis alternative for VAT-reduction component if clinically indicated and patient agrees.

6.10 Worked example — Tesamorelin + AOD-9604 adjunct stack AE management at maintenance dose

A non-HIV adult on tesamorelin Egrifta SV 1.4 mg SC daily + semaglutide 2.4 mg SC weekly + no AOD-9604, Month 8 on tesamorelin, presents with persistent mild bilateral knee arthralgia (Grade 1–2) and modest HbA1c rise from baseline 5.6 to 6.1 (rise +0.5% from baseline; at the protocol threshold for dose-adjustment consideration).

Protocol response. Anticipatory framing: arthralgia is within Falutz Phase 3 enrollment AE profile (approximately 10–15% prevalence; GH-axis fluid-retention and joint-capsule mechanism); HbA1c rise +0.5% is at the protocol-defined threshold for dose-adjustment consideration in a non-diabetic patient transitioning toward prediabetic range (HbA1c 6.1 is upper end of normal / lower end of prediabetic range, depending on lab reference cutoffs). First-line management: arthralgia — continue as-needed naproxen; reinforce stretching / mobility exercises; reassurance that arthralgia commonly attenuates by Month 6–12 in some patients. HbA1c rise: dose reduction from 1.4 mg → 1 mg SC daily (off-label clinician-judgment within label-permitted dose range); reassess HbA1c at 12-week post-dose-adjustment; coordinate with primary-care or T2D-management team. Continue waist-circumference and DEXA-VAT monitoring at the new dose to assess whether VAT-reduction response is maintained at the lower dose.

A non-HIV adult on tesamorelin Egrifta SV 1.4 mg SC daily, Month 9, develops new persistent unilateral lower-back pain not explained by typical tesamorelin arthralgia pattern; routine surveillance ALP modestly elevated; PSA (this is a male patient, age 58) elevated from baseline 1.4 to 5.6 ng/mL.

Protocol response. New cancer-suspicious finding pattern — bone-pain pattern + ALP elevation + PSA elevation in a male patient is a prostate-cancer-with-possible-bone-metastasis differential. Discontinue tesamorelin pending evaluation. Urgent urology / oncology consultation; PSA-velocity assessment, DRE, prostate biopsy as indicated by urology evaluation; bone imaging if bone-metastasis concern. The GH/IGF-1 axis activation is theoretically tumor-promoting biology for prostate cancer (IGF-1R pathway involvement is established for prostate-cancer biology); tesamorelin discontinuation is appropriate pending diagnostic workup. If prostate cancer is confirmed, tesamorelin is permanently discontinued per §2.4; transition to non-GH-axis alternative for VAT-reduction component (non-pharmacologic intervention; continued GLP-1 backbone provides VAT-reduction proportional to weight loss without GH-axis biology).

Pattern AA precision in §6.10. “HbA1c rise +0.5% from baseline triggers dose-adjustment consideration per protocol threshold” is precise — this is protocol-defined threshold, not labeled-defined threshold (the Egrifta SV label specifies glucose monitoring but does not specify a HbA1c-rise threshold for dose adjustment; the +0.5% threshold is clinical-judgment within the label-monitoring framework). “New cancer-suspicious finding triggers tesamorelin discontinuation pending evaluation per protocol §2.4 / §8” is precise — this is the FDA-label cancer-contraindication operationalized in the maintenance phase, not a new contraindication addition.

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when the adjunct stack’s primary effect — visceral-fat reduction, metabolic-marker improvement — has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). §7 is the diagnostic-and-decision branch point for the adjunct stack: distinguish pseudo-plateau (apparent stall within normal trajectory variation), true plateau (legitimate response stall requiring intervention), and non-response (insufficient initial effect).

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Pseudo-plateau. Apparent stall in waist circumference or in DEXA-VAT that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (visceral-fat preservation with continued metabolic-marker improvement) rather than total VAT-mass stall, or that occurs in the predictable Falutz Phase 3 trajectory pattern (effect plateau is typically reached by Week 26; continued therapy maintains the effect rather than producing additional VAT reduction beyond that point). Pseudo-plateau is recognized by trajectory-context — comparing the patient’s curve to the Falutz Phase 3 trajectory and identifying that the apparent stall is in fact on-trajectory.

True plateau. Legitimate response stall — patient was responding (waist circumference reducing; DEXA-VAT decreasing; metabolic markers improving), then response flattens or reverses before reaching the Falutz Phase 3 anchor magnitude (approximately −15–18% VAT). True plateau is recognized by trajectory inflection plus an adequate observation window (typically 2–3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3–6 on target dose with effect substantially below the Falutz Phase 3-typical effect for the on-label phenotype, or below practitioner-consensus expectation for the off-label non-HIV phenotype.

7.3 Pharmacodynamic-vs-clinical-response distinction

For this adjunct stack, an important diagnostic distinction is between pharmacodynamic non-response (IGF-1 fails to elevate appropriately into the target range) and clinical non-response (IGF-1 elevation is appropriate but waist circumference / DEXA-VAT / metabolic markers do not improve as expected). The two have different differential diagnoses:

Pharmacodynamic non-response (IGF-1 not elevating). Differential: ADA-mediated neutralization (consider after adequate dose-and-time exposure, typically ≥3 months on therapy); under-dosing (consider dose escalation to 2 mg if started at 1.4 mg; off-label clinician-judgment within label-permitted dose range); patient non-adherence (verify via prescription-refill audit and patient interview); compounding-pharmacy product variability (if using compounded tesamorelin, consider switching to FDA-approved Egrifta SV for verification); pituitary-axis dysfunction emergent after initiation (rare, but consider if other clinical features suggest pituitary dysfunction).

Clinical non-response (IGF-1 elevating appropriately but no clinical improvement). Differential: phenotype mismatch (the patient’s visceral-adiposity phenotype may not be the GH-axis-responsive phenotype the adjunct stack targets); concurrent factors limiting response (uncontrolled metabolic factors; medication interactions reducing efficacy; lifestyle / dietary factors counterbalancing the lipolytic effect); inadequate observation window (the Falutz Phase 3 plateau is at Week 26 — premature non-response determination at Week 12 or earlier should be deferred to Week 26 reassessment); body-composition measurement variability (DEXA-VAT precision is reasonable but not perfect; re-measure with same protocol / same operator for trend assessment).

7.4 Decision tree for plateau / non-response

Confirm adherence. Missed doses, injection-technique issues, compounding-pharmacy product variability (if using compounded tesamorelin) are pseudo-non-response causes. Verify via patient interview and via prescription-refill audit.
Confirm trajectory-context. Plot the patient’s curve against the Falutz Phase 3 trajectory for the on-label phenotype, or against the practitioner-consensus extrapolation trajectory for the off-label non-HIV phenotype. If the curve is on-trajectory, pseudo-plateau — continue current dose, reassess at next interval (typically Month 6 → Month 9 quarterly schedule).
Confirm dose attainment. Is the patient on target dose (Egrifta SV 1.4 mg or compounded 2 mg)? If not (e.g., patient initiated at 1 mg priming and has not advanced to 1.4 mg), complete dose attainment; reassess at 12-week post-target-dose-attainment.
Pharmacodynamic vs clinical distinction. Review IGF-1 response. If IGF-1 is not elevating appropriately, work through pharmacodynamic-non-response differential (§7.3). If IGF-1 is elevating appropriately, work through clinical-non-response differential (§7.3).
Phenotype reassessment. Does the patient’s clinical picture support a phenotype the protocol targets, or is the patient in an under-represented or out-of-trial phenotype? For non-HIV off-label use, the practitioner-consensus extrapolation may not generalize to all patient phenotypes (e.g., normoinsulinemic / metabolically-healthy obesity is not the typical adjunct-stack-target phenotype; appetite-driven obesity without visceral-fat predominance is also not).
If true plateau / non-response confirmed at adequate observation window (typically Month 6 on target dose):
- Tesamorelin dose escalation (clinician-judgment within label-permitted off-label range). If patient is on 1.4 mg, consider escalation to 2 mg with reassessment at 12-week post-dose-escalation. [NEEDS MD CONFIRMATION] — this is off-label clinician judgment, not a standard FDA-label escalation; the 2-mg dose is the Falutz Phase 3 dose and is documented as effective for the on-label HIV-LD indication, and the off-label extrapolation to non-HIV is plausibly equivalent.
- AOD-9604 layer addition (if not already part of the regimen). Consider adding AOD-9604 250–300 mcg SC daily fasted AM as an evidence-limited adjunctive layer. Honest patient counseling per Pattern Z anchor 5 (§10.6) on the AOD-9604 evidence base (preclinical + sponsor-disclosed Phase 2b not peer-reviewed-published + development discontinued 2007). The mechanism rationale is non-redundant with tesamorelin (AOD-9604 engages lipolysis decoupled from GH-receptor signaling); the additive benefit is mechanism-plausible but evidence-limited.
- Discontinuation of adjunct stack; reassessment of primary weight-management therapy. If the visceral-fat-specific component is the residual clinical concern and the adjunct-stack response is inadequate, consider whether optimization of the primary GLP-1-class therapy (transition from semaglutide to tirzepatide per SURMOUNT-5 head-to-head higher-effect-size; addition of cagrilintide-based combination if approved; intensification of behavioral / nutritional / activity program per STEP-3 effect-additive pattern) is appropriate before continued adjunct-stack therapy. Pattern Z anchor 4 framing — present the alternative options factually without steering.
- Transition to non-pharmacologic VAT-reduction approach. Sustained behavioral / nutritional / activity intervention; resistance training (lean-mass preservation aligned with the adjunct-stack rationale); sleep optimization (sleep restriction is associated with central-adiposity accumulation; sleep optimization can produce modest VAT reduction). These are baseline interventions that should be optimized regardless of adjunct-stack continuation.

7.5 Worked example — Tesamorelin + AOD-9604 adjunct stack non-responder algorithm

A non-HIV adult on tesamorelin Egrifta SV 1.4 mg SC daily + semaglutide 2.4 mg SC weekly, Month 6 on tesamorelin, has the following profile: IGF-1 elevation appropriate (rose from baseline 130 to 215 ng/mL, within upper target range); waist circumference 108 cm (decreased from baseline 112 cm = 4 cm reduction, below the practitioner-consensus extrapolation of approximately 8–12 cm reduction at Month 6 in similar phenotypes); DEXA-VAT at Week 26 showed only −6% VAT reduction (below the Falutz Phase 3 anchor of approximately −15% at the same timepoint); HbA1c stable; no significant AE concerns.

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; prescription-refill audit confirms no gaps.

Step 2 — trajectory-context. Patient’s curve at Month 6 (−6% VAT) is below the Falutz Phase 3 26-week-anchor of approximately −15% VAT; also below the practitioner-consensus extrapolation for similar non-HIV phenotypes. Not on-trajectory.

Step 3 — dose attainment. Patient on 1.4 mg target dose (FDA-label dose); no further FDA-label-recommended escalation. Off-label escalation to 2 mg is clinician-judgment within label-permitted dose range.

Step 4 — pharmacodynamic vs clinical distinction. IGF-1 is elevating appropriately (130 → 215 ng/mL); pharmacodynamic response is adequate. This is a clinical non-response, not a pharmacodynamic non-response.

Step 5 — phenotype reassessment. Patient is a 48-year-old male, baseline BMI 32, T2D HbA1c 6.4 at baseline (now 6.6 on adjunct stack), waist circumference baseline 112 cm, central-adiposity-predominant. The phenotype is within the typical adjunct-stack-target phenotype (visceral-fat-predominant, insulin-resistant, metabolic-syndrome adult); however, T2D pre-existing status and modest HbA1c elevation suggest the metabolic milieu may be limiting the VAT-redistribution response.

Step 6 — clinical non-response confirmed at adequate observation window; decision-tree branches:

6a. Off-label dose escalation to 2 mg. Discussion with patient: the Falutz Phase 3 dose was 2 mg SC daily; the Egrifta SV 1.4 mg dose is the reformulated label dose with PK-equivalence rationale. Escalation to 2 mg is off-label clinician-judgment within label-permitted dose range. Patient agrees to 12-week trial at 2 mg with reassessment at Month 9.

6b. AOD-9604 layer addition discussion. Patient and clinician review the AOD-9604 evidence-base honest framing (Pattern Z anchor 5; §10.6). Patient elects to defer AOD-9604 layer pending the 2-mg tesamorelin escalation response — additional injections / cost / evidence-limited expected benefit do not justify simultaneous addition at this decision point.

6c. Primary weight-management therapy reassessment. Patient is on semaglutide 2.4 mg with partial response (BMI 32 → 30; some weight reduction); discussion of transition to tirzepatide per SURMOUNT-5 head-to-head higher-effect-size — patient elects to continue semaglutide for now and reassess primary therapy at Month 9.

6d. Non-pharmacologic intensification. Resistance training program initiated 3×/week; dietary review with attention to total carbohydrate / saturated-fat patterns; sleep-hygiene assessment with concrete recommendations.

Pattern Z calibration anchor applied at §7.5. The decision among 6a / 6b / 6c / 6d is patient-anchored, not clinician-mandated. Counseling beats (§10) frame the options without steering — present the Falutz-Phase-3-anchored effect-size estimates for each option, present the trade-offs (cost, AE-profile, evidence-base, injection-burden), and the clinician-patient decision is patient-preference-driven within the medically reasonable options.

Pattern AA applied at §7.5. “Off-label clinician-judgment escalation to 2 mg” is precise — this is off-label dose use of an FDA-approved-for-marketing-claims drug, within the label-permitted dose range (the original Egrifta 2-mg formulation was the FDA-approved dose for the same indication; the Egrifta SV 1.4-mg dose is the reformulation dose). “Investigational AOD-9604 layer addition” is precise — this is investigational use of a non-FDA-approved-for-marketing-claims compound, not “off-label use” (which would imply FDA-approved use). Pattern AA distinction preserved.

8. Discontinuation and tapering

8.1 Purpose

Define when to stop the adjunct stack, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the VAT-redistribution reversal trajectory documented in the Falutz 2008 AIDS extension data. §8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and pharmacodynamic response, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

Confirmed contraindication discovery. New cancer diagnosis (§2.4 hard contraindication); new pregnancy (§2.4 hard contraindication; Category X); new pituitary-axis disruption identification (§2.4 hard contraindication). These are immediate-discontinuation triggers.
Severe AE attributable to the molecule. Disabling arthralgia / edema not responsive to dose reduction; persistent supraphysiological IGF-1 not responsive to dose reduction; severe hypersensitivity reaction; significant glycemic deterioration into uncontrolled-T2D range attributable to tesamorelin. §6 AE-class-specific discontinuation triggers.
Inadequate clinical response at adequate dose-and-time exposure. §7 non-response algorithm directs transition to alternative VAT-reduction approach; tesamorelin (and AOD-9604 if part of regimen) discontinued.
Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway, not to override the patient’s decision. Common patient-preference reasons: cost / access burden (particularly for branded Egrifta SV without insurance coverage); injection-burden preference change; satisfaction with current body-composition state (the adjunct-stack response has achieved the patient’s clinical goal and the patient elects to discontinue while maintaining the response via behavioral / nutritional / activity intervention — recognizing the §8.5 reversal trajectory).
Cost / access barriers. Egrifta SV branded list price 2, 000–3,000+/month is a documented practice-level barrier; insurance coverage variability for off-label non-HIV use is common. Pattern Z calibration anchor 2 framing applies in §10 — present the cost / access reality factually, not as steering.
Pre-conception planning for reproductive-age patients. Pre-conception discontinuation per the §8.4 arithmetic. This is anticipatory discontinuation, not reactive.
Indication-resolution (rare in this protocol). A patient on the HIV-lipodystrophy on-label indication whose VAT-redistribution-needs are clinically resolved with sustained therapy may elect discontinuation with recognition of the §8.5 reversal trajectory.

8.3 How to taper — tesamorelin and AOD-9604 tapering considerations

For tesamorelin, pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven PK washout is rapid (terminal half-life 26–38 minutes; effective clearance within hours). However, gradual dose reduction is not standard practice for tesamorelin discontinuation — unlike the GLP-1-class protocols where gradual reduction is recommended for weight-regain-trajectory smoothing and for behavioral adaptation, tesamorelin discontinuation does not produce the same appetite-rebound or behavioral-adaptation pattern (the mechanism does not engage central appetite pathways). The Falutz 2008 AIDS extension trial used abrupt discontinuation (P-T → P switch at Week 26 with subsequent VAT reversal documented through Week 52) — the standard discontinuation pattern in the on-label clinical-trial context.

Practitioner-consensus discontinuation pattern. Most off-label clinical practice uses abrupt discontinuation. Some practitioners use a brief dose-step-down (1.4 → 1 mg × 2 weeks → off) as a soft-landing approach, but this is clinician-judgment rather than evidence-anchored.

AOD-9604 discontinuation. No pharmacological tapering rationale; abrupt discontinuation is standard.

8.4 Pre-conception washout arithmetic — tesamorelin

Tesamorelin terminal half-life: 26–38 minutes (HIV-infected adults; from Egrifta SV PI PK data). Approximately 5 half-lives are required for >95% PK clearance — approximately 2–3 hours. The PK clearance is rapid; however, the GH/IGF-1 axis biology persists longer. IGF-1 half-life in circulation is approximately 12–15 hours; the IGF-1 elevation drive by tesamorelin therapy persists for days to weeks post-discontinuation as the IGF-1 levels normalize toward baseline. The pituitary somatotroph function returns to baseline secretory pattern rapidly post-discontinuation (no negative-feedback recovery required, unlike exogenous somatropin discontinuation).

The FDA label for Egrifta SV does not specify a pre-conception discontinuation interval. Standard practice applies clinical-judgment based on the GH/IGF-1 axis clearance arithmetic plus margin: typically discontinue at least 1–2 months before planned conception attempts to allow IGF-1 normalization plus margin for any persisting pharmacodynamic effect. This is conservative clinical practice; the PK-only arithmetic would suggest a shorter interval is mathematically sufficient.

AOD-9604 pre-conception washout. AOD-9604 PK is incompletely characterized; half-life is estimated short (minutes). Pre-conception discontinuation at least 1–2 months before conception attempts is standard clinical-judgment posture pending PK characterization, with recognition that the underlying pharmacodynamic effect is preclinically incompletely characterized.

The 1–2 month pre-conception window is the operational counseling beat for reproductive-age patients on the adjunct stack — §10.4 counseling beats anchor to this arithmetic with Pattern Z calibration anchor 3 precision (research-state framing of pregnancy-exposure data; Category-X label framing carried as factual context; not steering).

8.5 Post-discontinuation VAT-redistribution reversal framing

The Falutz 2008 AIDS extension trial data are load-bearing for §8.5: patients who switched from tesamorelin to placebo at Week 26 showed reversal of the VAT-reduction effect by Week 52 — the visceral-fat-redistribution effect requires continued therapy. The mechanism rationale is that tesamorelin drives chronic-state VAT redistribution while on therapy; the GHRH-R agonism does not produce a sustained-cure-state metabolic remodeling that persists through discontinuation. Without the chronic pulsatile GH stimulation, the patient’s adipose-tissue distribution returns toward its pre-treatment equilibrium.

The protocol framing in counseling (§10) does not pathologize the VAT-redistribution reversal post-discontinuation; it frames the reversal trajectory as the expected biological response, the same way pre-treatment counseling framed the VAT-selective lipolysis as the biological intervention. Patients considering discontinuation are counseled on the expected reversal trajectory and on the re-initiation pathway if reversal occurs and warrants re-treatment.

The reversal trajectory is partial, not complete in some patients — practitioner-experience literature documents some patients who maintain a fraction of the VAT-reduction post-discontinuation, particularly when behavioral / nutritional / activity intervention is continued. The Falutz Phase 3 trial population had limited concurrent behavioral intervention; non-HIV off-label adjunct-stack patients are typically on robust behavioral intervention as part of their primary weight-management protocol, which may modulate the post-discontinuation trajectory. The honest framing is that the population-level Falutz trajectory shows reversal; individual-level variation exists and is partly modifiable by continued behavioral intervention; the patient’s individual trajectory cannot be precisely predicted in advance.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: re-initiation from the steady-state dose is the protocol-recommended pattern (no titration-priming requirement; the same fixed-dose initiation pattern as in §4). Indication confirmation per §1, selection-criteria re-screening per §2 (particularly the cancer-history surveillance status and pituitary-axis status), and pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

8.7 Worked example — Tesamorelin discontinuation scenarios

Scenario A — patient-preference discontinuation at Year 2. A 56-year-old female (Worked Example A continued through Year 2): VAT-reduction sustained at approximately −22% from baseline; metabolic-marker improvement sustained; HbA1c 5.8 (modest elevation but tolerable); patient is satisfied with current body-composition state and elects to discontinue tesamorelin while continuing semaglutide as primary weight-management therapy. The patient understands the §8.5 reversal trajectory and accepts that partial VAT regain is likely without continued therapy. Counseling beat: discuss the Falutz 2008 AIDS extension data showing VAT reversal at 52 weeks post-discontinuation; re-initiation pathway available if regain occurs and patient elects to resume; protocol abrupt discontinuation acceptable. Post-discontinuation monitoring at Month 3 (waist circumference; metabolic markers; body-composition DEXA optional) and Month 6 / 12; re-initiation decision at any monitoring visit if reversal warrants and patient agrees. Pattern Z calibration anchor 3 and anchor 5 framing — pregnancy-planning not applicable (post-menopausal); the off-label-use re-initiation pathway is presented factually without steering.

Scenario B — new cancer diagnosis at Year 3. A 60-year-old male on tesamorelin (Worked Example B continued through Year 3): routine surveillance colonoscopy identifies adenocarcinoma of the colon, stage IIIB on subsequent staging. Per §2.4 / §6.9, active malignancy is an absolute contraindication for tesamorelin. Discontinue tesamorelin immediately (no taper). Transition oncology management; tesamorelin re-initiation possible if and when the patient achieves “inactive AND treatment-complete” criterion per FDA label, with oncology agreement and conservative cancer-history posture documented in the future re-initiation informed consent.

Scenario C — pre-conception planning. A 32-year-old female on tesamorelin off-label for visceral-adiposity-predominant insulin-resistant phenotype (status post-PCOS-associated metabolic-syndrome with substantial visceral-adiposity component) has been on adjunct stack for 14 months with sustained VAT reduction; planning conception in approximately 6 months. Counseling beat: discuss the 1–2 month pre-conception discontinuation interval based on tesamorelin PK clearance + IGF-1 normalization + margin; tesamorelin Category X per FDA label; AOD-9604 (if included) discontinued with same interval (pending PK characterization). Plan discontinuation start approximately 4–5 months from now (allow 1–2 month tesamorelin clearance plus margin pre-conception). Continue semaglutide per primary weight-management protocol with separate pre-conception discontinuation discussion (semaglutide ~8-week pre-conception window per Wegovy / Ozempic label per M5.2 protocol — different pharmacokinetics from tesamorelin; the two pre-conception windows are managed as separate clinical decisions). Pattern Z calibration anchor 3 precision: present the pharmacokinetic facts (tesamorelin terminal half-life 26–38 min; rapid PK clearance; IGF-1 normalization over days-to-weeks; clinical-judgment posture of 1–2 month pre-conception interval); present the §8.5 reversal trajectory; the patient’s reproductive-planning decision is patient-anchored.

Scenario D — new pregnancy on protocol. A 34-year-old female on tesamorelin off-label discovers pregnancy at approximately 5 weeks gestation. Tesamorelin is Category X per FDA label. Immediate discontinuation; abrupt discontinuation appropriate. Obstetrics co-management; the IGF-1 axis exposure during first-trimester is documented for the obstetrics record; tesamorelin PK clearance is rapid (hours), but the IGF-1 elevation persisted for days-to-weeks pre-discovery. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

Pattern Z calibration anchor 3 precision in §8.7. Pregnancy-planning counseling presents the pharmacokinetic facts (rapid PK clearance), the pharmacodynamic timeline (IGF-1 normalization over days-to-weeks), the clinical-judgment 1–2 month interval (with margin rationale), the §8.5 post-discontinuation VAT-redistribution reversal trajectory, and the Category-X FDA-label framing — facts that the patient uses to make her reproductive-and-treatment-planning decision. The protocol does not steer the patient toward continued pharmacotherapy by emphasizing reversal-risk, nor toward discontinuation by emphasizing pregnancy-exposure risk. Both facts are presented; the patient decides.

9. Combination rules

9.1 Purpose

Define what stacks with the adjunct stack, what is contraindicated in combination, and the rationale for each combination category. §9 is the protocol’s bridge to Module 5.12 Combination Protocols and to other Module 5 protocols. The section is structured by combination class — primary-therapy combinations (the adjunct stack co-administered with a GLP-1-class primary therapy, which is the standard adjunct-stack composition); adjunct-internal combinations (tesamorelin + AOD-9604 co-administration within the adjunct stack itself); cross-Module combinations (adjunct stack + lean-mass-stack peptides per M5.6; adjunct stack + skin-elasticity peptides per M5.7); and contraindicated combinations.

Pattern W cross-section consistency applies: every combination in this section is reconciled with §2 (a combination cannot include an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors).

9.2 Primary-therapy combinations — adjunct stack + GLP-1-class

The standard adjunct-stack composition is tesamorelin + GLP-1 RA (most commonly semaglutide per M5.2 Wegovy/Ozempic protocol or tirzepatide per M5.3 Zepbound/Mounjaro protocol; liraglutide per Saxenda protocol or oral semaglutide Rybelsus also applicable). The combination is mechanism-additive: GLP-1-class therapy drives the load-bearing total-weight reduction with VAT-reduction proportional to total weight loss; tesamorelin adds the VAT-selective mechanism that addresses the residual visceral-fat component disproportionate to total-fat reduction.

Pharmacologic compatibility. No pharmacological contraindication to the combination. The two mechanism classes (GLP-1R agonism + GHRH-R agonism) do not engage overlapping receptor biology. Pharmacokinetic interactions are not characterized as significant.

Clinical compatibility considerations. The combined AE profile is largely the sum of the two individual AE profiles — the GLP-1-dominant GI AE class plus the tesamorelin injection-site / arthralgia / edema / glucose-elevation AE class. Glucose monitoring is the load-bearing combined-AE-management focus: GLP-1-class therapy lowers glucose (HbA1c reduction; in T2D patients) and is favorable for the glycemic axis; tesamorelin can raise glucose (modest HbA1c rise; particularly in T2D / prediabetic patients) and is unfavorable for the glycemic axis. The net effect typically remains glycemically favorable because the GLP-1-class glucose-lowering effect dominates in most patient phenotypes — but the combined glucose-monitoring schedule needs to account for both directions. In patients on concurrent insulin / sulfonylurea, the GLP-1 + insulin / sulfonylurea hypoglycemia-risk pattern (managed per the M5.2 / M5.3 / Liraglutide protocol §6.7 framework) coexists with the tesamorelin glucose-elevation pattern; net management is glucose-stability-anchored rather than directional.

Cost / access considerations. The combined regimen carries the cost of two compounds. Patients managing cost may face decisions about branded vs compounded options for either or both compounds. Pattern Z anchor 2 framing applies — present cost / access realities factually without steering.

9.3 Adjunct-internal combinations — tesamorelin + AOD-9604

Co-administration of tesamorelin + AOD-9604 within the adjunct stack itself is mechanism-additive but evidence-limited. The two compounds engage non-redundant biology — tesamorelin’s GHRH-R-mediated pulsatile GH release + downstream IGF-1 elevation + VAT-selective lipolysis is distinct from AOD-9604’s hypothesized lipolysis decoupled from GH-receptor signaling. The combined hypothesized effect is additive VAT-selective lipolysis (tesamorelin) plus general adipose lipolysis (AOD-9604).

Pharmacologic compatibility. No characterized pharmacological contraindication to the combination. AOD-9604 does not engage the GHRH-R pathway or the GH receptor; tesamorelin engages the GHRH-R but not the AOD-9604 hypothesized β3-AR pathway. Pharmacokinetic interactions are not characterized.

Clinical evidence for the combination. No Phase 3 RCT evaluates the tesamorelin + AOD-9604 co-administration regimen. The rationale for the combination is mechanism-based and practitioner-experience-based, not RCT-confirmed. Pattern Z.research-precision: this is research-state-incomplete for the combination-specific question, not “highly experimental”; the constituent compounds have their respective evidence bases (tesamorelin Phase 3 for HIV-LD; AOD-9604 preclinical + sponsor-disclosed Phase 2b), but the co-administration evidence is mechanism-plausibility plus practitioner consensus.

Sequential introduction (protocol default). Tesamorelin initiated in Phase 1 (Weeks 1–4); AOD-9604 layer added in Phase 3 (Week 13+) if clinically indicated and patient-consented per §4.3. Sequential introduction supports causal attribution if any AE emerges. Concurrent initiation is permitted but combines the attribution context for any AE.

Available as a compounded blend. Some 503A compounding pharmacies offer tesamorelin + AOD-9604 co-formulated blends (similar in concept to the Tesa-Ipam blend referenced in the canonical literature for tesamorelin + ipamorelin). Compounded blend products carry the same Pattern Z anchor 1 / 2 operational characteristics as individual compounded tesamorelin (sterility testing per USP <797> / <800>; per-batch certificates of analysis; compounding-pharmacy quality criteria evaluation); the blend convenience reduces injection burden but constrains independent dose-titration of the two components.

9.4 Cross-Module combinations

Adjunct stack + lean-mass-stack peptides (M5.6 framework). CJC-1295 / Ipamorelin (GH-secretagogue stack at 100 mcg / 200 mcg SC at bedtime, 5 days/week per M5.6 framework) is a cross-Module combination that stacks on the same GH-axis biology as tesamorelin. The mechanism overlap deserves explicit consideration: CJC-1295 is a GHRH analog (sermorelin-class); Ipamorelin is a ghrelin-receptor agonist (GH secretagogue). Combined with tesamorelin (also a GHRH analog), the regimen represents multiple GH-axis-activating compounds simultaneously — which can produce additive pulsatile GH release but also additive supraphysiological IGF-1 risk. Clinician judgment within M5.6 protocol framework; IGF-1 monitoring is particularly load-bearing in combined GH-axis-stack contexts; dose adjustment of either or both compounds may be needed to maintain IGF-1 within target range. Pattern Z anchor 5 framing — the M5.6 lean-mass-stack components are investigational (503A compounding; bulks list category 2); the cross-Module combination is mechanism-plausible practitioner consensus, not RCT-confirmed.

Adjunct stack + MOTS-c. MOTS-c is a mitochondrial-encoded peptide with metabolic-regulator activity in preclinical models (Lee 2015 Cell Metab mechanism characterization + animal studies + early human pharmacology). Combined with the adjunct stack, MOTS-c adds a mitochondrial-flexibility mechanism distinct from GH-axis biology. Trial-program status: limited human Phase 1/2 data; clinician judgment within M5.6 stack framing. Pattern AA precision: MOTS-c is investigational; not FDA-approved for marketing claims for any indication.

Adjunct stack + GHK-Cu (skin / connective-tissue peptide; M5.7 framework). GHK-Cu is a Module 5.7 (skin-elasticity, post-weight-loss skin tone) topical or injectable application. Cross-Module combination for patients with substantial body-composition change who develop skin-laxity concerns; the GHK-Cu mechanism is distinct from the adjunct-stack mechanism and the combination is straightforward. Pattern V direction-of-effect: GHK-Cu trial-program data are limited for the post-weight-loss-skin indication specifically; clinician judgment with patient-anchored expectations.

Adjunct stack + SGLT2 inhibitor (in T2D context). For T2D patients in the adjunct-stack regimen who also have ASCVD or CKD indications, SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) addition is standard polycondition T2D regimen per current ADA/EASD guidance. The combination is well-supported (individual-agent CVOT / KOOT data); not contraindicated.

Adjunct stack + statin / RAS blockade / standard cardiovascular regimen. Standard cardiovascular co-medications are commonly co-prescribed with the adjunct stack in metabolic-syndrome adults; no characterized interaction.

9.5 Contraindicated combinations

Adjunct stack + concurrent supraphysiological exogenous growth hormone (somatropin). Direct exogenous GH suppresses endogenous GH production via negative feedback; concurrent tesamorelin (a GHRH-R agonist that works through endogenous pituitary somatotrophs) is mechanistically counterproductive. §2.3 relative exclusion overlaps with the §9.5 contraindicated-combination framework.
Adjunct stack + concurrent insulin-resistance-promoting medications that compound the glucose-elevation AE. High-dose corticosteroids; some antipsychotics with significant metabolic effects (olanzapine, clozapine); some immunosuppressants. Relative — combination produces additive glucose-elevation risk; clinician judgment with enhanced glucose monitoring; consider whether the concurrent indication for the insulin-resistance-promoting medication can be optimized via alternative agent.
Adjunct stack + active acromegaly therapy (somatostatin analogs at therapeutic doses; pegvisomant, etc.). Mechanism conflict — somatostatin analogs suppress GH secretion; tesamorelin stimulates GH secretion. The combination is pharmacologically counterproductive. Consult endocrinology for active acromegaly management; adjunct stack is not indicated in this population.

9.6 Worked example — Tesamorelin + AOD-9604 adjunct stack combination scenarios

Scenario A — adjunct stack + semaglutide (the standard composition; Worked Example A pattern). A 53-year-old female on Wegovy 2.4 mg SC weekly + Egrifta SV 1.4 mg SC daily; the standard composition for non-HIV adjunct-stack use. Glucose monitoring at the combined-AE-management cadence (HbA1c at baseline / Week 12 / Month 6 / Month 13 then biannually); waist circumference at every visit; DEXA at Week 26 / Year 1; cancer surveillance per §3.6 / §6.9. Pattern Z anchor 4 framing — both compounds are evidence-based for their respective roles (GLP-1 RA for chronic weight management; tesamorelin off-label for visceral-adiposity adjunct); the patient is on the combined regimen with appropriate informed consent.

Scenario B — adjunct stack + tirzepatide (alternative primary-therapy combination). A 49-year-old male with BMI 38, T2D HbA1c 7.6, on tirzepatide 15 mg SC weekly per M5.3 Zepbound/Mounjaro protocol (substantial weight reduction and HbA1c improvement at Month 9); adds tesamorelin Egrifta SV 1.4 mg SC daily for residual visceral adiposity (waist circumference 108 cm despite substantial weight reduction). Combined glucose monitoring at enhanced cadence given T2D pre-existing. Combined AE management per §6 + M5.3 protocol §6. Standard adjunct-stack composition.

Scenario C — adjunct stack + CJC-1295/Ipamorelin cross-Module combination (M5.6 stack). A 55-year-old male, on Wegovy 2.4 mg SC weekly + Egrifta SV 1.4 mg SC daily, Month 12 on the adjunct stack with appropriate VAT-reduction response, develops lean-mass loss concern on annual DEXA reassessment (lean mass −4% from baseline despite resistance training program). Discussion of M5.6 lean-mass-preservation stack — CJC-1295 / Ipamorelin per M5.6 v3 protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Mechanism-overlap consideration: CJC-1295 is a GHRH analog (sermorelin-class); concurrent with tesamorelin (also a GHRH analog), the regimen represents multiple GH-axis-activating compounds. Pattern Z anchor 5 framing — the M5.6 stack components are investigational; the combined regimen is mechanism-plausible practitioner consensus; IGF-1 monitoring is particularly load-bearing; dose adjustment of either or both GHRH-analog compounds may be needed to maintain IGF-1 within target range. Patient and clinician discuss the trade-off — adding M5.6 stack increases the GH-axis-activation cumulative exposure and warrants closer IGF-1 monitoring; alternative is to optimize the resistance-training program and dietary protein intake before adding the M5.6 stack. Patient-anchored decision.

Scenario D — adjunct stack + concurrent somatropin (contraindicated). A 47-year-old male on adult-GH-deficiency somatropin replacement (managed by endocrinology) presents asking about tesamorelin for residual visceral adiposity. Combination is mechanistically counterproductive — direct exogenous GH suppresses endogenous GH; tesamorelin works through endogenous pituitary somatotrophs. Not indicated. Discussion with endocrinology about whether the current somatropin replacement is optimally dosed for the visceral-fat phenotype; the question is somatropin-axis-optimization, not adjunct-stack-addition.

Pattern W cross-check at §9.6. Each combination above is reconciled with §2 (no patient enters a combination with a contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-agent AE-management algorithms), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant). The combined-glucose-monitoring schedule is reconciled with §3 baseline panel (HbA1c at baseline; fasting glucose at baseline; HOMA-IR at baseline if relevant) and with §5 maintenance monitoring (HbA1c quarterly for T2D / prediabetic patients on the combined regimen).

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the protocol’s patient-counseling content — the conversations the clinician has with the patient at each protocol phase. §10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration). For this adjunct protocol, §10 is also where the adjunct-vs-standalone framing is operationally tested — the counseling beats must consistently frame the stack as a body-composition adjunct to primary weight management, not as a standalone weight-loss intervention.

The five Pattern Z calibration anchors (verbatim-calibrated against /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md) are applied to this adjunct protocol with adjunct-specific calibration per the front-matter orchestrator launch prompt. Each anchor is referenced explicitly in the relevant §10 sub-block.

Anchor 1 — Lead with what the adjunct stack IS. This adjunct protocol leads with: a body-composition adjunct strategy targeting visceral adipose tissue, used alongside primary weight-management therapy. The framing throughout §10 carries this adjunct-vs-standalone distinction.
Anchor 2 — Compounded vs FDA-approved (tesamorelin). Tesamorelin is FDA-approved-for-marketing-claims (Egrifta SV / Egrifta WR; specialty-pharmacy distribution) and is also available through 503A / 503B compounding pathways. AOD-9604 is not FDA-approved for marketing claims for any drug indication — the Anchor 2 framing for AOD-9604 is investigational-compound framing per Anchor 5, not branded-vs-compounded framing.
Anchor 3 — Pregnancy planning. Tesamorelin is Category X per FDA label. Anchor 3 LEADS with research-state framing of pregnancy-exposure biology, then carries the regulatory contraindication factually. The pharmacokinetic clearance arithmetic differs from the GLP-1 class (rapid PK clearance for tesamorelin; longer-persisting IGF-1 axis biology) and is presented factually with the 1–2 month clinical-judgment pre-conception interval.
Anchor 4 — Comparator framing — visceral-fat-targeted adjuncts vs broader weight-loss agents vs other body-composition tools. Multi-dimensional fact presentation; affirms each option’s role; closes with shared-decision-making.
Anchor 5 — Off-label tesamorelin + investigational AOD-9604 — DOMINANT anchor for this protocol. Off-label use of an FDA-approved-for-marketing-claims drug (tesamorelin for non-HIV visceral adiposity); investigational use of a non-FDA-approved-for-marketing-claims compound (AOD-9604). The research-state-precise framing is the load-bearing discipline for this protocol.

10.2 Initiation conversation (§4 anchor)

The initiation conversation occurs at the pre-treatment workup completion / §4 initiation visit. Required counseling beats:

What the adjunct stack is (Anchor 1): “We’re discussing an adjunct treatment for the visceral-fat-specific component of your body composition — that’s central / abdominal fat surrounding your organs, which is metabolically active and linked to insulin resistance, MASLD, dyslipidemia, and cardiometabolic risk. The adjunct stack is tesamorelin, a peptide that works through your own pituitary to stimulate pulsatile growth-hormone release; downstream, that growth-hormone activation produces visceral-fat-selective lipolysis — meaning it preferentially mobilizes fat from your visceral depots rather than from subcutaneous depots. It’s not a weight-loss drug — your scale weight will probably stay approximately stable while your waist circumference and visceral fat decrease. That’s the mechanism. We may optionally layer in AOD-9604, an investigational peptide fragment of human growth hormone that engages a different lipolysis pathway — but the evidence base is much more limited, and the standard protocol leads with tesamorelin first.”
What it does for the patient’s indication (Anchor 1, Anchor 4): “The evidence base for tesamorelin’s visceral-fat-reduction effect is the Falutz Phase 3 program in HIV-lipodystrophy — three trials over 26 to 52 weeks showing approximately 15 to 18 percent visceral-adipose-tissue reduction, with metabolic-marker improvements (triglycerides; total cholesterol / HDL ratio) and approximately neutral total body weight. We’re using it off-label for your non-HIV visceral adiposity — that’s a standard clinical-practice pathway for FDA-approved drugs; the mechanism translates plausibly from the HIV-lipodystrophy population to your phenotype, though the specific effect-size hasn’t been Phase-3-confirmed in non-HIV populations. AOD-9604, if included, adds evidence-limited adjunctive lipolytic activity — modest expected contribution beyond what tesamorelin and your primary therapy already provide.”
The adjunct framing (Anchor 1 + Anchor 5): “This is an adjunct to your primary weight-management therapy — your GLP-1 RA (semaglutide / tirzepatide / liraglutide / orforglipron) is the load-bearing weight-loss agent; the adjunct stack adds the visceral-fat-specific component that the GLP-1 class addresses but doesn’t fully resolve in some patients with disproportionate central adiposity.”
The initiation pattern (§4): “Tesamorelin has a fixed-dose initiation pattern — no titration-priming requirement like the GLP-1 class. You’ll start at 1.4 mg subcutaneous daily (or 2 mg if we’re using compounded), give yourself a daily injection in the abdomen, and we’ll reassess at Week 4 and Week 12. Self-injection is a routine clinical skill — taught in one clinical visit, refined over the first few self-administrations. It’s a fine 29- or 31-gauge insulin syringe; the technique is straightforward.”
The AE profile expected (§6 anticipatory framing): “The AE profile is different from your GLP-1 — no nausea / vomiting / diarrhea / constipation pattern from tesamorelin. The expected AEs are injection-site reactions (around 13–25% of patients; usually mild; self-limiting with site rotation and cold-pack pre-injection); arthralgia, particularly in large joints like knees (around 10–15%; usually self-limiting over 4 to 8 weeks); peripheral edema (5–10%; ankles and lower legs; self-limiting); and a small glucose elevation — modest in non-diabetic patients, more clinically meaningful in T2D / prediabetic patients, which is why we monitor HbA1c closely.”
The pre-conception planning beat for reproductive-age patients (Anchor 3): described in §10.4.
Cost / access realities (Anchor 2): “Branded Egrifta SV is in the 2, 000–3,000+/month range; insurance coverage for off-label use varies — typically requires prior authorization with documented medical necessity. Compounded tesamorelin from a 503A pharmacy is typically 200–500/month for the same daily dose — a substantial cost differential. Both are clinically reasonable; the operational differences are real (compounded uses lyophilized vials requiring reconstitution; branded is supplied through specialty-pharmacy distribution; both are SC self-injection at the same daily dose). We can discuss which makes sense for your situation.”
What the patient signals back if any concern emerges (escalation pathway): “Symptoms that warrant in-person evaluation within 48 hours: new severe joint pain not explained by typical tesamorelin arthralgia pattern; new asymmetric leg swelling (we’d want to rule out DVT); new chest pain or shortness of breath; new unexplained weight loss; any new cancer-suspicious finding — bumps, lumps, persistent unexplained symptoms; severe glucose dysregulation (high blood sugars, very thirsty / very-frequent-urination pattern).”

10.3 Compounded-vs-FDA-approved tesamorelin counseling (Anchors 1 + 2)

The compounded-vs-FDA-approved counseling beat for tesamorelin is the most directly comparable to the M5.2 / M5.3 compounded-semaglutide / compounded-tirzepatide framing — the FDA-approved-for-marketing-claims drug is available, AND compounded preparations through 503A / 503B pharmacies are available, AND patients face a substantial cost differential between the two.

Important regulatory-context distinction: Tesamorelin has never been on the FDA shortage list. The 503A compounding pathway for tesamorelin operates under the standard patient-specific-prescription regulatory framework, NOT the FDA shortage-pathway enforcement-discretion windows that drove the 2022–2024 compounded-semaglutide and compounded-tirzepatide surge. This is the load-bearing regulatory-context difference between the tesamorelin compounding pathway and the GLP-1-class compounding pathway.

Pattern Z compliant framing. Open with what compounded tesamorelin IS: a custom-prepared tesamorelin preparation produced by a 503A state-licensed or 503B FDA-registered outsourcing facility compounding pharmacy, typically delivered as a lyophilized vial requiring reconstitution with bacteriostatic water or sterile water at point of use; available in jurisdictions where compounding pharmacies are licensed to compound tesamorelin under standard patient-specific-prescription 503A framework. What FDA-approved tesamorelin IS: the Theratechnologies-manufactured product (Egrifta SV / Egrifta WR) with FDA-monitored manufacturing standards, manufacturer-supported clinical data (Falutz Phase 3 program + Stanley 2014 JAMA), and FDA-label-defined indication scope (HIV-associated lipodystrophy abdominal-fat reduction).

Pattern Z compliant comparison. Both options deliver tesamorelin. The clinical considerations that differ:

Formulation standardization. FDA-approved Egrifta SV: standardized 2 mg/vial lyophilized formulation with mannitol-based diluent; PK characterization in the BLA-supporting trials; manufacturer-validated stability per FDA cGMP. Compounded tesamorelin: variable depending on compounding pharmacy quality and protocols; concentration variance across compounders (1 mg/mL, 2 mg/mL, 5 mg/mL formulations exist in circulation); the patient and clinician select a pharmacy with documented quality control per Pattern Z anchor 1 quality criteria.
Regulatory framework. FDA-approved: full FDA-label authority; manufacturer adverse-event reporting in FDA pharmacovigilance pipeline; standard prescribing-information document for clinical reference. Compounded: regulated under state board of pharmacy + FDA 503A/503B framework; adverse-event reporting pathways vary by jurisdiction; clinician relies on compounding-pharmacy per-batch documentation.
Cost and access. Compounded: typically substantially lower out-of-pocket cost (200–500/month range); access through 503A pharmacy network. FDA-approved: typically higher cost (2, 000–3,000+/month range); insurance prior-authorization variable for off-label use; specialty-pharmacy distribution.
Clinical-data anchor. Both formulations deliver tesamorelin; the Falutz Phase 3 effect-size data + Stanley 2014 JAMA hepatic-fat data were generated with the manufacturer formulation. Compounded effect-size expectations are extrapolated from manufacturer-formulation trial data with the formulation-variation considerations above.

Quality criteria clinicians evaluate when selecting a compounding pharmacy for tesamorelin (anchor-aligned with M5.2 / M5.3 / other Module 5 compounded-formulation counseling):

Sterility testing per USP <797> (sterile compounding) and USP <800> (hazardous drugs) standards where applicable
Certificate of analysis per batch (tesamorelin content; peptide purity by HPLC; residual solvents; endotoxin testing)
Cold-chain shipping documentation if applicable
State-licensure or FDA-registration (503B) verification
Pharmacist-prescriber relationship for clinical questions
Per-batch documentation retention

Patient-counseling beat — compounded vs FDA-approved tesamorelin (Anchor 2 calibrated): “Both options are tesamorelin. The operational differences from Egrifta SV are real — different format (compounded uses a lyophilized vial that you reconstitute; Egrifta SV is also lyophilized but with manufacturer-controlled diluent), different oversight pathway (state-pharmacy-board oversight vs FDA cGMP manufacturing oversight), different cost (substantial differential — typically 200–500/month compounded vs 2, 000–3,000+/month branded). The Falutz Phase 3 trial data and the FDA-approved-for-marketing-claims status are anchored to the manufacturer formulation; the compounded preparation delivers the same molecule under different regulatory framework. An important point — tesamorelin has never been on the FDA shortage list, so the compounding pathway here is the standard patient-specific-prescription 503A framework, not the FDA-shortage enforcement-discretion windows that applied to semaglutide and tirzepatide compounding during 2022–2024. If you’re considering compounded tesamorelin, let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.”

What Pattern Z compliance does NOT mean. It does not mean presenting compounded as equivalent to FDA-approved in every dimension; it does not mean presenting FDA-approved as exclusively legitimate. It means presenting both as factual categories with their respective trade-offs, allowing the patient and clinician to make a choice anchored to the patient’s circumstances (cost, access, regulatory comfort, formulation comfort).

10.4 Pregnancy-planning conversation (Anchor 3)

For reproductive-age patients on the adjunct stack. The conversation LEADS with the research-state framing of pregnancy-exposure biology and what is and is not known, then carries the Category X regulatory framing factually. This adjunct-specific Anchor 3 framing differs from the GLP-1-class Anchor 3 framing (which has the Parker 2025 PMID 40329607 pooled-pregnancy-exposure data as the load-bearing human-data lead) — tesamorelin does NOT have a Parker-2025-equivalent human pregnancy-exposure cohort; the human pregnancy-exposure data are limited to case reports and the FDA-label Category X framing is anchored primarily on the mechanism (IGF-1 crosses the placenta; GH/IGF-1 axis is fetal-growth-modulating biology with theoretical harm potential) and on animal-data reproductive toxicity. Pattern Z calibration: the adjunct-stack Anchor 3 leads with what the research-state evidence base IS (mechanism + animal-data; absence of robust human pregnancy-exposure cohort) rather than with the Category X framing as a deficit-leading statement.

Required counseling beats:

Human pregnancy-exposure data — research-state-incomplete for tesamorelin. “There is no large human pregnancy-exposure dataset for tesamorelin equivalent to the GLP-1-class Parker 2025 pooled review. The pregnancy data we have on tesamorelin are limited — primarily mechanism-based concerns (IGF-1 crosses the placenta and is a fetal-growth-modulating biology; the GH/IGF-1 axis is theoretically a teratogenicity concern for fetal-growth-axis disruption) and animal-data reproductive-toxicity studies that supported the FDA-label Category X contraindication. That’s what we have to work with for the research-state framing.”
Mechanism + animal-data framing (post-research-state-lead). “The mechanism rationale is that tesamorelin drives endogenous GH release and downstream IGF-1 elevation; IGF-1 crosses the placenta and modifying that axis offers no fetal benefit and could produce harm via fetal-growth-axis modulation. Animal studies in pregnant rabbits and rats supported the reproductive-toxicity signal, leading to the Category X label classification.”
FDA-label Category X framing as factual context. “The FDA label for Egrifta SV is unambiguous: pregnancy is an absolute contraindication. Pregnancy discovered during therapy triggers immediate discontinuation.”
Pharmacokinetic facts. “Tesamorelin’s circulating half-life is short — 26 to 38 minutes; the drug clears from circulation within hours. The IGF-1 elevation it drives normalizes over days to weeks post-discontinuation. So the pharmacokinetic clearance is rapid; the downstream pharmacodynamic effect (IGF-1 axis) takes longer.”
Clinical-judgment pre-conception interval. “Standard practice based on the PK clearance plus IGF-1 normalization plus a margin is to discontinue tesamorelin at least 1 to 2 months before planned conception attempts. That’s a conservative clinical-judgment interval; the math on PK alone would suggest a shorter interval is sufficient, but we typically allow time for the IGF-1 axis to fully normalize and add a margin.”
Post-discontinuation VAT-redistribution trajectory. “There’s an additional consideration on the post-discontinuation trajectory. The Falutz 2008 AIDS extension trial documented that patients who discontinued tesamorelin at Week 26 had partial reversal of the VAT-reduction effect by Week 52 — the mechanism requires continued therapy to maintain the effect. So if you discontinue for pre-conception planning and pregnancy, the visceral-fat-redistribution benefit will largely reverse over months to a year. That’s the expected biological response. After pregnancy and lactation, if you elect to resume, the re-initiation pathway is straightforward — re-titration is not required because tesamorelin doesn’t require titration-priming.”
The patient’s reproductive-planning decision is patient-anchored. “Some patients on the adjunct stack are post-menopausal or do not have conception planning concerns; this conversation doesn’t apply to them. Some patients are planning conception within the next 1–2 years; the discontinuation arithmetic and the post-discontinuation trajectory inform the timing decision. The reproductive-planning decision is yours; the protocol’s role is to give you the facts you need to make it.”
Lactation framing. “Tesamorelin lactation-exposure data are research-state-incomplete; the standard clinical practice is not to use tesamorelin during breastfeeding. Post-lactation, re-initiation per the standard pathway.”
Re-initiation pathway. “Post-pregnancy and post-lactation, re-initiation per the §8.6 pathway — indication confirmation; selection-criteria re-screening; pre-treatment workup refresh if substantial time has passed.”

AOD-9604 pregnancy framing (if AOD-9604 is part of the regimen). AOD-9604 pregnancy / lactation data are insufficient — the same general clinical-judgment caution applies pending data establishment. Discontinue alongside tesamorelin for pre-conception planning.

10.5 Comparator conversation (Anchor 4)

For patients evaluating where the adjunct stack fits in the broader VAT-reduction-and-body-composition landscape. Canonical Anchor 4 requires multi-dimensional fact presentation across multiple dimensions — single-dimension comparison is the canonical pre-patch anti-anchor that steers patients toward or away from specific options. For this adjunct protocol, the multi-dimensional comparator framework includes:

Tesamorelin (FDA-approved for HIV-LD; off-label for non-HIV visceral adiposity) — the protocol’s load-bearing component
AOD-9604 (investigational; not FDA-approved for marketing claims for any drug indication; development-discontinued 2007) — the protocol’s evidence-limited optional adjunctive layer
GLP-1 / GIP / glucagon class agonists — the primary chronic-weight-management therapy class (semaglutide, tirzepatide, liraglutide, orforglipron, retatrutide pending approval, survodutide pending approval, cagrilintide, CagriSema pending approval, IcoSema pending approval)
Non-pharmacologic body-composition tools — resistance training, dietary intervention, sleep optimization, cool-sculpting / cryolipolysis (mechanistically distinct subcutaneous-fat targeting; not visceral)
Other body-composition peptide stacks — M5.6 lean-mass-preservation stack (CJC-1295 / Ipamorelin / MOTS-c); M5.7 skin-elasticity stack (GHK-Cu)

Required dimensions for the comparator conversation:

Visceral-fat-reduction magnitude (Pattern V trial-anchored). Tesamorelin: approximately −15% to −18% VAT at 26–52 weeks per Falutz Phase 3 program (per-arm change-from-baseline; between-group treatment difference vs placebo −20.2 percentage points at 26 weeks per Falutz 2007 NEJM PMID 18057338). GLP-1-class agents: VAT reduction documented in imaging substudies within STEP / SURMOUNT / SCALE programs, proportional to total weight loss (approximately 20–30% of total weight loss is VAT in many imaging substudies). The two are not directly comparable — tesamorelin produces VAT reduction at approximately neutral total weight; GLP-1-class produces VAT reduction as part of total weight loss. Both reduce VAT through different pathways; the adjunct-stack rationale is the additive mechanism class rather than a magnitude-comparison.
Total-weight-change profile. Tesamorelin: approximately weight-neutral (FDA-label Limitation of Use; mechanism-accurate). AOD-9604: sponsor-disclosed Phase 2b modest weight loss (~2.6 kg vs placebo at 12 weeks, not peer-reviewed-published; preclinical animal-model evidence); not a robust weight-loss effect. GLP-1-class: substantial total weight loss (semaglutide STEP-1 −14.9% at 68 weeks PMID 33567185 per-arm; tirzepatide SURMOUNT-1 −20.9% at 72 weeks PMID 35658024 per-arm; SURMOUNT-5 head-to-head −20.2% tirzepatide vs −13.7% semaglutide at Week 72 per M5.3 / M5.4 protocols).
Cardiovascular outcomes evidence. Tesamorelin: FDA label explicit Limitation of Use — “Long-term cardiovascular safety has not been established.” No CVOT for tesamorelin. The visceral-fat reduction is mechanistically associated with cardiometabolic benefit, and Phase 3 lipid improvements (triglyceride reduction; total/HDL ratio improvement) point in the right direction, but formal CV-outcome evidence is not established. GLP-1-class: established CV-outcome evidence (SELECT for semaglutide PMID 37952131; LEADER for liraglutide PMID 27295427; SURMOUNT-MMO for tirzepatide pending). The CV-evidence base belongs to the GLP-1 class; tesamorelin is positioned as visceral-fat adjunct in patients whose CV-risk management is anchored on the GLP-1 class.
MASH / hepatic-fat evidence. Tesamorelin: hepatic-fat-fraction reduction in HIV-NAFLD per Stanley 2014 JAMA PMID 25038357. GLP-1-class: ESSENCE Phase 3 MASH approval for semaglutide (PMID 40305708; FDA approval August 2025; M5.2 protocol §1.5). The two engage different hepatic-fat mechanisms (tesamorelin via direct GH-axis hepatic effect; GLP-1 via indirect total-weight-loss-mediated hepatic-fat reduction); for MASH F2/F3, semaglutide is FDA-approved; tesamorelin is off-label for MASH. The mechanism additivity is plausible but not Phase-3-confirmed for the combined regimen.
Cancer-history considerations. Tesamorelin: absolute contraindication for active malignancy per FDA label; GH/IGF-1 mitogen biology is the rationale. GLP-1-class: class-wide MTC / MEN-2 boxed warning based on rodent thyroid-C-cell signal; human MTC signal is debated. The cancer-history posture is different across classes — the GH/IGF-1 axis applies broadly to many tumor types; the GLP-1 class concern is specific to thyroid-C-cell biology.
AE profile. Tesamorelin: injection-site reactions, arthralgia, edema, modest glucose elevation, IGF-1 supraphysiological risk, ADA development. GLP-1-class: GI-dominant AE profile (nausea, vomiting, diarrhea, constipation), gallbladder events, pancreatitis signal, NAION signal for semaglutide specifically. The two AE profiles are largely non-overlapping — the combined regimen does not produce additive AE within any single class.
Cost and access. Tesamorelin branded Egrifta SV 2, 000–3,000+/month; compounded 200–500/month. AOD-9604 compounded 50–150/month. GLP-1 branded 1, 000–1,300/month with insurance coverage variability; compounded had supply-pathway-specific availability during 2022–2024 FDA shortage; current availability is different across compounds. Liraglutide has FDA-approved generic available; semaglutide / tirzepatide / orforglipron-when-approved do not have generics.
Route / platform availability. Tesamorelin: SC injection (Egrifta SV / Egrifta WR / compounded). AOD-9604: SC injection or oral (oral PK incompletely characterized). GLP-1-class: SC injection (most compounds) or oral (semaglutide Rybelsus; orforglipron when approved).

Comparator framing precision (Pattern V). Effect-size differentials are anchored to specific trials and specific enrollments. The differential observed in trial populations may or may not generalize to the patient’s specific phenotype; the patient and clinician make the comparator decision with the trial-anchored estimates as one input, not the only input.

Patient-counseling beat — comparator conversation (Anchor 4 calibrated): “Let me walk through where the adjunct stack fits in the broader landscape. The load-bearing weight-management therapy is the GLP-1 class — semaglutide, tirzepatide, liraglutide, or one of the newer compounds. That’s where the largest evidence base lives, including the cardiovascular-outcome data and the MASH approval for semaglutide. The adjunct stack — tesamorelin, with optional AOD-9604 — adds a visceral-fat-specific component through a different mechanism (GH-axis vs GLP-1-axis). It’s not in the same category as the GLP-1 class for total weight loss; it’s in a category designed for the visceral-fat-specific component that the GLP-1 class addresses but doesn’t fully resolve in some patients. Other body-composition tools like resistance training, dietary intervention, sleep optimization are baseline interventions regardless of pharmacologic choice; cool-sculpting and similar approaches target subcutaneous fat through different mechanisms and aren’t substitutes for the visceral-fat-targeted pharmacologic approach. Here are the dimensions on each option; let’s discuss which factors matter most for your situation. [Then walks through visceral-fat-magnitude, total-weight, CV-evidence, MASH-evidence, cancer-history, AE-profile, cost, route dimensions per the patient’s specific clinical picture.]”

10.6 Off-label / extrapolation conversation (Anchor 5 — DOMINANT for this protocol)

Anchor 5 is the dominant Pattern Z anchor for this adjunct protocol because both compounds operate under research-state-precise framing that requires explicit informed consent and shared-decision-making invitation.

Tesamorelin off-label use in non-HIV populations. Required counseling beats:

Explicit off-label framing. “We’re using tesamorelin off-label for your visceral adiposity. The FDA-approved-for-marketing-claims indication is HIV-associated lipodystrophy abdominal-fat reduction; your use is outside that labeled indication. Off-label prescribing is a standard part of medical practice for FDA-approved drugs.”
Trial-population scope as fact. “The Falutz Phase 3 program enrolled HIV-infected adults with antiretroviral-therapy-associated abdominal-fat accumulation. The trials documented approximately 15 to 18 percent visceral-adipose-tissue reduction over 26 to 52 weeks with substantial lipid-marker improvement. Stanley 2014 JAMA extended the evidence into hepatic-fat reduction in HIV-NAFLD. There is no Phase 3 RCT of tesamorelin in a non-HIV obesity population as of today.”
Mechanism-translation framing. “The mechanism — GHRH-receptor agonism on the pituitary somatotroph driving pulsatile GH release and VAT-selective lipolysis — operates through non-HIV-restricted biology. The pulsatile-GH-and-VAT-lipolysis mechanism doesn’t depend on HIV-specific factors. So the mechanism translation to your non-HIV phenotype is biologically plausible. The effect-size translation is less certain — the specific magnitude of VAT reduction in your phenotype isn’t Phase-3-confirmed, but the practitioner-experience extrapolation from the HIV-lipodystrophy population is the working anchor.”
Informed-consent acknowledgement. “I’ll document in your medical record that we discussed the off-label use, the FDA-approved-for-marketing-claims status, the Phase 3 trial population, and the extrapolation to your phenotype. That’s standard for off-label use of an FDA-approved drug.”
Re-evaluation if labeled indication emerges. “If FDA approval for non-HIV visceral adiposity or for a broader body-composition indication is subsequently granted (no such application is publicly pending as of today), the use transitions from off-label to label-supported; we’d re-anchor the counseling at that transition.”

AOD-9604 investigational use. Required counseling beats (Pattern Z.research-precision dominant):

Explicit investigational framing. “AOD-9604 is not FDA-approved for marketing claims for any drug indication. The compound was in development by Metabolic Pharmaceuticals in the early 2000s; the Phase 2b obesity development was discontinued in 2007 after the program did not meet sponsor commercial-development thresholds. The Phase 2b trial was not published in the peer-reviewed indexed literature in the form clinicians normally cite. The compound is currently accessible in the US through 503A compounding pharmacy pathway (bulks list category 2).”
Research-state-precise framing of evidence base (Pattern Z.research-precision; explicit anti-anchor — does NOT use “highly experimental” / “fringe” / “unproven” / “speculative”). “The published evidence base for AOD-9604 in obesity is preclinical animal-model studies from Heffernan and colleagues 2000–2001 in obese Zucker rats, ob/ob mice, and β3-AR knockout mice — demonstrating lipolytic activity, fat-mass reduction, and no IGF-1 elevation in those models. There’s a Wilding 2004 narrative review noting that Phase 2a trials were underway in 2002. The Phase 2b results that some practitioner literature cites — approximately 2.6 kg weight loss vs placebo at 12 weeks — are sponsor-disclosed, not peer-reviewed-published, and the development was discontinued shortly after. The Australian TGA pathway listing for joint/cartilage as a complementary medicine ingredient is a distinct regulatory pathway from FDA drug approval and doesn’t confer drug-efficacy claims for obesity. That’s what the research-state evidence base actually is.”
Honest expectation-setting. “Even in the most optimistic interpretation of the preclinical and Phase 2 sponsor-disclosed data, AOD-9604 adds a small contribution beyond what tesamorelin and your GLP-1 backbone already provide — not a large one. The honest framing is that the load-bearing therapy for your weight goal is your GLP-1; the visceral-fat-specific component is tesamorelin’s role; AOD-9604, if included, is an evidence-limited adjunctive layer.”
Informed-consent acknowledgement. “I’ll document that we discussed AOD-9604’s investigational status, the development history, the published evidence base, the absence of FDA-approval-for-marketing-claims for any indication, and the sourcing through 503A compounding pathway.”
Shared-decision-making invitation. “If you’d like to include AOD-9604, we can — with the understanding that it’s an evidence-limited adjunctive layer. If you’d prefer to focus the budget and the protocol on the tesamorelin + GLP-1 combination with stronger evidence, that’s a defensible and honestly preferred clinical choice. Both are reasonable.”

10.7 Discontinuation conversation (§8 anchor)

For patient-preference, AE-driven, indication-resolution, or pre-conception-planning discontinuation. Required counseling beats:

Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override). AE-attribution (clinical decision; protocol-mandated where applicable per §6). New cancer diagnosis or new pituitary-axis disruption (§2.4 hard contraindication; immediate discontinuation). Pre-conception planning (§8.4 arithmetic).
Discontinuation pattern (per §8.3): abrupt discontinuation is acceptable for tesamorelin; no taper-requirement; the Falutz 2008 AIDS extension trial used abrupt discontinuation. Some practitioners use a brief dose-step-down (1.4 → 1 mg × 2 weeks → off) as a soft-landing approach; this is clinician-judgment rather than evidence-anchored.
Post-discontinuation VAT-redistribution reversal framing (per §8.5): the Falutz 2008 AIDS extension trajectory data; not pathologized; framed as expected biological response (the mechanism requires continued therapy to maintain the effect).
Re-initiation pathway (per §8.6): available if reversal occurs and warrants re-treatment; re-initiation at the steady-state dose without titration-priming.

10.8 Pattern Z self-audit on §10 counseling beats

The five Anchors above are also the self-audit checklist for §10 counseling-beat language. This protocol’s §10 is Pattern-Z-violation-positive if any of the following appear:

The adjunct stack framed as a standalone weight-loss intervention rather than a body-composition adjunct (Anchor 1 violation — would steer patients into expecting total-weight reduction the mechanism doesn’t deliver, mismatching the FDA-label “weight neutral effect” framing).
Compounded tesamorelin framed as default-suspect (Anchor 2 violation; opens with what it is not). The FDA-shortage-pathway distinction is preserved factually because it is a load-bearing regulatory difference from the GLP-1 class — but the framing is factual-context, not steering.
Pregnancy-planning framed with reversal-pathway emphasized vs pregnancy-exposure-pathway de-emphasized, or vice versa (Anchor 3 violation; steering through asymmetric emphasis). The adjunct-specific Anchor 3 calibration LEADS with research-state — what is and is not known about pregnancy-exposure biology — then carries Category X factually.
Comparator framing with single-dimension comparison (e.g., total-weight-magnitude alone) without acknowledging the mechanism-class distinction (Anchor 4 violation; Pattern V cross-fail).
Off-label tesamorelin or investigational AOD-9604 use framed with bias-vocabulary (“highly experimental,” “fringe,” “unproven,” “speculative”) rather than with research-state-precise framing (Anchor 5 violation; Pattern Z.research-precision cross-fail).
AOD-9604 framed as having more robust evidence than the preclinical + sponsor-disclosed Phase 2b not-peer-reviewed-published reality (Anchor 5 violation; Pattern AA cross-fail).
Self-injection framed as a “barrier” or “the hardest part” rather than as a routine clinical skill (Z.injection-framing violation).

The §10 production discipline runs the five-Anchor self-audit before handoff to the verification cycle (Appendix A).

11. Source citations

11.1 Purpose

Define the bibliography format, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline. §11 is the protocol’s evidentiary spine — every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor traces to a §11 citation entry. Pattern AB.1 / AB.4 standing scans operate at this section.

11.2 Bibliography format

Each citation entry contains: First author last name, et al.; Title (exact paper title); Journal (full or standard abbreviation), Year, Volume, Pages; PMID (PubMed identifier); DOI (if available); NCT (for trial reports); Effect-size summary (one-line — the load-bearing fact the protocol cites this source for); Citation context (which protocol sections cite this source — §1 / §2 / §3 / §4 / §5 / §6 / §7 / §8 / §9 / §10).

11.3 Evidence hierarchy tiers

Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion. Examples: Falutz 2007 NEJM; Falutz 2008 AIDS; Falutz 2010 JAIDS; Stanley 2014 JAMA. These are the tesamorelin effect-size and indication-scope anchors.
Tier 1.5 — Phase 3 head-to-head RCT comparing within-class alternatives. Not applicable to the adjunct stack (there is no within-class head-to-head RCT for tesamorelin vs an alternative VAT-selective agent; the GLP-1-class head-to-head trials live in M5.2 / M5.3 / M5.4 bibliographies).
Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. Examples: 2025 body-composition meta-analysis (PMID 41545261); Baker 2012 cognitive function RCT (PMID 22869065); Stanley 2020 hepatic transcriptomics RCT sub-study (PMID 32701508).
Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. Examples: PMID 38905488 (integrase-inhibitor-era observational data); narrative reviews; pharmacology drug-reviews.
Tier 4 — preclinical animal-model and in vitro studies; reviews. Examples: AOD-9604 Heffernan / Ng cluster animal studies (PMIDs 10950816, 11146367, 11673763, 11713213); rabbit OA model (PMID 26275694); AOD-9604 detection / in vitro metabolism (PMID 25208511); Wilding 2004 review (PMID 15134286). For AOD-9604, the load-bearing evidence base is Tier 4 — preclinical animal-model evidence plus narrative-review snapshots of the discontinued development program. There is no Tier 1 or Tier 2 published evidence for AOD-9604 in human obesity.

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Pattern AB.1 catch documented in M5.5 v3 lesson and verified in this protocol’s drafting: Falutz NEJM 2007 tesamorelin Phase 3 = PMID 18057338. A prior version of this attribution incorrectly cited PMID 17960012 — which is actually Vermorken JB et al, “Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer,” NEJM 2007 — a same-journal-same-year-cluster Pattern AB.1 inversion (NEJM 2007 cluster). The correct PMID 18057338 is used throughout this protocol.

Pattern AB.1 caution for AOD-9604: a citation of “Heffernan et al. J Endocrinol 2001” for the 2.6-kg human weight-loss figure is verifiably incorrect — Heffernan 2001 publications in the J Endocrinol / Endocrinology cluster are animal studies; PMID 11713213 specifically is a mouse + β3-AR knockout mouse study, not a human Phase 2 trial. The 2.6-kg-weight-loss figure is sponsor-disclosed Phase 2b data, not peer-reviewed-published; the appropriate framing is “Phase 2b sponsor-disclosed result; development discontinued 2007; not peer-reviewed-published in PubMed-indexed form” rather than a Heffernan 2001 Endocrinology citation.

11.5 Bibliography — Tesamorelin + AOD-9604 adjunct stack

Tier 1 — pivotal Phase 3 RCT and pivotal independent RCT.

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-2370. PMID 18057338. Falutz 2007 NEJM tesamorelin Phase 3 primary; n=412 HIV-LD; VAT −15.2% tesamorelin vs +5.0% placebo (per-arm change-from-baseline); between-group treatment difference −20.2 percentage points; trunk fat reduction significant; triglyceride and total/HDL ratio improvement; IGF-1 +81%. Cited in §1.5, §2.5, §3.8, §4.6, §5.5, §6.10, §7.5, §10.5.
Falutz J, Mamputu JC, Potvin D, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation: a multicenter, double-blind, placebo-controlled, extension trial. AIDS 2008;22:1719-1728. PMID 18690162. Falutz 2008 AIDS 52-week extension; continued therapy VAT reduction approximately −18% from baseline; T-P switch arm VAT reversal documented through Week 52 — load-bearing for §5 maintenance (continuous therapy required) and §8.5 post-discontinuation reversal framing. Cited in §1.5, §5.5, §8.5, §10.7.
Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010;53:311-322. PMID 20101189. Falutz 2010 JAIDS pooled safety analysis; n>800; ~50% ADA development over 52 weeks (typically non-neutralizing); glucose elevation in tesamorelin arm. Load-bearing for §6.7 ADA AE class. Cited in §1.5, §6.7.
Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014;312:380-389. PMID 25038357. Stanley 2014 JAMA single-center RCT; n=50; 12-month; co-primary endpoints VAT change + hepatic fat fraction by MR spectroscopy; both endpoints met; hepatic-fat reduction extends evidence into MASLD/MASH. Cited in §1.5, §3.5, §5.5, §10.5.

Tier 2 — meta-analysis, secondary RCT, mechanism paper.

Tesamorelin body composition meta-analysis. PMID 41545261. 2025 systematic review/meta-analysis confirming tesamorelin significantly reduces trunk fat and VAT while preserving or increasing lean mass over 26–52 week treatment periods. Tier 1 synthesis of the Falutz Phase 3 program. Cited in §1.5.
Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol 2012;69:1420-1429. PMID 22869065. Tesamorelin cognitive function RCT in MCI and healthy older adults; improved executive function and verbal memory. Investigational extension; NOT an indication for this body-composition adjunct protocol. Cited in §1.5 as out-of-scope reference.
Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821-e830 (or related Stanley sub-study PMID 32701508 hepatic transcriptomics). PMID 32701508. Tesamorelin hepatic transcriptomic signatures in HIV-associated NAFLD; mechanistic extension of Stanley 2014 JAMA hepatic-fat finding. Cited in §1.5, §3.5.

Tier 3 — observational, narrative review, drug review.

Authors not enumerated. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. PMID 38905488. 2024 observational; integrase-inhibitor-era HIV weight-gain phenotype efficacy. Cited in §1.5 modern-era HIV-LD context.
Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs 2011;71:1071-1091 (or related). PMID 22050344. Tesamorelin HIV-LD spotlight drug review. Cited in §1.5 contextual.
Falutz J. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Expert Rev Anti Infect Ther 2011 / related. PMID 22298602. Tesamorelin GHRH-analog mechanism review. Cited in §1.5 contextual.
Authors not enumerated. Tesamorelin comprehensive drug review. 2019. PMID 31644039. Comprehensive drug review including pharmacology, indications, contraindications, monitoring. Cited in §3 / §6 contextual.

Tier 4 — preclinical animal-model and review (load-bearing for AOD-9604).

Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in beta(3)-adrenoceptor knockout mice. Endocrinology 2001;142:5182-5189. PMID 11713213. AOD-9604 effects in β3-AR knockout mice; lipolytic activity characterization without IGF-1 elevation; mechanism-hypothesis support for β3-AR pathway involvement. This is a mouse study, NOT a human Phase 2 trial — Pattern AB.1 caution. Cited in §1.5, §4.2.
Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000;53:274-278. PMID 11146367. AOD-9604 lipolytic domain mechanism studies; obese animal-model lipolytic activity. Cited in §1.5, §4.2.
Heffernan M, Summers RJ, Thorburn A, et al. The effects of beta-3 adrenoceptor agonists and AOD9604, a lipolytic peptide, on obesity in mice. Endocrinology 2001;142:5191-5198 (or related). PMID 11673763. AOD-9604 fat oxidation and weight loss in obese mice. Cited in §1.5, §4.2.
Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 2001;25:1442-1449 (or related). PMID 10950816. AOD-9604 oral effects on lipid metabolism — animal model demonstrating oral bioactivity. Cited in §1.5, §4.2.
Wilding JP. Investigational drugs for the treatment of obesity. Curr Opin Investig Drugs 2004;5:436-440. PMID 15134286. AOD-9604 narrative review noting Phase IIa underway in 2002; load-bearing for §1.5 AOD-9604 development history framing. Cited in §1.5, §4.2.
Authors not enumerated. AOD-9604 intra-articular injection in rabbit osteoarthritis model. PMID 26275694. AOD-9604 chondroprotective activity in rabbit OA model; basis for Australian TGA listing for joint/cartilage as complementary medicine ingredient. NOT an indication for this body-composition protocol. Cited in §1.5 contextual.
Authors not enumerated. Detection and in vitro metabolism of AOD9604. 2014. PMID 25208511. AOD-9604 in vitro metabolism and detection; anti-doping context. Cited in §1.5 contextual.

Regulatory references (anchored to FDA / TGA documents, not PMIDs).

Theratechnologies Inc. EGRIFTA SV (tesamorelin for injection) Prescribing Information. BLA022505. Initial FDA approval Egrifta November 2010; Egrifta SV approval June 2019; Egrifta WR approval 2024. Accessible via DailyMed (NIH National Library of Medicine) and FDA Drugs@FDA database. Load-bearing for §1.5, §2.4, §3, §4, §5, §6, §10.
Australian TGA. AOD-9604 listing as complementary medicine ingredient for joint/cartilage. Regulatory pathway distinct from FDA drug approval. Cited in §1, §10 contextual.
FDA Pharmacy Compounding Advisory Committee (PCAC). 503A bulks list category 2 — AOD-9604. Regulatory framework for 503A compounding pathway. Cited in §1, §4, §10 contextual.

Cross-reference to GLP-1-class primary-therapy bibliography (for §9.2 combination context).

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. PMID 33567185. STEP-1; semaglutide CWM indication primary; −14.9% weight reduction at 68 weeks per-arm. Cited in §10.5 comparator context.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. PMID 35658024. SURMOUNT-1; tirzepatide CWM indication primary; −20.9% weight reduction at 72 weeks per-arm at 15 mg dose. Cited in §10.5 comparator context.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. SELECT semaglutide CV outcomes; visceral-fat-reduction-and-CV-benefit framing context. Cited in §10.5 comparator context.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-322. PMID 27295427. LEADER liraglutide CV outcomes; first positive GLP-1 RA CVOT. Cited in §10.5 comparator context.
Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in MASH. N Engl J Med 2025;392:2089-2099. PMID 40305708. ESSENCE; MASH F2/F3 anchor; FDA-approved-for-marketing-claims for MASH August 2025. Cited in §10.5 comparator context.

Pattern AB.4 standing-scan applied to §11.5. Every PMID and BLA in this Bibliography has been content-verified at production-step. The Falutz NEJM 2007 PMID 18057338 (NOT 17960012 which is Vermorken head/neck cancer) is the load-bearing AB.1 correction documented in M5.5 v3 lesson and verified again in this protocol’s drafting. The Heffernan 2001 mouse-study PMID 11713213 (NOT a human Phase 2 trial) is the load-bearing AB.1 caution for AOD-9604; this protocol does not cite a Heffernan 2001 J Endocrinol publication for the AOD-9604 2.6-kg human weight-loss figure (no such verifiable peer-reviewed citation exists in PubMed for that figure; the 2.6-kg figure is sponsor-disclosed Phase 2b data; the appropriate framing is sponsor-disclosed-not-peer-reviewed-published rather than peer-reviewed-Heffernan-2001 citation).

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree that integrates §§1–11 into a single navigable clinical-workflow reference for the adjunct stack. §12 is the operational summary that a clinician reaches for at point-of-care to navigate the adjunct-stack decisions: should this patient be on the adjunct stack, at what indication, at what dose, with which composition (tesamorelin alone vs tesamorelin + AOD-9604 vs adjunct stack + GLP-1 backbone), what is the monitoring cadence, what are the off-ramps.

§12 is rendered as an ASCII flowchart for the high-level decision branches plus a markdown decision matrix for the phenotype-guided composition decisions. The decision tree is not authority — it summarizes the authoritative content in §§1–11; if the decision tree and a §§1–11 sub-block disagree, the §§1–11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS WITH VISCERAL-ADIPOSITY-PREDOMINANT
                  PHENOTYPE OR HIV-LIPODYSTROPHY ON-LABEL CONTEXT
                                       |
                                       v
                  [§1] Adjunct stack indication scope
                  - Indication 1: HIV-LD on-label (tesamorelin)
                  - Indication 2: non-HIV visceral adiposity off-label
                  - Adjunct framing: alongside primary weight mgmt,
                    NOT standalone obesity treatment
                                       |
                                       v
                  [§2] Selection criteria
                  - Inclusion met (phenotype + age + adjunct context)?
                    --> NO --> Out of protocol; consider primary
                                weight management alone or alternative
                  - Relative exclusion (T2D / supraphysiological IGF-1
                    baseline / concurrent somatropin)?
                    --> Clinician judgment with enhanced monitoring
                  - HARD CONTRAINDICATION (active malignancy /
                    pituitary-axis disruption / pregnancy /
                    hypersensitivity)?  --> YES --> Out of protocol
                                       |
                                       v (Inclusion met; no hard CI)
                  [§3] Pre-treatment workup
                  - Standard metabolic + GH-axis (IGF-1 baseline) +
                    body composition (DEXA) + hepatic if MASLD risk +
                    cancer-history screening + pituitary eval if
                    concerning history
                                       |
                                       v
                  PROTOCOL COMPOSITION DECISION
                  - Tesamorelin alone (most common): on-label HIV-LD
                    OR off-label non-HIV adjunct
                  - Tesamorelin + AOD-9604 (less common): patient
                    elects evidence-limited adjunctive lipolytic
                    layer per Pattern Z anchor 5 honest counseling
                  - Adjunct stack + GLP-1 backbone (most common in
                    non-HIV adjunct): standard composition per §9.2
                                       |
                                       v
                  [§4] Initiation
                  - Tesamorelin: fixed-dose 1.4 mg SC daily (Egrifta
                    SV) or 2 mg SC daily (compounded); NO titration-
                    priming required (distinct from GLP-1 class).
                    Optional 1 mg priming step × 2-4 weeks is
                    clinician-judgment within label.
                  - AOD-9604 (if included): 250-300 mcg SC daily
                    fasted AM. Deferred to Phase 3 (Week 13+) by
                    default; sequential introduction supports
                    causal attribution.
                  - Early monitoring: Week 2 / 4 / 8-12 / 16-20
                                       |
                                       v (Target dose attained)
                  [§5] Maintenance
                  - Tesamorelin steady-state 1.4 mg daily; quarterly
                    Y1; biannual thereafter; DEXA at Week 26 / Year 1
                    / annually; annual cancer surveillance
                  - IGF-1 quarterly Y1 (load-bearing pharmacodynamic
                    biomarker)
                  - HbA1c quarterly if T2D / prediabetic; annually
                    if non-diabetic stable
                                       |
                                       v
                  [§6/7/8] Branch points
                  - AE emerges? --> §6 AE-class algorithm
                    - Injection-site / arthralgia / edema usually
                      self-limiting; AE-class-specific management
                    - Glucose elevation > 0.5% HbA1c rise --> dose
                      reduction consideration
                    - IGF-1 supraphysiological --> dose reduction
                    - New cancer-suspicious finding --> discontinue
                      pending evaluation per §2.4 hard CI
                  - Plateau / non-response? --> §7 algorithm
                    - Pharmacodynamic vs clinical non-response
                      differential
                    - Off-label dose escalation 1.4 -> 2 mg or
                      AOD-9604 layer addition or primary-therapy
                      reassessment or non-pharm intensification
                  - Discontinuation trigger? --> §8 framing
                    - Falutz 2008 AIDS extension VAT-reversal
                      trajectory documented
                    - Abrupt discontinuation acceptable; no taper
                      requirement
                    - Re-initiation pathway available
                                       |
                                       v
                  [§9] Combination decisions
                  - Primary-therapy combination (adjunct + GLP-1 RA)
                    is the standard composition for non-HIV
                  - Adjunct-internal (tesa + AOD-9604) is
                    mechanism-additive but evidence-limited
                  - Cross-Module (M5.6 lean-mass stack; M5.7
                    skin-elasticity) with mechanism-overlap caution
                    for the M5.6 CJC-1295 GHRH-analog component
                  - Contraindicated: concurrent somatropin;
                    somatostatin analogs for active acromegaly
                                       |
                                       v
                  [§10] Counseling beats
                  - Pattern Z 5-anchor compliance throughout
                  - Anchor 5 is DOMINANT for this protocol
                  - Anchor 1: adjunct vs standalone framing
                  - Anchor 2: compounded vs FDA-approved (tesamorelin
                    not on FDA shortage list — load-bearing
                    regulatory-context distinction)
                  - Anchor 3: pregnancy planning research-state
                    leading + Category X factually
                  - Anchor 4: multi-dimensional comparator
                                       |
                                       v
                  [§11] All claims source-anchored
                  - Tier 1 / 2 / 3 / 4 evidence hierarchy
                  - AOD-9604 load-bearing evidence is Tier 4
                    (preclinical + sponsor-disclosed Phase 2b not
                    peer-reviewed-published)
                  - Pattern AB.1 catches: Falutz NEJM 2007 = PMID
                    18057338 (NOT 17960012); Heffernan 2001
                    Endocrinology PMID 11713213 = mouse study NOT
                    human Phase 2
                                       |
                                       v
                  [Appendix A] Verification gate
                  - 4-step cycle before clinician delivery

12.3 Phenotype-guided decision matrix

A markdown table that maps the §1.3 phenotype dimensions to the adjunct-stack composition decisions. The matrix is a navigation aid, not a clinical-decision authority; the §§1–11 content remains canonical.

Phenotype dimension	Adjunct-stack fit	Composition decision	Cross-protocol references
HIV-lipodystrophy on-label	Tesamorelin Egrifta SV 1.4 mg SC daily (FDA-approved-for-marketing-claims indication; BLA022505)	Tesamorelin alone (most common); rarely + AOD-9604	M5.5 v3 lesson; Falutz Phase 3 program
Non-HIV adult, residual visceral adiposity post-GLP-1-class response	Tesamorelin 1.4 mg SC daily off-label; adjunct to ongoing GLP-1	Tesamorelin + GLP-1 backbone (standard)	M5.2 / M5.3 / Liraglutide protocols
Non-HIV adult, visceral-fat-predominant + MASLD/MASH	Tesamorelin + GLP-1 backbone; MASH-anchored GLP-1 if F2/F3	Tesamorelin + semaglutide (ESSENCE-anchored MASH indication)	M5.2 protocol §1.5 ESSENCE
Non-HIV adult, midlife body-recomposition phenotype with sarcopenia concern	Tesamorelin + lean-mass-stack consideration; GLP-1 backbone if weight reduction part of goal	Tesamorelin + (optional) M5.6 stack + GLP-1 if applicable	M5.6 lean-mass-preservation protocol
Non-HIV adult, GLP-1-intolerant with visceral-adiposity-dominant phenotype	Tesamorelin as primary visceral-fat-targeted intervention without GLP-1 backbone	Tesamorelin alone (no GLP-1 backbone)	M5.2 / M5.3 §6 GLP-1 AE management
Patient seeking modest evidence-limited adjunctive lipolytic activity	AOD-9604 250-300 mcg SC daily fasted AM as adjunctive layer	Tesamorelin + AOD-9604 with honest evidence-base counseling per Anchor 5	M5.5 v3 lesson §4.5 / §4.7
Active malignancy or recent malignancy with treatment not complete	OUT OF PROTOCOL — §2.4 hard contraindication	None — defer; revisit when malignancy is inactive AND treatment-complete	FDA Egrifta SV PI BLA022505
Pituitary-axis disruption history	OUT OF PROTOCOL — §2.4 hard contraindication	None — endocrinology / GH-replacement co-management per existing pituitary regimen	FDA Egrifta SV PI BLA022505
Pregnancy or active conception planning within tight timeline	OUT OF PROTOCOL (active pregnancy) or pre-conception planning discontinuation (planning)	Discontinuation per §8.4 arithmetic; re-initiation post-pregnancy/lactation per §8.6	FDA Egrifta SV PI Category X
Patient asking about tesamorelin as primary weight-loss agent	Adjunct framing — NOT a primary weight-loss agent	Re-frame conversation: GLP-1 class is load-bearing weight management; tesamorelin is visceral-fat adjunct	M5.2 / M5.3 protocols
Patient asking about AOD-9604 as primary fat-loss agent	Evidence-limited adjunctive role — NOT a primary fat-loss agent	Honest evidence-base counseling per Anchor 5; route to GLP-1 class as primary	M5.5 v3 lesson §4.7
Patient seeking highest-magnitude weight-loss intervention	Adjunct stack is not in the highest-effect-size tier	Route to triagonist (retatrutide pre-approval) or dual GIP/GLP-1 (tirzepatide) class	M5.3 protocol / Retatrutide protocol
Pre-existing T2D / prediabetic	Adjunct stack feasible with enhanced glucose monitoring	Tesamorelin + GLP-1 backbone; glucose monitoring per §5 enhanced cadence	M5.2 / M5.3 T2D management
Cancer-history patient with treatment-complete malignancy in remission >2 years	Adjunct stack feasible with cancer-history conservative posture	Tesamorelin + (optional) GLP-1 + oncology co-management; documented informed consent	FDA Egrifta SV PI BLA022505
Cost / access barrier (insurance prior-authorization denied or unaffordable)	Compounded tesamorelin option available	Compounded tesamorelin (503A) + standard quality-criteria pharmacy evaluation per Anchor 2	M5.2 / M5.3 compounding framework
Patient on concurrent supraphysiological exogenous somatropin	OUT OF PROTOCOL — §2.3 + §9.5 mechanistic contraindication	None — endocrinology co-management of existing somatropin regimen	M5.6 GH-replacement framework

12.4 Worked example — Tesamorelin + AOD-9604 adjunct stack phenotype-guided decision tree application

Worked Example (composite of A + clinical-decision walkthrough): A 53-year-old female presents with BMI 28 (down from baseline 34 over 18 months on semaglutide 2.4 mg weekly), waist circumference 102 cm, MASLD on ultrasound + FibroScan CAP 290 dB/m, HbA1c 5.6 (non-diabetic; pre-diabetic baseline normalized), no T2D, DCIS status post-lumpectomy 2017 with 8 years clear surveillance, post-menopausal, on rosuvastatin and semaglutide.

Decision-tree walkthrough.

Step 1 — Adjunct stack indication scope (§1). Indication 2 applies (non-HIV adjunct for visceral adiposity; scenario (a) residual visceral adiposity post-GLP-1-class response + scenario (b) visceral-fat-predominant phenotype with concurrent MASLD/MASH). Adjunct framing: alongside primary semaglutide weight management; NOT standalone.

Step 2 — Selection criteria (§2). Inclusion met (age ≥18; visceral-fat-predominant; one of four adjunct scenarios; on primary weight management; informed consent for off-label tesamorelin). Relative exclusion: cancer-history conservative posture for DCIS in remission with oncology clearance. Hard contraindications: DCIS history requires careful “inactive AND treatment-complete” evaluation — 8 years clear surveillance + treatment complete satisfies the FDA-label criterion; conservative posture documented.

Step 3 — Pre-treatment workup (§3). Standard metabolic + GH-axis (IGF-1, TSH) + body-composition DEXA + hepatic panel (FIB-4, FibroScan) + cancer-history review.

Step 4 — Protocol composition decision. Phenotype matrix maps to “non-HIV adult, residual visceral adiposity post-GLP-1-class response” → Tesamorelin + GLP-1 backbone (standard composition); the visceral-fat-predominant + MASLD dimension also applies. AOD-9604 layer deferred (patient elects to focus on evidence-stronger tesamorelin first).

Step 5 — Initiation (§4). Tesamorelin Egrifta SV 1.4 mg SC daily (patient elects branded after Anchor 2 counseling). Bedtime dosing. Continue semaglutide 2.4 mg SC weekly. Phase 1–3 sequenced; AOD-9604 deferred at Phase 3 decision after Week 12 reassessment.

Step 6 — Maintenance (§5). IGF-1 quarterly Y1; HbA1c at Month 4 / 7 / 10 / 13; DEXA at Week 26 / Year 1; cancer surveillance per §3.6 + §6.9.

Step 7 — Branch points. Anticipated AE profile per §6 — manage as standard; monitor for cancer-suspicious findings continuously given DCIS history.

Step 8 — Combination decisions. Tesamorelin + semaglutide is the standard composition (§9.2); no cross-Module additions at initiation; M5.6 lean-mass stack consideration deferred unless lean-mass loss emerges at Month 6–12 monitoring.

Step 9 — Counseling beats. Initiation conversation per §10.2. Off-label and FDA-approved-vs-compounded conversation per §10.3. Pregnancy-planning not applicable (post-menopausal). Comparator conversation per §10.5 — present tirzepatide as an alternative GLP-1 backbone if needed at any future plateau decision. Off-label tesamorelin + adjunct-stack framing per §10.6.

Step 10 — Source citations. All claims traced to §11.5 Bibliography: Falutz 2007 NEJM PMID 18057338; Falutz 2008 AIDS PMID 18690162; Stanley 2014 JAMA PMID 25038357; 2025 meta-analysis PMID 41545261; Egrifta SV BLA022505 PI. Effect-size anchors precise per Pattern V.metric-axis; PMIDs verified per Pattern AB.

Step 11 — Verification gate. Per Appendix A, this protocol-application case passes through the four-step cycle if formalized as a case write-up; for a real-patient encounter, the clinician applies the same discipline (primary-source check, adversarial scrutiny, peer-review pause-point).

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with trial-anchored effect-size estimates; the phenotype is anchored to multiple indication-relevant dimensions without inflating cross-indication benefit; the tesamorelin + semaglutide combination is presented as standard adjunct-stack composition for this phenotype (Pattern Z compliant — what the combination IS for this phenotype); the comparator framing (semaglutide vs tirzepatide as alternative GLP-1 backbone) is presented without steering; the off-label tesamorelin + cancer-history conservative posture is anchored to the FDA-label criterion with explicit informed-consent documentation. Anchor 1 / 4 / 5 compliance.

Appendix A. Verification gate — the four-step cycle applied to this protocol

A.1 Cycle overview

This protocol passes through the four-step verification cycle documented in the Protocol Template Appendix A before delivery to clinicians. The cycle is the operational discipline that prevents the failure modes documented in the AC2-26 System Observations log — Pattern R framing drift, Pattern V direction-of-effect generalization, Pattern V.metric-axis disclosure gaps, Pattern W cross-section inconsistency, Pattern AA regulatory imprecision, Pattern AA.marketing-claims expansion gaps, Pattern AB identifier-cascade, Pattern Z.injection-framing violations, Pattern Z.research-precision bias-vocabulary — from reaching the clinician-facing deliverable.

The four steps are sequential, not parallel; each step’s output is the next step’s input.

A.2 Step 1 — Production agent draft

The production agent for this protocol applied the Protocol Template v1.0 structural authority, the canonical content authority (/Peptides/Tesamorelin.md + /Peptides/AOD-9604.md + M5.5 v3 lesson), the Pattern Z calibration anchors (/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md), the Editorial Framework v1.2, and the AC2-26 System Observations v2.4.2-compatible Pattern discipline (including the five new sub-patterns: V.metric-axis, V.estimand-axis, AA.marketing-claims, Z.injection-framing, Z.research-precision).

Production-agent self-audit on draft completion:

Pattern R.1 / R.2 framing applied — every section opens with research-state content; section ordering design-time-locked; adjunct-vs-standalone framing carried throughout
Pattern V direction-of-effect anchoring on every effect-size claim — Falutz Phase 3 effect-sizes with per-arm and between-group metric-axis disclosure at first-mention (Pattern V.metric-axis); on-label vs off-label phenotype qualification preserved
Pattern V.metric-axis disclosure applied — Falutz NEJM 2007 VAT effect-sizes carry per-arm change-from-baseline (−15.2% / +5.0%) AND between-group treatment difference (−20.2 percentage points) at first-mention; HbA1c and IGF-1 effect-sizes also disclose metric-axis where reported
Pattern V.estimand-axis — Falutz Phase 3 program did not formally distinguish treatment-policy vs treatment-regimen estimands in the publication era; not applicable as a load-bearing disclosure for this protocol
Pattern AA regulatory-claim precision on every contraindication, every label claim, every off-label claim — Egrifta SV BLA022505 label-anchored; off-label use of FDA-approved drug distinguished from investigational use; AOD-9604 not-FDA-approved-for-marketing-claims framing preserved
Pattern AA.marketing-claims expansion at first-mentions — Tesamorelin “FDA-approved for marketing claims for HIV-associated lipodystrophy abdominal-fat reduction” at first-mention in front-matter and §1.5; “FDA-approved-for-marketing-claims” shorthand used after expansion; off-label / investigational expanded where applicable
Pattern AB.1 identifier integrity at draft-step — Falutz NEJM 2007 PMID 18057338 verified (not 17960012); Heffernan 2001 PMID 11713213 verified as mouse study (not human Phase 2)
Pattern Z 5-anchor self-audit complete (§10.8) — Anchor 5 dominant for this protocol; Anchor 1 adjunct-vs-standalone framing throughout; Anchor 2 tesamorelin-not-on-FDA-shortage-list regulatory-context distinction preserved
Pattern Z.injection-framing applied — daily SC self-injection framed as routine clinical skill throughout; not as barrier
Pattern Z.research-precision applied — AOD-9604 framed as “investigational; development-discontinued 2007; preclinical + sponsor-disclosed Phase 2b not peer-reviewed-published” throughout; explicit anti-anchor against “highly experimental” / “fringe” / “unproven” bias-vocabulary

Production-agent handoff to Step 2 with explicit declaration of “draft complete; ready for primary-source verification.”

A.3 Step 2 — Primary-Source-Verification-Agent iteration 1

PSV-agent responsibilities per Protocol Template Appendix A.3, applied to this protocol’s Bibliography (§11.5):

For every PMID in §11.5: retrieve PubMed abstract; verify title, authors, journal, year, study type, intervention, population
For every NCT (if present in Bibliography expansion): retrieve ClinicalTrials.gov entry; verify sponsor, intervention, indication, phase, status
For every effect-size claim in §1.5 / §4.6 / §5.5 / §6.10 / §7.5 / §10.5: confirm effect-size matches primary source’s reported value, including trial-enrollment qualification AND metric-axis (per-arm vs between-group)
For every dose threshold (1.4 mg SC daily tesamorelin Egrifta SV; 2 mg SC daily compounded; 250–300 mcg SC daily AOD-9604), contraindication (active malignancy; pituitary-axis disruption; pregnancy Category X; hypersensitivity), label-recommended monitoring: verify against FDA Egrifta SV PI BLA022505
Run Pattern AB.4 standing scan across the document — verify Falutz 2007 PMID 18057338 consistency across §1.5, §11.5, and any other location citing this paper; verify no recurrence of the AB.1 inversion to PMID 17960012; verify Heffernan 2001 PMID 11713213 consistency as mouse-study citation

PSV-agent handoff to Step 3 with explicit declaration of “primary-source verification complete; cascade-report attached if applicable.”

A.4 Step 3 — Independent-Adversarial-Reviewer-Agent iteration 1

IAR-agent six-axis scrutiny per Protocol Template Appendix A.4:

Framing (Pattern R / R.1 / R.2). Every section opens with research-state content before regulatory / cautionary framing? Adjunct-vs-standalone framing applied consistently? Pattern Z 5-anchor compliance in §10? Specific challenge: does §1.1 actually lead with what the adjunct stack IS, or does the “NOT standalone” framing dominate at the expense of the affirmative lead? Specific challenge: does §10 counseling beats consistently apply Anchor 5 dominant framing for both tesamorelin off-label and AOD-9604 investigational, or does AOD-9604 framing slide toward Anchor 4 comparator framing (which is also valid but secondary)?
Completeness. All twelve sections substantively populated? Worked examples present where the template specifies? Cross-references to canonicals, M5.5 v3 lesson, M5.2 / M5.3 / Liraglutide / Module 5.6 / M5.7 protocols complete?
Consistency (Pattern W). Structural-count claims consistent (eight Module 5 indication categories framed precisely; six §3 panels — not seven, because the CV-risk-specific panel does not apply as a standalone for this adjunct protocol; AE classes in §6 cross-referenced with §5 monitoring and §3 baseline panels)?
Direction-of-effect (Pattern V). Null / negative / protective findings characterized with primary-source effect-size and population qualification? Adjunct-stack effect-size in non-HIV populations framed as “biologically-plausible mechanism translation; no Phase 3 RCT in non-HIV population as of 2026-05-13” rather than as Phase-3-confirmed? Pattern V.metric-axis disclosure at first-mention?
Regulatory precision (Pattern AA + AA.marketing-claims). Every regulatory claim precise — FDA-approved-for-marketing-claims with specific indication and date; off-label use of FDA-approved drug; investigational with development-history precision; boxed warning vs labeled contraindication vs precaution distinguished?
Identifier integrity (Pattern AB.1 / AB.2 / AB.4 standing scans). PSV-agent’s cascade-report resolved? Cross-document identifier references (M5.5 v3 lesson; canonical files; this protocol) consistent on Falutz NEJM 2007 = PMID 18057338?

IAR-agent handoff to Step 4 with explicit declaration of “adversarial review complete; six-axis scrutiny report attached; any unresolved findings flagged for clinical-judgment review.”

A.5 Step 4 — Dr. Gross verification gate

Dr. Jeff Gross MD applies the final clinical-judgment review before this protocol is delivered to the clinician audience. Dr. Gross’s review is not mechanical — it is the senior-clinician-judgment layer that the agent layers cannot replicate.

Dr. Gross verification-gate review items specific to this protocol:

Adjunct-vs-standalone framing fidelity. Does the protocol consistently frame tesamorelin + AOD-9604 as a body-composition adjunct alongside primary weight-management therapy, NOT as a standalone obesity treatment? Particular attention to §1.1 lead-framing, §4 initiation framing (Phase 0 confirms primary therapy established before adjunct addition), §10 counseling beats (the adjunct-framing is explicit at every counseling beat).
FDA-label fidelity for Egrifta SV / Egrifta WR (BLA022505). The “weight neutral effect” Limitation of Use is preserved verbatim and operationalized correctly in counseling (the visceral-fat-redistribution-at-approximately-neutral-total-weight framing). The cancer-history absolute contraindication is preserved with the “inactive AND treatment-complete” criterion. The pituitary-axis disruption absolute contraindication is preserved with the mechanism rationale (mechanism requires intact pituitary somatotroph function). The Category X pregnancy contraindication is preserved.
Pattern AA precision throughout. Tesamorelin FDA-approved-for-marketing-claims for HIV-LD; off-label use for non-HIV visceral adiposity = off-label use of an FDA-approved drug (distinct from research-use-only). AOD-9604 not FDA-approved for marketing claims for any drug indication; current US clinical access via 503A compounding (bulks list category 2); 2007 FDA GRAS determination is food-regulatory category distinct from drug approval; Australian TGA listing is for joint/cartilage as complementary medicine, regulatorily distinct.
Pattern Z anchor 1, 2, 4, 5 calibration. Compounded vs FDA-approved tesamorelin: tesamorelin-not-on-FDA-shortage-list regulatory-context distinction preserved as load-bearing factual context (not steering). Comparator framing: multi-dimensional fact presentation across mechanism classes (tesamorelin GH-axis vs GLP-1 / GIP / glucagon class vs non-pharmacologic body-composition tools); affirms each option’s role; closes with shared-decision-making. Off-label tesamorelin + investigational AOD-9604: research-state-precise framing throughout; Pattern Z.research-precision discipline applied (no “highly experimental” / “fringe” / “unproven” bias-vocabulary).
Pattern AB.1 catches. Falutz NEJM 2007 = PMID 18057338 (NOT 17960012 = Vermorken head/neck cancer) — verified throughout. Heffernan 2001 Endocrinology PMID 11713213 = mouse + β3-AR knockout study (NOT human Phase 2 trial) — verified; the 2.6-kg AOD-9604 human weight-loss figure is framed as sponsor-disclosed Phase 2b not peer-reviewed-published, not as Heffernan 2001 citation.
Tesamorelin / sermorelin disambiguation. Both are GHRH analogs but differ in molecular size (sermorelin 29 residues vs tesamorelin 44 residues), DPP-IV resistance (tesamorelin has trans-3-hexenoic acid N-terminal modification; sermorelin does not), half-life (~10–20 min vs 26–38 min), evidence base (sermorelin older pediatric GH-deficiency data; tesamorelin Falutz Phase 3 HIV-LD program). Do not conflate.
§5.2 dosing precision. Egrifta SV 1.4 mg SC daily is the FDA-label dose for the on-label indication; original Egrifta 2 mg SC daily was the pre-reformulation dose and the Falutz Phase 3 dose; the two doses have FDA-required PK-equivalence rationale. Off-label clinician-judgment dose escalation to 2 mg in non-HIV adjunct context is documented as [NEEDS MD CONFIRMATION].
§9 combination rules. Mechanism-overlap consideration for adjunct stack + M5.6 lean-mass stack (CJC-1295 is a GHRH analog with mechanism overlap to tesamorelin; combined regimen warrants closer IGF-1 monitoring). Concurrent somatropin contraindication preserved (mechanistic conflict).
AOD-9604 honest evidence-base framing. Development history precision (Phase 2a 2002 per Wilding 2004 review; Phase 2b 2006–2007 discontinued; not peer-reviewed-published primary citation); preclinical animal-model evidence base; 503A compounding bulks list category 2 status; Australian TGA complementary-medicine listing regulatorily distinct.

Dr. Gross authorizes delivery, or returns to Step 1 (production agent) with revision notes.

The Dr. Gross gate is the only gate that authorizes delivery. The agent layers prepare the protocol; the clinical-judgment gate releases it.

A.6 Cycle iteration

If Step 4 returns to Step 1, the cycle iterates. Each iteration is numbered and documented in the per-protocol iteration log at /Process/Tesamorelin-AOD-9604-Visceral-Fat-Adjunct/ if formalized.

Appendix B. Pattern discipline summary — adjunct-specific enforcement

B.1 Pattern R / R.1 / R.2 — framing discipline (adjunct-specific)

Pattern R (paragraph-level framing): every section opens with research-state content before regulatory / cautionary / contraindication / deficit framing. Adjunct-specific application: §1.1 opens with what the adjunct stack IS (body-composition adjunct for VAT-selective reduction, alongside primary weight management); the “NOT a standalone obesity treatment” framing appears explicitly because the adjunct-vs-standalone distinction is the load-bearing protocol framing, but the affirmative lead precedes the not-this framing.

Pattern R.1 (structural framing): §2 inclusion → relative-exclusion → contraindication ordering preserved. §6 anticipatory framing precedes discontinuation triggers in each AE-class sub-block. §8 discontinuation triggers framed as legitimate clinical pathway, not therapeutic failure.

Pattern R.2 (design-time enforcement): adjunct-vs-standalone framing locked at §1.1 design step; carried through §4 initiation (Phase 0 confirms primary therapy established before adjunct addition), §5 maintenance (continuous-therapy framing aligned with Falutz 2008 AIDS extension), §9 combination (primary-therapy combination is the standard composition), §10 counseling beats (Anchor 1 adjunct-framing throughout).

B.2 Pattern V — direction-of-effect verification (adjunct-specific)

Every effect-size claim is anchored to its primary source with population qualification. The Falutz Phase 3 effect-sizes (VAT −15–18%; trunk fat reduction; lipid improvement; IGF-1 +81%) are anchored to “HIV-lipodystrophy enrollment” — extrapolation to non-HIV populations is biologically-plausible mechanism translation, not Phase-3-confirmed effect-size. The Stanley 2014 JAMA hepatic-fat-reduction finding is anchored to “HIV-NAFLD enrollment” — extrapolation to non-HIV-MASH is mechanistically additive to GLP-1-axis hepatic effect but the combined-regimen effect-size in non-HIV-MASH is research-state-incomplete.

B.3 Pattern V.metric-axis — per-arm vs between-group effect-size disclosure

Every load-bearing Falutz Phase 3 effect-size citation discloses metric-axis at first-mention. Example from §1.5: “the per-arm 26-week change was −15.2% with tesamorelin vs +5.0% with placebo (per-arm change-from-baseline metric); the between-group treatment difference was −20.2 percentage points (between-group treatment-difference metric); p<0.001.”

B.4 Pattern V.estimand-axis — not load-bearing for this protocol

The Falutz Phase 3 program publications did not formally distinguish treatment-policy vs treatment-regimen vs efficacy estimands in the publication-era convention; the estimand-axis is not a load-bearing disclosure for this protocol. Future regulatory submissions or peer-reviewed publications applying the modern estimand framework to tesamorelin Phase 3 data would warrant Pattern V.estimand-axis disclosure if the canonical evidence base is updated.

B.5 Pattern W — cross-section enumeration consistency (adjunct-specific)

Structural-count claims: “eight Module 5 indication categories” (with only Indication 1 HIV-LD and Indication 2 non-HIV visceral adiposity applying to this adjunct protocol; other six categories are not adjunct-stack indications). “Six §3 panels” (standard metabolic, GH-axis-specific, body-composition, hepatic-if-MASLD, cancer-history-screening, pituitary-eval-if-concerning) — NOT the seven panels of the Module 5 Protocol Template (the CV-risk-specific panel does not apply as a standalone for this adjunct protocol; CV-risk monitoring is handled via the primary GLP-1-class therapy protocol). “Nine §6 AE classes” applied to this protocol (injection-site, arthralgia, peripheral edema, glucose elevation, IGF-1 supraphysiological, ADA-mediated neutralization, AOD-9604 limited human characterization, cancer-history surveillance, hypersensitivity per §2.4 / §6 cross-reference) — these are reconciled with §3 baseline panels and §5 monitoring intervals.

B.6 Pattern Z — 5-anchor calibration in §10 (Anchor 5 dominant for this protocol)

The five Pattern Z calibration anchors with adjunct-specific calibration:

Anchor 1 — Lead with what the adjunct stack IS (body-composition adjunct; not standalone weight-loss).
Anchor 2 — Compounded vs FDA-approved (tesamorelin); tesamorelin-not-on-FDA-shortage-list distinction preserved.
Anchor 3 — Pregnancy planning; LEADS with research-state framing of what is and is not known (no Parker-2025-equivalent human pregnancy-exposure cohort for tesamorelin); Category X factually.
Anchor 4 — Multi-dimensional comparator framing across tesamorelin / AOD-9604 / GLP-1 / non-pharmacologic.
Anchor 5 — Off-label tesamorelin + investigational AOD-9604 — DOMINANT anchor for this protocol.

§10.8 carries the 5-anchor self-audit before handoff to Appendix A verification cycle. Cumulative-tone scan: multi-section coverage of compounded vs FDA-approved tesamorelin (across §2.5 worked examples, §4.6 worked example, §9.6 combination scenarios, §10.3 counseling beat) passes Pattern Z when each individual occurrence is anchored and the cumulative tone does not steer.

B.7 Pattern Z.injection-framing — applied throughout

Daily SC self-injection of tesamorelin and AOD-9604 framed as routine clinical skill (taught in one clinical visit; refined over first few self-administrations; fine 29–31G insulin syringe; subcutaneous depth; technique straightforward). Not framed as “burden,” “barrier,” “the hardest part,” “what patients struggle with most.” The substantive titration-management discussion is AE tolerance and pharmacodynamic response (IGF-1, glucose, body-composition trajectory), not injection mechanics.

B.8 Pattern Z.research-precision — applied throughout (load-bearing for AOD-9604)

AOD-9604 framing throughout uses research-state-precise vocabulary: “investigational; not FDA-approved for marketing claims for any drug indication; development-discontinued by sponsor 2007; preclinical animal-model evidence base + sponsor-disclosed Phase 2b not peer-reviewed-published; current US clinical access via 503A compounding bulks list category 2; Australian TGA listing for joint/cartilage as complementary medicine ingredient regulatorily distinct.” Explicit anti-anchor against “highly experimental,” “fringe,” “speculative,” “unproven,” “untested” bias-vocabulary.

B.9 Pattern AA — regulatory-claim precision (adjunct-specific)

Tesamorelin: FDA-approved for marketing claims for HIV-associated lipodystrophy abdominal-fat reduction (Egrifta SV / Egrifta WR; BLA022505; initial FDA approval Egrifta November 2010; Egrifta SV approval June 2019; Egrifta WR approval 2024). Off-label use for non-HIV visceral adiposity = off-label use of an FDA-approved drug — distinct from research-use-only / non-FDA-approved compound use. Egrifta SV PI Limitation of Use #2 “weight neutral effect” preserved verbatim and operationalized in counseling. Cancer-history absolute contraindication preserved with “inactive AND treatment-complete” criterion. Pituitary-axis disruption absolute contraindication preserved with mechanism rationale.

AOD-9604: NOT FDA-approved for marketing claims for any drug indication. Current US clinical access via 503A compounding (bulks list category 2). 2007 FDA GRAS determination is food-regulatory category for oral food-supplement use — distinct from drug approval. Australian TGA listing as complementary medicine ingredient for joint/cartilage — regulatorily distinct pathway from FDA drug approval. Development-discontinued by sponsor 2007 after Phase 2b did not meet commercial-development thresholds.

B.10 Pattern AA.marketing-claims — first-mention expansion (adjunct-specific)

First-mention contexts use full expansion: “FDA-approved for marketing claims for HIV-associated lipodystrophy abdominal-fat reduction (Egrifta SV / Egrifta WR; BLA022505)” at first-mention in front-matter, §1, §10 patient-counseling beats. Shorthand “FDA-approved” used after expansion within a section. Cross-indication discussions use the full convention “FDA-approved for marketing claims for [X]; off-label for [Y].” Compounded tesamorelin framed at the pathway level (503A / 503B framework), not as “not FDA-approved.”

B.11 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

Pattern AB.1 catches verified:

Falutz NEJM 2007 tesamorelin Phase 3 = PMID 18057338 (NOT 17960012; PMID 17960012 is Vermorken JB et al, head/neck cancer Phase 3, NEJM 2007 — same-journal-same-year cluster inversion documented in M5.5 v3 lesson and verified throughout this protocol)
Heffernan 2001 Endocrinology PMID 11713213 = mouse + β3-AR knockout study, NOT a human Phase 2 trial; the 2.6-kg AOD-9604 human weight-loss figure is framed throughout as sponsor-disclosed Phase 2b not peer-reviewed-published, NOT as Heffernan 2001 Endocrinology citation

Pattern AB.4 standing scan: every PMID in §11.5 cross-referenced with M5.5 v3 lesson; consistency verified.

B.12 Pattern N.1 — peptide-path classification

Both tesamorelin (44-residue GHRH analog peptide) and AOD-9604 (16-residue hGH C-terminal lipolytic fragment peptide) belong at /Peptides/. This protocol lives at /Protocols/ under the peptides folder structure. Orforglipron and aleniglipron (small-molecule oral GLP-1 RAs) are the Pattern N.1 contrast cases; this protocol does not share that classification.

B.13 Pattern discipline self-audit checklist (adjunct-specific)

This protocol passes the full Pattern discipline audit when:

Appendix C. Byte-count audit + production commits

C.1 Protocol length

Final byte-count audit (post-Commit 6). The protocol is approximately 26,500–27,000 words across the twelve sections and three appendices, within the target range (22,000–27,000 words) specified by the orchestrator launch prompt. Section length distribution is approximately proportional to evidence density and adjunct-specific framing load:

§1 indication scope: substantial length given the adjunct-vs-standalone framing load and the two-indication scope (on-label HIV-LD + off-label non-HIV visceral adiposity)
§10 patient counseling beats: substantial length given the Anchor 5 dominant framing and the multi-dimensional comparator landscape
§11 Bibliography: full Bibliography with Tier 1 / 2 / 3 / 4 hierarchy; AOD-9604 load-bearing evidence is Tier 4 preclinical
§12 decision tree: ASCII flowchart + phenotype-guided matrix + worked-example walkthrough
Appendices A / B / C: full Pattern discipline summary with adjunct-specific enforcement

C.2 Worked-example coverage

All twelve sections carry worked examples or worked-example walkthroughs anchored to either Worked Example A (53-year-old female non-HIV adjunct context; visceral-fat-predominant + MASLD; DCIS in remission) or Worked Example B (47-year-old male HIV-LD on-label context). Sections 4–8 develop the Worked Example A through initiation / maintenance / AE / non-response / discontinuation scenarios. Section 12 integrates the worked-example walkthrough end-to-end.

C.3 Cross-reference inventory

This protocol references the following canon / methodology files:

/obsidian-peptides/Methodology/Protocol Template.md — structural authority
/obsidian-peptides/Methodology/Synergy Editorial Framework.md v1.2 — voice / framing / Pattern AA.marketing-claims §1.2.1
/obsidian-peptides/Methodology/Voice Profile - Dr. Jeff Gross MD.md — clinician-voice calibration
/obsidian-peptides/Methodology/AC2-26 - System Observations.md — Pattern R / V / V.metric-axis / V.estimand-axis / W / Z / Z.injection-framing / Z.research-precision / AA / AA.marketing-claims / AB.1–AB.4 / N.1
/obsidian-peptides/Peptides/Tesamorelin.md — content authority (tesamorelin canonical)
/obsidian-peptides/Peptides/AOD-9604.md — content authority (AOD-9604 canonical)
/Peptide Projects/Pepteon Academy/m5-content/M5.5 - Tesamorelin + AOD-9604 — Targeted Visceral & Adipose Fat Protocols - v3.md — clinical-education structural anchor
/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — Pattern Z calibration anchors (verbatim source for Anchors 1–5)
/Internal/Module-5-Pipeline/orchestrator-launch-prompt.md — adjunct-protocol-specific calibration directives
Other Module 5 protocols (cross-references in §9 combination rules and §10 comparator framing): /Protocols/Semaglutide Protocol.md, /Protocols/Tirzepatide Protocol.md, /Protocols/Liraglutide Protocol.md, /Protocols/Orforglipron Protocol.md, /Protocols/Retatrutide Protocol.md, /Protocols/Survodutide Protocol.md, /Protocols/Cagrilintide Protocol.md, /Protocols/CagriSema Protocol.md, /Protocols/IcoSema Protocol.md

C.4 Six-commit production audit

The protocol was produced in six strict incremental commits per the production-discipline standard:

Commit 1 (20100b7) — Front-matter + intro (adjunct-protocol framing; Pattern AA.marketing-claims load-bearing precision; adjunct-specific calibration notes) + TOC + §1 Indication scope and patient phenotypes.
Commit 2 (27da884) — §2 Selection criteria (inclusion, relative exclusion, hard contraindications, four worked examples including stack-not-initiated scenarios) + §3 Pre-treatment workup (six-panel adjunct-scaled).
Commit 3 (8bfc2b0) — §4 Initiation protocol (fixed-dose initiation; no titration-priming required; Phase 0–3 sequenced introduction) + §5 Maintenance protocol (continuous-therapy framing aligned with Falutz 2008 AIDS extension; IGF-1 quarterly Y1) + §6 Side-effect management (nine AE classes; GLP-1-dominant GI AE pattern NOT characteristic of tesamorelin).
Commit 4 (10c109e) — §7 Plateau and non-response algorithm (pharmacodynamic-vs-clinical distinction; six-step decision tree) + §8 Discontinuation and tapering (Falutz 2008 AIDS VAT-reversal trajectory; 1–2 month pre-conception clinical-judgment interval) + §9 Combination rules (primary-therapy combination standard; adjunct-internal combination; cross-Module with mechanism-overlap caution).
Commit 5 (b37efdd) — §10 Patient counseling beats (Anchors 1–5 with adjunct-specific calibration; Anchor 5 dominant; tesamorelin-not-on-FDA-shortage-list distinction preserved) + §11 Source citations (Tier 1–4 hierarchy; Pattern AB.1 catches verified: Falutz 2007 = PMID 18057338, Heffernan 2001 = mouse study).
Commit 6 — §12 Clinical decision tree (ASCII flowchart + phenotype-guided matrix + worked-example walkthrough) + Appendix A verification gate + Appendix B Pattern discipline summary (adjunct-specific enforcement) + Appendix C byte-count audit + production commits.

Each commit followed the CLAUDE.md commit-message format with Protocol: Tesa+AOD-9604 §X-Y (Commit N/6) subject prefix and the standard Co-Authored-By trailer.

C.5 Protocol version and next-iteration trigger

Protocol version v1.0-draft. The next-iteration trigger is the Step 4 Dr. Gross verification gate review or a Step 2/3 PSV-agent or IAR-agent finding requiring revision. The protocol version is tracked in the front-matter; iteration history will be appended at this section as it accrues.

C.6 Adjunct-protocol Wave 3 pipeline position

This protocol is the first of five Wave-3 adjunct-compound protocols in the Module 5 pipeline. The four subsequent Wave-3 protocols (per orchestrator launch prompt) will be produced under the same Protocol Template structural authority with their own adjunct-specific calibration notes, Pattern Z anchor application, and verification-gate cycle. The Wave-3 adjunct compounds include the lean-mass / metabolic-flexibility / skin-elasticity stacks (M5.6 / M5.7 framework compounds) plus the decision-tree-and-module-master integration protocols.

Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol